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Introduction: Infectious diseases are endemic in Africa, especially tuberculosis (TB), malaria 
and human immunodefiency virus (HIV)/acquired immunodeficiency syndrome (AIDS). 
Genomics research has the potential to improve the health of Africans through identification of 
genetic markers associated with either disease susceptibility or therapeutic drug response. This 
project was set to investigate the genetic correlates for drugs associated with mitochondrial 
toxicity that are used as part of HIV therapy, especially nucleoside reverse transcriptase 
inhibitors (NRTIs). Toxicity from NRTIs manifests through metabolic diseases such as 
peripheral neuropathy, lipodystrophy, lactic acidosis and hyperlactatemia but show interpatient 
variability. Studying African populations is likely to open the door for the population to benefit 
from novel diagnostic tools and drugs developed on the basis of pharmacogenomics knowledge. 
In an effort to contribute to this knowledge, the role of variati n in mitochondrial DNA 
(mtDNA) and polymerase gamma (POL-γ) on how patients respond to stavudine-containing 
antiretroviral therapy (ART) among adult Malawian HIV/AIDS patients was investigated. 
 
Methodology: Two hundred and fifteen (n = 215) adult HIV/AIDS patients on stavudine 
containing ART regimens were recruited from antiretroviral therapy clinic at Queen Elizabeth 
Central Hospital, Blantyre, into a cross sectional study to investigate the effects of genetic 
variants in mtDNA and polymerase-γ. The patients were required to have been on stavudine 
(d4T) containing antiretroviral therapy (ART) for at least six months. The HIV/AIDS patients 
were categorised into their respective clinical manifestation groups as follows: those presenting 
with 1) peripheral neuropathy, 2) lipodystrophy, 3) hyperlactatemia, and 4) patients presenting 
with no signs and symptoms of stavudine associated toxicity. The whole mitochondrial DNA 
coding region for each patient was sequenced while a section of mtDNA POL –γ was sequenced. 
In addition, mtDNA levels were quantified, CD4 count, viral load and creatinine levels were 
determined. Different statistical methods were used to analyze the data and these included 
network analysis, distance based phylogenetic analysis, principal component analysis, manova, 















Results: With respect to mtDNA characterisation, 184 haplotypes were observed which belong 
to 9 mtDNA L lineage subhaplogroups and placing Malawian ethnic groups with other groups 
from Southern and Southeast Africa. Mitochondrial DNA subhaplogroup L0a2 was 
independently associated with increased risk of peripheral neuropathy (OR 2.23; 95% CI, 1.14 – 
4.39; p = 0.019) and subhaplogroup L2a was independently associated with reduced risk of 
peripheral neuropathy (OR, 0.39; 95% CI, 0.16 – 0.94; P = 0.036). Mitochondrial DNA 
subhaplogroup L3e appeared to be protective against lipodystrophy as none of the individuals 
with this subhaplogroup presented with lipodystrophy. No mutations in POLG-γ were associated 
with stavudine toxicities.  It was observed that mitochondrial levels were lower in HIV/AIDS 
patients (P = 0.05) when compared to health controls, patients with peripheral neuropathy (P = 
0.039) and patients presenting with hyperlactatemia (P = 0.024) when compared to those 
without.  Significantly low mitochondrial levels (P = 0.01) were observed in the subhaplogroup 
L0a2 compared with L2a.  
 
Conclusion: Variation in clinical response and susceptibility to drug associated side effects 
observed with respect to mtDNA subhaplogroups could point to effects of subhaplogroup 
specific mutations on the structure of mitochondria and associated proteins. Our result shows that 
the Malawian population, although related to other African populations, exhibit a unique mtDNA 
genetic pattern. Our data also shows that genetic predisposition may play an important role in the 
pathophysiology of stavudine-associated mitochondrial disorders in patients on NRTIs. We 
suggest that the current efforts for genomics, proteomics, metabolomics science and personalized 
medicine applications in Africa should to be expanded in scope to include mitochondrial 






















This thesis includes written chapters and manuscripts for journals in accordance with general provision 
6.7 in the General Rules for the degree of Doctor of Philosophy (PhD) of the University of Cape Town, 
with the approval of 2013 of the university Doctoral Degrees Board. Chapter 1 gives an introduction to 
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Lastly, Chapter 9 is a comprehensive discussion bringing the findings from the different publications 
together and synthesizing their meaning. Highlighting what this thesis is contributing in terms of new 
knowledge as well as outlining possible gaps in knowledge that still need to be covered that is likely to 
form part of future projects.  Conclusions that are informed by findings from all the publications. 
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1. CHAPTER 1: INTRODUCTION 
1.1.  Overview 
Human immunodeficiency virus/Acquired immunodeficiency syndrome (HIV/AIDS) is one of 
the major health problems in the world with 34 million people infected  and sixty eight percent 
(23.5 million) of them residing in Sub-Saharan Africa  [1]. As a result of the WHO ―3 by 5‖ call 
to action, over 6 million individuals have been started on highly active antiretroviral therapy 
(HAART) in resource poor areas [1]. There are several classes of antiretroviral (ARV) drugs that 
have been approved for the treatment of HIV (Table 1.1). The ARV drugs are classified 
according to their mechanisms of action. They include nucleoside reverse transcriptase inhibitors 
(NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), 
integrase and fusion inhibitors, blocking viral activities at different stages of the HIV life cycle 
as shown in Figure 1.1. The World Health Organisation (WHO) recommends a combination of 
two NRTIs and one NNRTI as first-line therapy for the treatment of HIV. The idea behind 
combination ARV drug therapy of is based on the synergistic or additive potential of two or 
more drugs with independent modes of action and different biochemical targets (Figure 1.1) in 
order to improve therapeutic efficacy and prevent or delay the development of resistance of the 
virus to the individual components of the combination.  
Table 1.1: List of FDA approved antiretroviral drugs and their classification 




stavudine (d4T), zidovudine (ZDV), didanosine (ddi), zalcitabine (ddc), 






ripivirine (RPV), etravirine (ETR),  delavirdine (DLV), nevirapine (NVP), 




tipranavir (TPV), indinavir (IDV), saquinavir (SQV), lopinavir (LPV), ritonavir 
(LRTV), fosamprenavir (FOS), darunavir (DRV), atazanavir (ATV), nelfinavir 
(NFV), Lopinavir/ritonavir (LPV/RTV) 
  
Integrase Inhibitors  raltegravir (RAL), dolutegravir (TAF) 
  
Fusion inhibitors Maraviroc (MVC), enfuvirtide (T-20) 

















Figure 1.1: HIV life cycle showing the different stages targeted by antiretroviral drugs 
(yellow arrows)     
 Diagram adapted from  Sohn  HA, and Ananworanich J [2]  
 
Amongst adult Malawians, HIV/AIDS is the leading cause of death and a major contributing 
factor to the country‘s low life expectancy of 52 years. According to WHO report, the country 
has an HIV prevalence of 11% among the 15 – 49 year olds with high prevalence among women  
(13%) compared to men (8%) [1]. At the end of September 2011, the Malawi National 
antiretroviral therapy (ART) programme reported nearly 500, 000 people had been initiated on 
ART since 2004. The first-line regimen that was chosen by the Malawi ART program is a 
generic combination of stavudine (d4T), lamivudine (3TC) and nevirapine (NVP) [3]. This 
combination therapy is effective against the virus; however, one of the limitations of ART in 














been the most associated with adverse drug events in many studies [4,5,6]. Common adverse 
events include peripheral neuropathy and lipodystrophy [5].  Much less common but equally 
important adverse drug effects include lactic acidosis, dyslipidemia, pancreatitis and glucose 
intolerance [7,8]. As a result of these adverse drug events, WHO in 2010 recommended the 
phasing out of use of stavudine replacing it with alternative NRTIs with better safety profiles  
such as tenofovir or zidovudine [9]. However, many low and middle income countries are still 
using stavudine in their standard first-line ART regimen due to lack of resources [10].  
 
Toxicities  related to stavudine (d4T) use are thought to occur as a result of defective 
mitochondrial DNA (mtDNA) replication [11].  Phosphorylated d4T has structural resemblance 
to natural dNTPs and inhibits mitochondrial DNA polymerase gamma activities by competing 
for the binding site (POL-γ) [12] . Phenotype characteristics of stavudine associated toxicities in 
HIV infected patients receiving antiretroviral therapy are similar to diseases associated with 
mtDNA dysfunction.  Researchers have identified some mitochondrial DNA mutations 
(haplotypes) that are associated with increased risk of stavudine toxicities, but these haplotypes 
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2. CHAPTER 2:  LITERATURE REVIEW 
2.1. Mitochondrial Structure and Functions 
2.1.1. Mitochondrial structure 
Mitochondria are small intracellular organelles that live, divide and fuse in an endosymbiotic 
relationship in the cytosol of all human cells except red blood cells. The human mitochondrion is 
a circular, double stranded molecule and has 16,569 base pairs coding for 37 genes. These genes 
encode 13 polypeptides that are essential for ATP production as well as 22 transfer RNAs 
(tRNA) and 2 ribosomal RNAs (rRNA), which form part of the organelle‘s internal protein 
synthesis machinery  [1] (Figure 2.1). The polypeptides encoded in the mitochondrial genome 
are subunits of the respiratory chain of complexes I - III, cytochrome c oxidase and ATP 
synthase  [2] as indicated in Table 2.1. Mitochondrial (mtDNA) has a continuous coding region 
without introns and a non-coding region called the displacement loop (D-Loop) [3].  The D-Loop 


















Figure 2.1: A diagrammatical representation of human mtDNA molecule  
mtDNA consist of  the displacement loop (D loop) (non-coding) region anchors promoters for transcription of light 
strand promoter (LSP) and heavy strand promoter (HSP) and the origin of leading strand replication (OH). The 
coding region has 13 mtDNA genes (ND1–6, Cyt b, COI–III, ATP6, and ATP8) in orange, genes for the two rRNAs 
(in yellow), and 22 tRNAs (in green) are indicated by boxes. The origin of lagging strand replication (OL) is 
embedded in a cluster of tRNA genes. Modified from Park and Larson 2011 [3] 
 
Mitochondria play an important role in cellular respiration and are regarded as the powerhouse of 
the cells. In stepwise processes, which are controlled by genes encoded within mtDNA and a 
number of oxidative enzymes, nutrients and oxygen are processed into adenosine triphosphates 
(ATP). Cellular respiration can be aerobic or anaerobic and mitochondrion is involved in aerobic 
respiration which is divided into three main categories; glycolysis, Kreb‘s cycle (citric acid 
cycle) and electron transport chain. Glycolysis and the Krebs cycle are suppliers of the electrons 
that are necessary for energy production within the electron transport chain.  
Glycolysis occurs in the cytosol independent of the mitochondria where glucose is partially 
oxidized to yield only two ATP molecules, two pyruvate and 2 NADH (Nicotinamide Adenine 














[20] which is also metabolized by citrate synthase to acetate which enters the Krebs cycle where 
a number of oxidative reactions take place that regenerate oxaloacetate at the end of the cycle. 
Apart from pyruvate, fatty acid and proteins are degraded to form Acetyl-CoA as well, which 
enters the Krebs cycle. Fatty acids are transported across the outer mitochondrial membrane and 
once inside the mitochondrial matrix, fatty acids undergo β-oxidation to form Acetyl-CoA. 
Proteins are broken down by proteases into their constituent amino acids and their carbon 
backbones become a source of energy by being converted to acetyl-CoA. The high energy 
electrons generated during this process reduce oxidized nicotinamide adenine dinucleotide 
(NAD
+
), along with another electron carrier, flavin adenine dinucleotide (FAD) to form  NADH 
and FADH2 [5,7]. However during this process less energy is generated via substrate-level 
phosphorylation. In the final stage of energy metabolism, the high-energy electrons within 
NADH and FADH2 are passed to a set of mitochondria-membrane-b und enzymes in a process 
referred to as the respiratory chain (Electron Transport Chain) or oxidative phosphorylation [5].  
 
2.1.2. Electron transport chain 
The electron transport chain is the primary site for ATP synthesis, which occurs within the 
mitochondrion, consists of five multimeric protein complexes (Table 2.1 and two electron carrier 
molecules called coenzyme Q (CoQ) and cytochrome c (Cyt c) [8]. The process involves transfer 
of electrons in a sequence from NADH and FADH by complex 1 through II, III and IV 
respectively, to molecular  oxygen as shown in Figure 2.2 [5,9]. At the same time hydrogen ions 
are pumped out of the mitochondrial matrix into the intermembrane space, whilst an 
electrochemical gradient is generated in the matrix. The flow back of hydrogen ions into the 
matrix is enhanced by ATP synthase protein complex (Complex V) and these protons release 




















Table 2.1:  Respiratory chain complexes and their composition 
Complex Nuclear subunits Mitochondrial subunits Total subunits 
I 39 7  (ND1 – 6, ND4L) 46 
II 4 0 4 
III 10 1 (CYB) 11 
IV 10 3 (COX I –III) 13 
V 14 2 (ATPase 6 and 8) 16 
ND: NADH-dehydrogenase, CYB: cytochrome-b, COX: cytochrome oxidase. ND 1-6 are genes from the leading 





Figure 2.2  Schematic presentation of the electron transport chain.  
NADH and FADH convey its electrons to complex I and II respectively, in the genes involved in electron transport 
chain. Coenzyme Q (CoQ) and cytochrome c carries electrons from between complexes I and IV and free energy is 
generated as electrons are transferred which is used to pump protons from the matrix to the intermembrane space. A 
proton gradient across the inner membrane is established and the energy stored is used to drive ATP synthesis as 
protons flow back to the matrix through complex V. Adapted from DiMauro and Schon 2003 [8] 
 
 
Most of the genes involved in the mitochondrial complex are coded for by mitochondrial DNA. 
Mitochondrial DNA has no protective histones, and is exposed to harmful reactive oxygen 
species (ROS) that are generated as by-product of oxidative phosphorylation (OXPHOS) during 
ATP production. Mitochondrial DNA therefore has a higher rate of spontaneous mutations than 
nuclear DNA [10,11]. The reactive oxygen species  include superoxide (O2
-
  ), hydrogen peroxide 
(H2O2) and the hydroxyl free radical (
•














I and II may leak into the matrix and react with oxygen to form superoxide which is 
disproportionated by the mitochondrial superoxide dismutase (Mn-SOD) to hydrogen peroxide 
[11,12]. The hydrogen peroxide is further reduced to water by glutathione peroxidase. In the 
presence of transition metals, iron (II) ion (Fe
2+
) and copper (II) ion (Cu
2+
), hydrogen peroxide 
can be converted to reactive hydroxyl radical (
•
OH) [10,12]. Accumulation of these reactive 
oxygen species in the cell may cause damage to mtDNA, cellular proteins, lipids, nucleic acids 
and also may inhibit iron sulfur (Fe-S) centres of Electron Transport Chain (ETC) complexes I, 
II, and III, and Krebs cycle aconitase, resulting in a shutdown of mitochondrial energy 
production [10,12]. The reactive oxygen species peroxidizes lipids in the mitochondrial and 
cellular membranes increasing their permeability [10,11]. Damage to mitochondrial proteins, for 
example polymerase gamma, may result in deletions, rearrangements, and other mutations in 
mtDNA [10,11].  
 
In addition to energy production, mitochondrial are also involved in other biochemical processes 
including calcium storage and mobilization, ammonia detoxification via the urea cycle, 
apoptosis, recycling and decomposition of carbohydrates and fats [13]. Unlike nuclear DNA, all 
mtDNA is maternally inherited. 
 
 
2.2.  Mitochondrial genetics and inheritance 
In Mendelian genetics, the emerging single cell embryo from the union of egg and sperm 
contains equal matching sets of chromosomes from mother and father. During replication the cell 
duplicates its chromosomes, so that each daughter cell receives equal numbers of paternal and 
maternal chromosomes. The result is that each cell in the body will carry identical genes and 
identical mutations. In contrast, the mtDNA is maternally inherited, the mtDNA in sperm cells 
are present at the base of the tail which is usually degraded and lost during fertilization. 
Therefore a woman carrying mtDNA mutations will pass these on to all her children and only her 
daughters will transmit them to their offspring  [14,15]. The result is that each cell in the body 
will carry identical mtDNA genes and identical mutations. However mtDNA may exhibit both 















2.3.  Heteroplasmy  
Most of the diseases caused by mtDNA mutations that are inherited have a wide tissue 
distribution [16]. However further mutations can accumulate either in mitochondrial molecules 
in a single cell or particular tissue during a person‘s life time [8]. Accumulation of mutations 
may have detrimental effects over time, affecting some of the processes catalyzed by 
mitochondrial derived genes [10]. Unlike nuclear DNA (nDNA), mtDNA may exhibit different 
genotypes (mutant gene coexists with wild type) in the same cell, a term referred to as 
heteroplasmy [8,17].  The condition in which only wild type mtDNA is observed in the cells, is 
referred to as homoplasmy [8].   
 
Mitochondrial DNA has been used to associate population genealogies as well as determining 
risk of human disease because of  its unique characteristics such as maternal inheritance, lack of 
recombination, high mutation rate and high copy numbers within the cell [2,18,19]. Studies of 
the human mtDNA genome have been carried out by analyzing single nucleotide polymorphisms 
(SNPs). These studies have demonstrated distinct geographical distributions of mtDNA and that 
SNPs patterns can be classified into groups of haplotypes [2,8,18].  
 
2.4.  Genetic variation and human population profiling: role of mtDNA    
Mitochondrial and Y-chromosome DNA variation has been used to define population relatedness 
for a long time. Unlike mtDNA, Y-chromosome DNA variations are morphologically male 
specific. Therefore  the world population has been characterised on the basis of specific 
haplotypes or sets of single nucleotide polymorphisms (SNPs) in the mtDNA called haplogroups 
[18]. There are many haplogroups including A, C, H, J, T, M and V representing different human 
populations [19]. Mitochondrial DNA lineage termed L geographically characterises African 
populations [18]. Haplogroup L has been divided into two branches, L0 and L1-6 [20]. 
Furthermore these haplogroups are differentiated into subhaplogroups, [19,21] and L0 comprises 
of five branches of L0a, L0b, L0d, L0f and L0k. The distribution and frequencies of these L 
subhaplogoups within Africa is structured around geographic areas and ethnic groups [19,21]. 
According to Anderson-Mann [22] the distribution frequencies of subhaplogroups across Africa 
varies (Figure 2.3). For example, the frequency of haplogroup L0 is more than 90% in the 














who have similar origin [23]. Subhaplogroup L0a is believed to have originated in Eastern Africa 
and is common in eastern, central, and southeastern Africa, but is hardly found  in northern, 
western, and southern Africa [24]. L0d and L0k are found almost universally among southern 
African Khoisan (SAK) speakers, although a recent study indicates that L0k is also found in the 
Southeast African population while haplogroup L0d is also present among the Turkana of Kenya 
and populations in Mozambique [24,25,26]. Despite being confined to the Khoisan, studies have 
shown that there is no phylogenetic relationship between L0d and L0K haplogroups [27,28]. In 
contrast L0f is relatively rare and is geographically confined to East Africa, mainly in Tanzania 
and Uganda [23,24]. 
 
The L1-6 branches are widespread all over the African continent with L2 being dominant in 
West Africa  [24]. However, recent work has shown that Mozambique in Southeastern Africa has 
42% prevalence of subhaplogroup L2a, compared to 15% among the Tanzania, Kenyan and 
Ugandan Bantu speakers while L2a has a frequency of 38% among non-Bantu speakers in these 
countries [22,26].  This shows that within and between populations subhaplogroup distribution 
can be highly variable, probably due to population dispersal, migration and intermarriages. 
Haplogroup L1 is divided into two subhaplogroups  L1b and L1c with L1b being most frequent 
in West Africa while L1c is common in Central Africa with some presence in Southeastern 
Africa [22,24].  Although L3 is the most frequent haplogroup (34%) in Africa and is the most 
prolific haplogroup in Ethiopia its subhaplogroup L3e is equally distributed between the west 
and east Africa [22,24]. Furthermore L3 haplogroup also gives rise to M and N haplogroups 
sometimes referred to as haplogroups L3M and L3N, respectively. Thus, studies on mtDNA have 
been used to investigate genetic relatedness of sometimes linguistically distinct populations. 
Malawi is one geographical area that has remained understudied with respect to the genetic 

















Figure 2.3: The mtDNA haplogroup L distribution in African populations.  
The haplogroups are not equally distributed with majority of the population haplogroup L3 followed by L2, L0 and 
L1 [22]. L3 derivatives are present in nearly all the African populations mostly in western and eastern/southeastern 
sub-Saharan Africa, particularly among speakers of the Bantu language and is thought to have originated in eastern 
Africa [24] 
 
2.4.1. Bantu migration and the people of Malawi 
Mitochondrial DNA genetic differences between different populations are thought to have come 
mainly as result migration patterns followed by different groups; an example is the migration of 
the Bantu speaking people. It is believed that Bantu-speaking people came from an area around 
northwestern Cameroon/southern Nigeria and spread throughout sub-Saharan Africa [29,30,31]. 
However, before the Bantu expansion, the region is thought to have been inhabited by hunting 
and iron foraging peoples, such as Pygmies from central Africa, proto-Khoisan around the 
Kalahari Desert, Hadza and Sandawe from East Africa and Khoe and San from South Africa and 
Namibia. The people participating in the  Bantu migration split into two routes;  one group 
followed the western route travelling south and roughly following the Atlantic coastline through 
the Democratic Republic of Congo, while the second group moved eastwards and settled near the 
Great Lakes of East Africa (see Figure 2.4) [32,33]. Those following the Eastern Bantu 
migration split into two more groups, with one group travelling along the Ruvuma River toward 
the coast, reaching present-day Natal by the end of the third century A.D., and the other 
travelling along the shores of Lake Malawi, through what is now Eastern Zimbabwe, reaching 


















Figure 2.4: Map of Africa showing the two proposed Bantu speakers migration routes from 
their homeland.  
Adapted from Beleza et al 2005 [32] 
 
Following this migration, the Malawian population is thought to have emerged. The Republic of 
Malawi is located in the Southeast of Africa and its 16 million populations is made up of eight 
major ethnic groups comprised of the following: Chewa/Nyanja (38%, ~ 6 million); Lhomwe 
(18%, ~ 3 million) Yao (13%, ~ 2 million); Ngoni (12%, ~ 2 million); Tumbuka (9%, ~ 1.5 
million); Sena (3.5%, ~ 700 000); Tonga (2%, ~ 300 000);  and Ngonde (1%, ~ 160 000) and 
other small ethnic groups of Bantu speakers as well as a few Asians and Europeans (3.5%, ~ 700 
000) [34,35]. The Chewa tribe (Phiri and Banda clans) of Malawi also known as Nyanja in other 














Luba area known as Malambo in what is now called the Democratic Republic of Congo and is 
one of the tribes which is highly concentrated in the central region [36,37]. Earlier settlement 
shows that the Chewa were the first Bantu speakers to settle in Malawi and established the 
Maravi kingdom in the 16
th
 century [38]. They are concentrated in the central region but also 
show their presence in Chikwawa and Nkhata-Bay districts in southern and northern Malawi 
respectively, which are dominated by other ethnic groups. Generally people identify themselves 
by languages of major tribes in their area of geographical residence [36]. They follow matrilineal 
system and their language (called Chichewa or Chinyanja) is the official language of Malawi.  
 
The Lhomwe people were the last group to have migrated into Malawi from Mozambique in the 
1930s with the majority settling in Thyolo, Mulanje and Phalombe. They are thought to be 
descendants of the Bantu speakers who migrated East from Central Africa [24]. On arrival mixed 
with people whom they found already there, for example Mang‘anja and practice small scale 
farming. They share with the Chewa the culture or practice of matrilineal kinship. Although the 
Lhomwe ethnic group constitutes the second largest ethnic group in Malawi (18% of the total 
population), their language is spoken by a mere 2.4% of the population.  
 
Ngoni is one of the tribes whose distribution is highly dispersed throughout Malawi as they are 
found in all three regions of Malawi and lead to the decline of the Maravi Kingdom. The Malawi 
Ngoni (also referred to as Nguni), are offshoots of the Zulu-Swazi who emigrated from Natal and 
Swaziland in Southern Africa [39,40] and their migration was referred to as mfecane. They 
mainly migrated in two groups; one group moving towards the north and settling in Mzimba 
(northern Malawi) later a group proceeded to Tanzania, while the other group moved southwest 
and settled in Ntcheu (central Malawi) [40]. Later a number of offshoots arose from these groups 
in the nineteenth and early twentieth century and settled in various parts of the country 
(including Dedza, Mchinji, Mwanza, Neno and Thyolo) [41].  
 
Another ethnic group found in Southern Malawi is the Sena whose name derives from a 
Mozambican town of Sena where they are thought to have migrated from. Sena are thought to be 
a group of languages with dialects being Sena, with sub ethnic groups  Makua, Shona, Rabu and 














Chikwawa districts and to a lesser extent in parts of Mwanza and Thyolo highlands which are 
dominated by the current the Chewa, Ngoni and Lhomwe [42].  
 
The Tumbuka people are part of Bantu speakers of Malawi and are mainly found in the northern 
part of Malawi [43] but also in neighboring countries such as Zambia and Tanzania [37]. 
Tumbuka is spoken in Zambia by the Senga, Fungwe and Yombe ethnic groups [44].  They form 
the major ethnic groups of the Northern region of Malawi and there are an increasing number of 
Tumbuka women within Ngoni society because of intermarriages. The Tonga is another tribe 
which is found in the Northern part of Malawi and their language is known as Chitonga. While 
traditionally the Tumbuka are agriculturists, the Tonga are fishermen. Like the northern Ngoni 
and Sena, Tumbuka and Tonga practice patrilineal descent. 
 
Yao is the third largest ethnic group and are widely distributed in the southern part of Malawi, 
originating from northern Mozambique and parts of Tanzania [37,45]. They migrated in two 
different groups, the Mangochi Yao who settled in Chiradzulu, Blantyre, Zomba and Mulanje 
districts, and the Machinga Yao settled in the Mangochi, Machinga and Liwonde and they hardly 
mixed [45]. The latter group established themselves as fishermen due to their proximity to the 
lake and was the first people to be agents of Arabs during slave trade.  They assimilated the 
Chewa practice of matrilineal lineage. Despite political boundaries, it has proven difficult to 
distinguish the Malawian population by language. Considering the main groups of African 
languages Afro-asiatic, Niger-Congo, Nilo-Saharan, and Khoisan, Malawian Bantus are related 
to other groups within the African populations found in Southern Africa. Despite language 
relatedness with other African populations, their lineage based on the mtDNA haplogroup is not 
known. 
 
Mitochondrial DNA haplogroup and sub-haplogroup distribution in Africa has been used for 
unraveling demographic phenomena that contributed to the settlement of ethnic groups over the 
continent. However, little is known about population and ethnic characteristics in relation to 
haplogroups of Southeast African countries, for instance Malawi, Zambia and Zimbabwe 
[25,46]. It is important to describe the phylogeography of the Malawian population in the context 














within Southeastern Africa. Furthermore, researchers have also embarked on human genetics 
studies in order to unveil population mtDNA haplogroup dispersions with the aim of 
understanding haplogroups or subhaplogroups that may be associated with differential 
susceptibility to disease or poor response to treatment at individual as well as population levels, 
therefore more data is required, especially from Africa. 
 
2.5.  Mitochondrial Mutations and Diseases  
Mitochondrial diseases have been related to molecular defects in human mtDNA determined by 
a set of factors including mutations acquired or inherited, either in mitochondrial DNA or in 
nuclear genes that code for mitochondrial components [47,48]. In additio , adverse effects of 
drugs, infections and other or environmental factors may result in mitochondrial dysfunction 
[47,48]. Disorders may either affect only a single organ (e.g. the eye in Leber hereditary optic 
neuropathy [LHON]) or may involve multiple organ systems and present with prominent 
neurologic and myopathic features irrespective of age. Disease prevalence ranges between 1:8 
500 – 1:39 000 in Europeans [49]. The more common clinical syndromes associated with 
mitochondrial disorders, include the Kearns-Sayre syndrome (KSS), chronic progressive external 
ophthalmoplegia (CPEO), mitochondrial encephalomyopathy with lactic acidosis and stroke-like 
episodes (MELAS), myoclonic epilepsy with ragged-red fibers (MERRF), neurogenic weakness 
with ataxia and retinitis pigmentosa (NARP), and Leigh syndrome (LS) with 11.5:100 000 
prevalence of all mitochondrial diseases in both adults and children  [8,15,50]. Furthermore,  the 
characteristic features of the disorders could be categorized as either neurological or systemic 
[51]. An example of a systemic manifestation is lactic acidosis and of a neurological disorder is 
Kearns-Sayre syndromes both of which are associated with dysfunction of the mitochondrial 
respiratory chain [51]. A unique characteristic of mitochondrial diseases is that the same mtDNA 
mutation can produce quite different phenotypes (genocopies of mitochondrial disease), and 
different mutations can produce similar phenotypes (phenocopies of mitochondria disease) hence 
patients are classified by mtDNA genetic defect rather than by clinical manifestation [2,48].  
 
Phenotypic expression in relation to mitochondrial disorders depends on the molecular and 
genetic features of the mutation, its tissue distribution and the relative dependence of each organ 














tRNA (Leu(uur)) gene which is associated with either maternally inherited diabetes and deafness 
(MIDD) or chronic progressive external opthalmoplegia (CPEO) characterised by a limitation of 
eye movement, ptosis, and muscle weakness [53,54]. It has been reported that the tRNA 
(Leu(uur)) gene variant m.A3243G causes dysfunction of β cells in the pancreas that impairs 
insulin secretion in response to an increase in the glucose level, a situation which may lead to 
development of hyperglycemia [55,56]. In another study, high mutation load of the same variant 
in the skeletal muscle compared to blood was found to be associated with myopathy [57]. 
 
Leigh syndrome is a mitochondria disease associated with symmetrical magnetic resonance 
imaging (MRI) abnormalities in the brain stem, cerebellum, basal ganglia mostly accompanied 
with increased lactic acid level either in the blood or cerebrospinal fluid. It is thought to be 
caused by mutations in the NADH dehydrogenase but similar signs and symptoms may also 
occur with mutations in COX III, ATPase 6, and certain tRNA genes [58]. An example is the 
ATPase 6 T8993G mutation, which may present maternally inherited Leigh syndrome (MILS) or 
as neuropathy, ataxia and retinitis pigmentosa (NARP) depending on whether the proportion of 
mutated mtDNA is more than 90% or 70-90% of the total cell mtDNA, respectively, [59]. The 
mutation leads to the change in the amino acid leucine to proline which decreases the flow of 
hydrogen protons through ATP synthase protein complex by 30% [60]. Another relatively 
common mitochondrial disease is the Leber‘s hereditary optic neuropathy (LHON) which is 
characterised by the bilateral loss of central vision, caused by atrophy of the optic nerve. It 
normally only affects vision, but in some instances there are also cardiac conduction 
complications, peripheral neuropathy and cerebellar ataxia. The disease is associated with the 
mutations m.G3460A, m.G11778A and m.T14484C found in ND2, ND4 and ND6 genes, 
respectively, which make up complex I [61,62,63,64].  A mutation at position m.G11778A in the 
NADH dehydrogenase gene is considered as the primary pathogenic and is responsible for 50% 
of cases and also causes the most severe form of the disease that involves cardiac pre-excitation 
syndrome [50,61]. The m.G14459A mutation has been suggested to alter the coenzyme Q 
binding site of complex I by reducing the protein activity [65]. Mutations in the genes coding for 
rRNAs and tRNAs are also associated with disease, for example the syndrome of mitochondrial 
encephalo-myopathy with lactic acidosis and cerebrovascular accident episodes (MELAS) is 














leucine 1 [50,66,67,68,69]. The frequencies of these mutations in different populations are 
poorly characterised. 
 
2.5.1. Mitochondrial diseases and the risk of neurodegeneration with infections 
Mitochondrial disorders also underlies sensorineural hearing loss/aminoglycoside induced 
deafness (SNHL/DEAF) [70]. Upper respiratory tract infections were observed to trigger the 
hearing loss and neurodegenerative episodes in patients with mitochondrial disease [71]. A 
mechanism by which these infections may cause hearing loss in patients with mitochondrial 
disease is not well established.  In addition, cells with mitochondrial mutations are susceptible to 
Legionella pneumophila, an intracellular pathogen that cause Legionnaire‘s disease, a severe 
form of pneumonia [72].  
 
2.5.2. Mitochondrial polymorphisms and risk of metabolic disorders 
Mitochondrial DNA polymorphisms have been implicated in the pathophysiology of several 
metabolic diseases including diabetes and obesity [73]. It has been observed that mitochondrial 
dysfunction in pancreatic beta cells caused by the tRNA (Leu(uur)) gene mutation A3243G on 
the tRNALeu gene usually occurs in the heteroplasmic form. This variant impairs insulin 
secretion in response to an increase of glucose levels, which may lead to development of 
hyperglycemia [55,74]. An increase in insulin secretion is needed to enhance glucose or lipids 
entry into the cells in order to increase the ATP production [74].  
 
On the other hand metabolic disorder (MELAS) may occur in individual carrying mutation 
A3243G in the tRNALyS gene when its heteroplasmy level is more than 85% [47,67]. This 
disease is clinically characterised by generalized convulsions, headaches, deafness, muscle 
weakness, vomiting, loss of appetite, dementia and, at times, red-ripped fibers [67]. Biochemical 
studies have shown that substitution of adenine to guanine has transition effects on the tertiary 
structure of transfer RNA lysine (tRNALys) gene, as well as on methylation, acetylation and 
taurine modification of the anticodon, thus distorting translation [75]. Further investigations have 
revealed that m.T4291C mutations in the mitochondrial tRNA gene are associated with 














risk factor for cardiovascular diseases, including myocardial infarction, stroke, and congestive 
heart failure [76]. Cytidine substitution causes a change in the amino acid and cannot form 
hydrogen bonds  with the other base, therefore the substitution of cytidine for uridine markedly 
impairs ribosome binding which leads to phenotypic consequences [76,77]. Studies have 
demonstrated that stavudine is associated with dyslipidemia in HIV/AIDs patients, but its 
relation to mitochondrial mutations is not well established. 
 
2.5.3. Mitochondrial polymorphisms and drug induced toxicities 
Many mitochondrial clinical symptoms manifest when the bearer is exposed to environmental 
toxins; examples are presented in Table 2.2. Many drugs have been withdrawn from use due to 
mitochondrial associated toxicities (Table 2.2) and some have received black box warning (Table 
2.3). The mechanism by which mitochondria are damaged by medications can be described as 
either direct or indirect. Thus, drugs can directly inhibit the mtDNA transcription or affect the 
activity of enzymes required for any of the steps of glycolysis and oxidative phosphorylation 
[78]. For instance, barbiturates directly inhibit NADH dehydrogenase which is part of complex I 
of the electron transport chain while aspirin affect coenzyme A (CoA) [78]. Other examples are 
aminoglycosides, which includes gentamicin and streptomycin (used for treatment of 
tuberculosis), neomycin and amikacin among others. Pharmacologically they inhibit the 
ribosomal translation hence blocking protein synthesis resulting into inhibition of bacterial 
growth and ultimately killing of bacteria. There are similarities in the structure of the bacterial 
ribosome and the mitochondrial ribosome  residing in all eukaryote cells [79]. Studies in humans 
have shown that patients harboring mutations at m.1555A>G in the m.12SrRNA gene develop 
aminoglycoside-induced hearing loss when exposed to aminoglycoside [80].  
 
Most of the idiosyncratic adverse drug responses due to nucleoside reverse transcriptase 
inhibitors (NRTIs) resemble inherited mitochondrial diseases (i.e. hepatic steatosis, lactic 
acidosis, myopathy, nephrotoxicity, peripheral neuropathy and pancreatitis). Histologic evidence 
demonstrates abnormal mitochondria and/or mtDNA depletion in affected tissues [81,82]. 
Studies have demonstrated that  stavudine is associated with dyslipidemia in HIV/AIDs patients 
[83], but its relation to mitochondrial mutations is not well established. Although NRTI toxicities 














stavudine associated toxicities have been carried in Caucasians where it is no longer used, while 
it is still used in resource poor countries where pharmacogenetic research in this area among 
African populations is limited.  
 
Table 2.2: Drugs withdrawn from the market due mitochondrial toxicity since 1960s   














































Angina and High Blood Pressure 
Antihyperglycemic 
Irritable bowel syndrome (IBS)  
Gastrointestinal Dysmotility 




Attention Deficit Hyperactivity Disorder 
(ADHD) and Narcolepsy 
Attention Deficit Hyperactivity Disorder 
(ADHD) 
Analgesic 
Multiple Sclerosis (MS) 




























Overdose with alcohol 
CNS viral inflammation 
Withdrawn 









































Table 2.3: Drugs receiving black box warnings due to mitochondrial impairment that are  



























































































Lactic acidosis is a reflection of mitochondrial impairment. Modified from Neustadt J and  Pieczenik SR [78]; 
Dyken [89];  Labbea et al [90];   Kakuda TN [82] 
 
2.6.  Stavudine disposition and pharmacokinetics 
Stavudine is an analogue of thymidine, one of the building blocks of deoxyribonucleic acid and 
is a potent, selective, and orally active antiretroviral agent.  The difference between stavudine 
and thymidine is the lack of a 3'-hydroxyl group on the stavudine deoxyribose moiety, thus, 
incorporation of stavudine in a new DNA strand leads to termination of the elongation of the 
strand because the next incoming deoxynucleotide cannot form the next 5'-3' phosphodiester 
bond needed to extend the DNA chain (Figure 2.5). Stavudine is lipophilic and is rapidly 
absorbed with peak plasma concentrations occurring within 1 hour after dosing. The absolute 
bioavailability is between 82 to 99% [91,92]. The prodrug enters the cells by non-facilitated 














active d4Ttriphosphates moiety (d4T-TP) [93,94] as shown in Figure 2.5. The phosphorylated 
NRTIs in the cytoplasm are also transported into the mitochondrial matrix by mitochondrial 
protein carriers which act as deoxynucleotide carriers (DNC) [95]. Phosphorylated molecules in 
the mitochondrial matrix inhibit the activity of mitochondrial polymerase gamma by competing 
with dNTPs for the binding site and then as they get incorporated into the growing DNA strands 
by causing inhibition in the synthesis of mtDNA, thus prematurely terminating chain elongation 
[82,96]. 
 
Phosphorylated stavudine inhibits the activity of HIV-1 reverse transcriptase by competing with 
natural substrates of DNA polymerization, thymidine triphosphates. Thymidine kinase is the 
only rate limiting enzyme, hence the intracellular concentrations of stavudine monophosphates 
(d4T-MP), stavudine diphosphates (d4T-DP) and stavudine triphosphates (d4T-TP) have been 
observed to be similar in vitro. Differences in this rate limiting enzyme may cause variations in 
intracellular stavudine-TP levels [97,98]. The absorption of the parent compound is rapid, and it 
has a terminal elimination half-life of 1.3-1.4 hours but the phosphorylated drug (d4T-TP) has a 
longer half life of around 7 hours [92,99]. The main elimination route is renal, studies have 
shown that about 40% of the parent compound is eliminated unchanged through the kidney [91] 
 
Higher NRTI drug levels have proven to be associated with toxicities [91,94]. In 2006 the World 
Health Organization (WHO) recommended a reduction in dosage of stavudine from 40mg to 
30mg in patients weighing >60 kg (the recommended dose for patients <60 kg was already 
30mg), following reports of reduced  toxicities at the lower dose with retention of efficacy [100]. 
Despite this recommendation, stavudine associated side effects continue to occur in HIV patient 
on the regimen containing stavudine. Nevertheless, data on a minimum recommended dose of 30 
mg/kg/day in relation to intracellular tri-phosphorylated drug levels that retain robust antiviral 
activity while reducing drug related toxicities is limited.  
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Figure 2.5: A comparison of the molecular structures of stavudine (d4T) and thymidine.                
A: stavudine; B, thymidine 
   
2.6.1. Stavudine induced/associated mitochondrial toxicities 
Human organs such as bone marrow, liver, peripheral nerves, muscle, and pancreas, depend 
heavily on oxidative phosphorylation in mitochondria for supplying their energy. These organs 
are at particular risk of toxicity when exposed to NRTIs. There are various suggested 
mechanisms by which stavudine causes mitochondrial toxicities as shown in Figure 2.6 [81]. 
Stavudine is one of the nucleoside reverse transcriptase inhibitor (NRTIs) that lacks a 3'-
hydroxyl group on the deoxyribose moiety  
 
Because of its chemical properties phosphorylated stavudine is transported into the 
mitochondrial matrix and competes with dNTP. Stavudine has been implicated in the 
development of mitochondrial toxicity related adverse effects such as peripheral neuropathy, 
lactic acidosis, pancreatitis, lipoatrophy and hepatic steatosis [101,102,103]. These toxicities are 
believed to be related to defective mitochondrial DNA replication due to the inhibition of the 














polymerase gamma inhibition, mitochondria dysfunction could be the a result of mtDNA 
mutations as well as oxidative stress (an imbalance between reactive oxygen species and 




Figure 2.6: Indicating proposed mechanisms of NRTI mitochondrial toxicity.  
These includes (1) inhibition of polymerase gamma activities which result in mitochondrial DNA depletion; (2) 
getting inserted in the electron transport chain genes which may result in termination of replication of ETC as well 
as cause leakage of the electrons from the system which react with oxygen producing more reactive oxygen species 
(ROS) which in turn damages the mtDNA (electron transport chain I –V)  a consequence which results into 
oxidative phosphorylation failure and lead to ATP depletion; (3,4) interferes with adenylate kinase (AK) and 















2.6.2. Peripheral neuropathy 
Peripheral neuropathy refers to the damage of the peripheral nervous system. It is the most 
common neurological complications  associated with HIV infection, occurring in up to 35% of 
the patients [83,105]. Patients may experience numbness, tingling, and pricking sensations 
(paresthesia), sensitivity to touch, or muscle weakness. Others may suffer more extreme 
symptoms, such as burning pain, muscle wasting, paralysis or organ or gland dysfunction 
(autonomic sensory neuropathy) [106]. These complications may results from HIV infection 
itself or from neurotoxic antiretroviral therapy such as NRTIs [105,107]. It has been clinically 
difficult to distinguish between drug induced and HIV associated neuropathy, although the 
timing of symptom onset may help to differentiate the aetiology [108,109].  
 
2.6.3. HIV associated peripheral neuropathy  
HIV associated peripheral nerve syndrome is an axonal neuropathy that is distal, symmetric, 
painful, and predominantly sensory. The symptoms may differ in different stages of HIV 
infection; and increase with progression of disease [110].  It is also more common in HIV/AIDS 
patients with CD4 count less than 200 X 10
6
/L and HIV RNA >10,000 copies/mL [82,110]. 
HIV-1 viruses found in the brains of AIDS patients are chemokine receptor type 5 (CCR5) 
dependent and macrophage-tropic. The binding of virus on the CCR5 receptor on macrophages 
induces the proliferation of pro-inflammatory cytokine interleukin-1 beta 1 (IL-1β1) in response 
to HIV-1 infection [111]. Studies of the central nervous system have led to the suggestion that 
HIV-1 peripheral neuropathy is mediated by the pro-inflammatory cytokine interleukin-1 beta 
(IL-1β) that is both produced by neurons and macrophages and acts by promoting neurite 
degeneration [111]. Damage to peripheral nerves can interfere with the communication between 
the area it serves and brain, therefore affecting the ability to move certain muscles or feel normal 
sensations. Neurons are heavily energy dependent suggesting that they have the greatest 
concentration of mitochondria [112]. Reports show that mitochondria are found close to the 
terminal neurite membrane, ideally located for supplying energy for membrane mechanisms 














2.6.4. Stavudine associated neuropathy 
Although it is well established that HIV virus infection causes neuropathy, an increase in 
incident cases has been observed since the introduction of antiretroviral therapy, particularly the 
NRTIs [113]. Cui et al [114] showed that stavudine inhibits neurite regeneration, however the 
mechanism by which it induces neurotoxicity is not well established [114]. In support Lake-
Bakaar et al (2001) observed that the NRTIs didanosine (ddI), zidovudine (AZT), zalcitabine 
(ddC) stavudine (d4T), damage the mitochondrial DNA by inhibiting the expression of 
cytochrome c oxidase II and ribosomal RNA suggesting that this could be due to chain 
termination, a possible mechanism of inhibition of mtDNA replication [115]. Recently observed 
polymorphisms in mitochondrial genes have been suggested as possible explanation for 
variations in the response to therapy between individuals [102]. Mitochondrial mutations at 
positions  m.4216T>C, m.4917A>G, m.7028C>T, m.10398G>A, and m.13368G>A in 
mitochondrial haplogroup T have been shown to be associated with increased risk of developing 
peripheral neuropathy in patients on stavudine containing anti-retroviral regimens  [102,116]. 
Mitochondrial DNA variant m.4216T>C, m.4917A>G, and m.10398G>A variants are non-
synonymous resulting in amino acid change in ND1:p.Tyr304His, ND2:p.Asp150Asn and 
ND3:p.Thr114Ala respectively. Variant m.4216C has been suggested to affect the structural 
integrity of complex 1 associated with a decrease in the activity of the enzyme [117]. On the 
contrary, point mutations m.7028C>T and m.13368A>G in the cytochrome C oxidase and ND5 
do not result in amino acid changes. However these polymorphisms in the mitochondrial DNA 
may affect efficiency of oxidative phosphorylation and impair energy production, that may 
trigger the clinical onset of peripheral neuropathy after the exposure to some NRTIs [118]. 
Molecular mechanisms underlying functional differences between mtDNA haplogroups are not 
fully understood. Most studies that have reported polymorphisms related to mtDNA haplogroups 
are not relevant to African populations, as they report non mtDNA L lineage haplogroups 
[102,116,119] except for a study conducted by Canter et al [120].  
 
Although African mtDNA genetics has been studied with the aim of unraveling the demographic 
phenomena that has contributed to the settlement of populations  and ethnic groups on the 
continent, little is known about population mtDNA characteristic in relation to drug toxicities in 














dispersal, migration, consanguinity and other population characteristics of these countries vary 
widely. Therefore, more data is required from African populations to describe mtDNA 
haplogroups and their role in the observed differential response to drug treatment as well as 
emergence of adverse effects.  
 
2.6.5. Mitochondrial polymorphisms and stavudine induced lactic acidosis  
Lactic acidosis is a life threatening metabolic complication that results from overproduction of 
lactic acid [121,122], with increased lactate levels in the blood. A differentiation between severe 
and symptomatic hyperlactatemia has been suggested,  with severe hyperlactatemia being 
defined as lactate levels greater than 5 mmol/L without symptoms or metabolic acidosis; 
symptomatic hyperlactatemia as lactate levels greater than 5.0 mmol/L with symptoms but no 
metabolic acidosis; whereas lactic acidosis is characterised by a lactate level greater than 5.0 
mmol/L, with symptoms and an arterial blood pH <7.35, bicarbonate (HCO3) level of <20 
mmol/L and anion gap >20 mEq/L  [122]. During cellular respiration glycolysis produces lactate 
as the end product of oxygen-independent cellular energy production. In the mitochondrial 
matrix the pyruvate dehydrogenase complex (PDC) controls the accumulation of lactate and 
decarboxylates it into acetyl CoA which is a substrate of the Krebs cycle. The acetyl CoA is 
further metabolized into carbon dioxide and water by the Krebs cycle and oxidative 
phosphorylation [5,7]. Post-translational regulation of pyruvate dehydrogenase complex 
expression is controlled by substrate activation, end point inhibition and reversible 
phosphorylation in which the enzyme is inactivated [123]. In normal physiological conditions 
blood lactate concentration is maintained below 2 mmol/l. However lactate production increases 
when the rate of pyruvate formation in the cytosol exceeds rate of its use by the mitochondria. 
The liver and kidneys play an important role in the metabolism and removal of lactate [124]. 
Hyperlactatemia in normal aerobic conditions is classified as Type B and may indicate excessive 
tissue lactate production and impaired hepatic metabolism attributed to mitochondrial 
dysfunction  [123]. High incidences of hyperlactatemia and lactic acidosis have been observed in 
association with drugs such as stavudine [122]. If mitochondrial function is affected following 
treatment with NRTIs, NADH formation from glycolysis, by way of oxidation of pyruvate via 
the citric acid cycle may be impaired. This results in a shift towards anaerobic oxidation of 














levels are a sign of mitochondrial dysfunction. Abnormal functioning of the mitochondria will 
result into a shift towards anaerobic oxidation of pyruvate by lactate dehydrogenase and the 
formation of lactate which does not contribute to ATP production. Increase in glycolysis induces 
overproduction of lactate, resulting in imbalances in the lactate:pyruvate balance [125]. 
Mitochondrial DNA chain elongation termination results also into impaired β-oxidation of fatty 
acids that lead to accumulation of fat droplets within cells as shown in Figure 2.7 [125,126,127]. 
Despite the wide-spread use of stavudine in first line treatment regimens in many low income 
countries there is limited data about the effect of this drug in African populations. In particular, 
there is no established information on the relationship between mitochondrial polymorphisms 
and the use of nucleoside reverse transcriptase inhibitors lactic acidosis and other toxicities. 
 
Figure 2.7: Mechanisms of nucleoside reverse transcriptase inhibitor (NRTI)-induced lactic 
acidosis.  
NRTIs disrupt -oxidation, the Kreb's cycle and transcription of essential enzymes needed for ATP production by 
inhibiting DNA polymerase-γ; Accumulated triglycerides cause hepatic steatosis; Lactic acid increases more rapidly 














2.6.6. Stavudine induced pancreatitis 
The pancreas is a very important organ in metabolism that releases the hormones, insulin and 
glucagon, as well as digestive enzymes that help in food digestion and absorption. Enzymes 
produced are in an inactive form and only become active in the small intestine. Pancreatitis is 
inflammation of the pancreas where pancreatic enzymes autodigest the gland, a situation which 
occurs when pancreatic enzymes such as trypsin are activated within the pancreas instead of in 
the small intestine. The condition is classified as either acute or chronic pancreatitis. Acute 
pancreatitis is mostly caused by gallstones, alcohol ingestion, infections, for example, HIV, 
trauma and medications, while chronic pancreatitis is commonly associated with increased 
alcohol abuse, hyperparathyroidism and also can be hereditary [128,129,130,131]. Genetic 
defects and depletion of mitochondria are also associated with pancreatic abnormalities [132]. 
Medications such as cortosteroids (e.g. prednisolone), diuretics, anticonvulsant (e.g. valproic 
acid), antihyperglycemic agent (e.g. sitagliptin) and antiretroviral drugs (e.g. nucleoside reverse 
transcriptase inhibitors) can cause pancreatitis [133,134]. Acute pancreatitis is a potentially life-
threatening condition which occurs more frequently in HIV infected patients [131] and may also 
be induced by antiretroviral drugs, particularly stavudine, didanosine and lamivudine [126,135]. 
Suggestive clinical manifestations of pancreatitis include abdominal pain, nausea, vomiting, 
hyperamylasemia with dysglycemia, rising triglycerides, decreasing serum calcium and fever. 
Antiretroviral therapy should be discontinued if clinical pancreatitis develops [135,136]. It has 
been postulated that pancreatitis in HIV patients on treatment could be a result of mitochondrial 
toxicity from the NRTIs [126,136]. The mechanism by which NRTIs cause pancreatitis in 
relation to mitochondrial toxicity is not known. It has been suggested that depletion of 
mitochondrial DNA which result in a drop of ATP production below a certain required threshold 
can lead to tissue and organ malfunction and apparent clinical manifestation [137]. CD4 cell 
count of less than 200 X10
6
 cells/microlitres in AIDS patients on NRTI containing therapy has 
been regarded as a potential confounding factor for pancreatitis [136]. Furthermore, pancreatitis 















2.6.7. Mitochondria dysfunction and stavudine mediated lipodystrophy  
HIV-associated lipodystrophy is a condition characterised by peripheral fat loss especially of the 
limbs, hollowing of the cheeks, and/or flattening of the buttocks (lipoatrophy), or relative 
accumulation of central fat in the abdomen, neck and/or breasts (lipohypertrophy). In HIV-
infected subjects it can be characterised as metabolic abnormalities with peripheral fat loss and 
abdominal fat accumulation; metabolic abnormalities with fat accumulation but without fat loss; 
metabolic abnormalities with fat loss but without fat accumulation; and body shape changes 
[138]. Even though lipoatrophy and lipohypertrophy are influenced by different risk factors and 
occur independently from each other, they coexist [139]. Lipoatrophy syndrome  has been 
associated with nucleoside analogue therapy mainly stavudine [140]. Mitochondrial dysfunction 
in the liver results in the inhibition of fatty acid oxidation, a mechanism which results in 
accumulation of triglycerides and fatty acids in vesicles [125].  
 
Skeletal muscles are one of the tissues with a high energy demand and are affected by 
mitochondria dysfunction. It has been suggested that the mechanism of fat loss depends on the 
activity of adiponectin on adipose tissues [141]. Adiponectin a protein that is secreted 
exclusively by body fat cells, up-regulates insulin activities and energy homeostasis, by 
increasing the insulin level to suppress gluconeogenesis, accelerating the oxidation of 
nonesterified fatty acids by muscles, lowering free fatty acids and plasma triglycerides 
[125,141]. Studies have shown that in patients treated with stavudine, levels of the enzyme 
adiponectin decrease [141]. This decrease accelerates the oxidation of nonesterified fatty acids 
by muscle, lowers circulating fatty acid, reduces the plasma levels of triglycerides and prevents 
lipid accumulation in skeletal muscle and liver which result into fat wasting syndrome called 
lipodystrophy [141]. The pathogenesis of medication induced lipodystrophy is possibly 
associated with adipocyte mtDNA depletion and mitochondrial cell proliferation inhibition 
[142]. That is the NRTIs inhibit the activities of polymerase gamma an enzyme responsible for 
replication of the mtDNA. The interference with the replication mechanism result in depletion of 
mtDNA encoded enzymes and finally leads to mitochondrial dysfunction [137,143,144].  
 
However, phenotype features of lipodystrophy in HIV infected patients receiving antiretroviral 














mtDNA mutations at position mt.8344 A>G  [145,146]. These mutations have been found to 
affect the structure and functional activity of the mtDNA ATPase gene [146]. Similarly, NRTIs 
have been associated with mitochondrial disorder a consequence which results in lipodystrophy 
[147]. The disorder has been common in specific subpopulation who carry the specific mutation 
mt.9055 G>A in the ATP6 gene of mtDNA,  for example,  subpopulations characterised with 
mitochondrial haplogroup K [148]. In two separate studies carried out among European patients, 
enrolled in a Multicenter AIDS cohort study and at the Clinic of Infectious Diseases of the 
Catholic University in Rome, analysis showed that individuals carrying the haplogroup H had 
increased risks of atrophy while those harboring the haplogroup T exhibited decreased risk, 
further confirming that specific subpopulations have different risk profiles in developing 
mitochondrial associated  disorder [119,148]. However, the question of whether mutations in the 
mtDNA are associated with stavudine induced lipodystrophy has n t been fully addressed in 
African populations where a different pattern of mtDNA haplogroups exist which 
characteristically define African populations.  
 
2.7.  Polymerase Gamma (POL-γ) gene  
The nuclear-encoded DNA polymerase gamma (POL-γ) is the enzyme solely responsible for 
replication and repair of mitochondrial DNA [74]. Mitochondrial DNA replication requires the 
combined action of many proteins including mitochondrial single stranded DNA-binding protein 
(mtSSB) which stimulates POL-γ activity and the accessory subunits of DNA polymerase 
gamma that confer processivity [149]. The human POL-γ is a heterotrimer composed of trimeric 
protein complex of a catalytic subunit of 140 kDA referred to as POL-γ and coded from 
chromosome 15q25 and a dimeric accessory subunit of 55 kDa referred to as POL-β whose gene 
is located on chromosome 17q [150]. The catalytic subunit is divided into four active domains; 
 the N-terminal domain (26 -170) which is responsible for stimulating the unwinding 
activity of the DNA. 
 the exonuclease domain (171 - 440) which proof reads and repairs the nascent strand 
 the spacer (476 – 785) where the accessory subunits bind 














POL-γ increases the affinity of nucleotides to the enzyme DNA complex and also enhances 
processivity by simultaneously accelerating the polymerization rate and suppressing exonuclease 
activity which may help maintain the integrity of the replisome at the mitochondrial replication 
forks [74].  
 
2.7.1. POL-γ structure and function 
The POL-γ active site domain conforms to canonical polymerase ―right hand‖ configuration that 
comprises of finger, palm and thumb subdomains important in catalyzing a nucleotidyl transfer 
reaction [74,152]. The palm, which lies between 816-910 and 1096 -1239, is the most conserved 
subdomain [151,153]; It is positively charged, plays an important role in the attraction of the 
domain to the negatively charged DNA backbone. In addition, the magnesium ions within the 
aspartate residue in the domain increases the affinity by forming phosphodiester bonds between 
the 3´- OH end of the growing nascent strand and phosphate groups on the incoming nucleotide. 
The finger binds to the DNA template and incoming dNTPs. In order to release the incoming 
dNTP into the catalytic groove of the palm and bring it into contact with the magnesium ions that 
will enhance the formation of the new phosphodiester bonds. The finger domain changes its 
conformation immediately after the base of the dNTP has been proved to correctly match with 
the corresponding base at the 3´-end of the template [4,152]. Further conformational changes in 
the DNA are due to the significant movement of the thumb sub domain, a residue at 441-445 
polymerase domains. The thumb interacts with the growing DNA strand and helps to keep the 
polymerase on its template DNA, thereby increasing processivity [4,151,152] . 
 
The POL-γ also contains a domain for exonuclease (exo) which is separated by a linker (spacer) 
and is important in repairing replication errors by excision [153,154]. Exonuclease proofreading 
activity exhibits a preference for mismatched rather than matched bases  [155]. The kinetic 
partitioning of polymerase and exonuclease activities determines the selectivity between forward 
polymerization and excision repair [154]. The rate of polymerization for suitable nucleotide over 
the mismatch is nucleotide concentration-dependent such that forward polymerization is fast 
(300 bases/second) compared to the rate of transfer of correctly base-paired DNA from the 
polymerase to the exonuclease active site which is 0.2 bases/second, resulting in low 














added to the polymerization at the 3‘-end, two things may happen; POL- γ may either proceed 
adding the next nucleotide, or may allow the exonuclease activity to remove the newly 
incorporated nucleotide [4,155]. However when a mismatched nucleotide has been inserted there 
is a reduction in forward polymerization activity, while the rate of dNTP transfer to the 
exonuclease active site increases strongly, favouring exonuclease removal [154,156]. Though 
some studies show that the exonuclease activity remains highly active for excision of A> C and 
T>C mispairs even under extreme reaction conditions [155], the exact mechanisms by which 
base mismatches are recognized by the human mitochondrial DNA polymerase remains 
unknown. Johnson et al [167] reported that incorrect nucleotides bind with a tighter affinity than 
the correct indicating that lack of hydrogen bonding may also play an important role in low rate 
of excision [154]. This was supported by Bailey et al [157] who found that polymerase gamma‘s 
binding affinity of a phosphorylated stavudine (d4T-TP) was twofold tighter than for the natural 
substrate 2'-deoxythymidine 5'-triphosphate (dTTP).  
 
The polymerase and exonuclease domains are separated by a spacer or linker region that interacts 
with POL- β. The subdomain comprises of an intrinsic processivity subdomain between amino 
acid residues 475-510 and 571-785 and an accessory interacting determinant subdomain between 
amino acid residues 511-570 which binds to the accessory subunit [158]. The POL-β activity 
through interaction with the spacer subdomain increases holoenzyme processivity and reduces 
fidelity by enhancing the DNA affinity and polymerization rate and at the same time suppressing 
exonuclease activity [159].  
 
It has been postulated that the mechanisms by which the accessory subunit increases processivity 
of the holoenzyme depends on the intrinsic processivity subdomain that contains an area rich in 
positively charged amino acids termed the K tract. When the accessory subunit binds the spacer 
interacting determinant subdomain, it brings up a conformational change which exposes 
positively charged amino acids, that then interact with the template DNA, increasing its contact 
















2.7.2. Polymerase gamma defects and human disease 
Over  160 mutations have been identified in all domains of mitochondrial polymerase gamma 
(MIM 174763; http://www.tools.niehs.nih.gov/polg/) and these mutations have been associated 
with many human diseases [151]. Diseases due to mitochondrial dysfunction are related to 
mitochondrial DNA depletion or deletion disorders both leading inhibition of POL-γ activities 
[74,151,153]. The clinical manifestations of diseases associated with polymerase gamma 
mutations include: sensory ataxia neuropathy with (SANDO) or without ophthalmoplegia; 
autosomal dominant (ad) (adPEO; MIM 157640) and recessive (arPEO; MIM 258450) forms of 
chronic progressive external ophthalmoplegia (CPEO); a mitochondrial neurogastrointestinal 
encephalomyopathy (MNGIE)-like syndrome; and MELAS (mitochondrial encephalomyopathy, 
lactic acidosis, and stroke-like episodes) [151]. A few of the syndromes or disorders with 
mitochondrial DNA mutations as basis are described below.   
 
2.7.2.1. Alpers’ Syndrome 
Alpers‘ Huttenlocher syndrome is an autosomal recessive inherited disease within the group of 
encephalopathy‘s related to progressive degenerative disease of the central nervous system that 
occurs mostly in infants and children due to mutations in the catalytic domains of the POL-γ  
[160]. It is an autosomal recessive disorder that is sometimes seen in siblings and is characterised 
by epilepsy, psychomotor retardation and liver failure that leads to early death [160,161]. The 
most common POL-γ mutations necessary for the disease to manifest are 1399G >A (A467T) 
and 2243G > C (W748S) [161,162]. Disorders associated with polymerase gamma would result 
in damage of  mitochondrial DNA which leads to low ATP production [161]. Likewise drugs 
such as didanosine (ddI; Videx) and stavudine (d4T; Zerit) inhibits mtDNA polymerase gamma 
activities which in turn depletes/damages mtDNA a mechanism which results in liver steatosis 
and enlargement [125]. Whether patients with these mutations are at increased risk when 
exposed to stavudine containing regimen is not known. 
2.7.2.2. POL γ myopathies - Progressive external ophthalmoplegia (PEO) 
Progressive external ophthalmoplegia (PEO) is  an autosomal dominant (adPEO) mitochondrial 
disorder caused by depletion of mitochondrial DNA and/or accumulation of mutations within 














patients may present initial symptoms at almost any age from early childhood to over 70 years. 
PEO is a progressive weakness of the external eye muscles accompanied by proximal limb and 
neck muscle weakness [163]. Interestingly, most of the mutations associated with PEO occur in 
the polymerase domain. This domain is associated with binding of the incoming dNTP and 
increasing polymerization of the mtDNA [4,151,152,163]. Mutations at position 2828G>A and 
2864A>G (R943H and Y955C) in the active site of POLG have been associated with a decrease 
in processivity, increases in nucleotide misinsertion and replication errors increase by 10–100 
fold in the absence of exonucleolytic proofreading [163]. The 3428A>G (E1143G) mutation has 
been found in the region  has been associated with PEO features [163]. Several studies have 
indicated that POL-γ mutations were associated with sporadic mitochondrial disorders, however 
very little information is available on the role POL-γ mutations play in stavudine associated 
toxicities experienced by patients on HIV antiretrovirals treatment.  
 
2.7.3. POL-γ Mutations and NRTI associated toxicities 
Studies have shown that mutations in the active domain of the POL-γ at position 18939C>T 
(2890C>T, R964C) of the gene are associated with hyperlatactemia [164]. The mechanistic 
studies show that these mutations decrease POL-γ catalytic domain activities by 10% [96,164]. 
The mutation 2890C>T decreases the incorporation of the natural substrate by 33% and a 
threefold lower d4TTP discrimination when compared with wild type polymerase, indicating that 
mutations at this position result in loss of selectivity for the natural dTTP substrate [96].  
 
Furthermore, Bailey et al (2009) reported that mutated polymerase gamma‘s binding affinity to 
d4T-TP was stronger for the natural substrate dTTP. The affinity of the incorrect nucleotide is 
stronger compared to wild type resulting in a decrease in rate of excision [154]. Lack of 
hydrogen bonding and inability to remove the incorrect nucleotide will result in mtDNA chain 
elongation termination [154], a mechanism which has been proposed to explain mtDNA 
depletion. In another study it was found that individuals with mutation 3428A>G on amino acid 
E1143G are at high risk of developing lipodystrophy when exposed to stavudine [154,165].  
Although several studies have looked at mutations in POLG and predicted their role in diseases, 
little is known about the role of these mutations in relation to stavudine toxicities such as 














2.8.  AIM  
The aim of this study was therefore, to investigate the extent of genetic variation in mtDNA and 
polymerase gamma among Malawians and to evaluate the effects of the observed variation on 
how HIV/AIDS patients responded to stavudine- containing antiretroviral therapy. 
 
2.9.  Specific Objectives 
 To characterise the Malawi population with respect to mtDNA variation and how this can 
be used to genetically differentiate the different ethnic groups . 
  To evaluate specific mtDNA haplotypes on their effects  on treatment outcome among 
HIV/AIDS patients  using HAART containing stavudine (e.g. effects on immunological 
and virological failure) 
 To correlate the specific mtDNA subhaplogroups are associated with stavudine induced 
metabolic syndromes, such as lipodystrophy and hyperlactatemia and the neurological 
outcome, peripheral neuropathy. 
 To characterise the extent of POL-γ variation among Malawian ethnic groups and 
evaluate if any of the POL-γ variants are associated with stavudine induced toxicities. 
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3. CHAPTER 3: EFFECTS OF STAVUDINE USE AND ITS TREATMENT 
OUTCOMES 
3.1. Materials and Methods 
3.1.1. Participants recruitment 
Unrelated adults were recruited from an HIV/AIDS treatment cohort at Queen Elizabeth Central 
Hospital in Blantyre, Malawi as part of a study to determine factors associated with antiretroviral 
drug toxicities.  Eligibility criteria included the following: 1) participants had to be on stavudine 
containing antiretroviral therapy for at least 6 months and 2) participants had to have 100% 
adherence to therapy in the past three days before entry into the study.  Patients were excluded if 
they were on antituberculosis treatment, pregnant or unable to provide informed consent. All 
completed a structured questionnaire that collected demographic information, medical records as 
well as individuals‘ ancestry up to their grandparent‘s level. The protocol was approved by the 
College of Medicine Research Ethics Committee (COMREC) protocol NO. P.02/10/861, 
University of Malawi and Human Research Ethics Committee University of Cape Town (UCT) 
protocol NO. HREC REF 231/2010. The participants gave written informed consent and the 
study conformed to the declarations of Helsinki 2008. 
 
3.1.2. Clinical measurements 
For all patients, data were collected on the following parameters: patients‘ clinical status at visit, 
and past medical history including any previous ART regimen, potential stavudine related 
clinical complications (including peripheral neuropathy, lipodystrophy, lactic acidosis and 
hypertension). Data were collected using personal interviews, physical examination of the 
participants as well as through an extensive systemic review of medical records. Participants 
with history of peripheral neuropathy that predated the start of ART and those on TB treatment 
were excluded from the study. Peripheral neuropathy due to HAART was based on patients‘ 
presentation with symptoms of numbness or dysesthesia (tingling, and pricking sensations 
(paresthesia), sensitivity to touch, or muscle weakness) after 6 months of initiation of treatment 
as defined according by van Oosterhout [1]. Lipodystrophy was diagnosed based on a 
predetermined case definition. The study questionnaire captured information that combined 














(face, neck, chest, abdomen, arms, legs and buttocks) [2]. The procedure is based on objective 
approach of quantifying the impacts of HAART associated lipodystrophy syndrome (HALS) and 
other lipodystrophy syndromes in Africa settings.  
 
3.1.3. Laboratory measurements 
3.1.3.1. Blood Collection  
Venous blood was collected in three 5 ml ethylenediaminetetraacetic acid (EDTA) coated tubes 
and a plain vacutainer tube labeled for each participants´ identification. The first sample of blood 
collected in the EDTA coated tube was used for CD4 cell count measurement, the second blood 
sample was stored at -20
0
C for genetic analysis (DNA extraction) while the remaining samples in 
EDTA coated tube and plain vacutainer tubes were used for the collection of plasma and serum, 
respectively, aliquoted into 250 µl vials each. Plasma was used for viral load determination while 
serum aliquots were used for blood chemistries (creatinine, triglycerides and cholesterol). 
 
3.1.3.2. CD4 T-cell absolute count  
CD4 receptors are molecules on T-lymphocytes cells that send signals to start the immune 
response that protects the body from infectious invaders such as bacteria and viruses. The normal 
CD4 cell count range for adults is between 500 and 1,500 cells per microliter. HIV/AIDS patients 
CD4 cell count is one of the important parameters to predict how disease is progressing, and 
individuals with CD4 cell count below 200 cells per microliter are at high risk of developing 
opportunistic infections. The absolute CD4 cell count (a measurement of how many functional 
CD4 T-cells is circulating in the blood) was carried on BD FACScount flow cytometer (BD 
Biosciences, CA, USA) within 6 hours of sample collection. Fifty (50 µl) microlitres  of patients 
fresh whole blood from one of the 5 ml EDTA coated tube was mixed and pipetted into each of 
FACSCount fluorochrome-labeled antibodies reagent tubes. The tubes were capped and the 
mixture was vortexed and then incubated in the dark for 60-120 minutes at room temperature 
(20-25° C). Fifty microlitres (50µl) of fixative solution was added into reaction mixture, 
vortexed and further incubated for at least 30 minutes at room temperature (20-25 °C) in the 
dark. The product contents were run on the FACSCount instrument within 2 hours of fixation. 














absolute values. The CD4 T-cell count was computed by the Multiset software (BD Biosciences, 
CA, USA) using the formula: CD4 T cell count = (sample CD4 events/bead events) × (beads per 
test/volume) room temperature (20-25 °C) in the dark.   
 
3.1.3.3. Clinical chemistry parameters (Creatinine, cholesterol, triglycerides and 
lactate) 
Clinical chemistry parameters are important in elucidating the aetiology of chemical and 
biochemical mechanisms of the body in relation to disease. Stavudine has been associated with 
changes in the biochemical levels (such as lactate, triglycerides cholesterol) of the body. 
Although studies have shown that stavudine has not been associated with renal failure, creatinine 
levels were measured in the study participants. Creatinine, triglycerides and cholesterol 
measurements were run on Beckman SYNCHRON CX5 analyzer Pro (Beckman Coulter Inc., 
Massachuessate, USA) following the CX5 protocol manual and reagent insert according to 
College of Medicine - Johns Hopkins laboratories (JHP) laboratories standard operating 
procedures.  
 
Creatinine is generated from muscle metabolism and excreted through the kidney. Creatinine 
levels with normal kidney function results are 0.7 to 1.3 mg/dL for men and 0.6 to 1.1 mg/dL for 
women. Elevated creatinine level signifies impaired kidney function or kidney disease. It has 
been shown that HIV infection and antiretroviral drugs are associated with the abnormal renal 
function [3,4]. Creatinine levels were determined by an end point method where creatinine 
reagents were used to measure the creatinine concentration by the modified rate Jaffé method 
[5]. Five hundred microlitres (0.5 ml) of each freshly drawn serum specimen was pipetted into a 
cuvette. In the reaction, creatinine in the sample combined with picrate in an alkaline solution to 
form a creatinine-picrate complex. The system monitored changes in absorbance at 520nm 
wavelength. Change in absorbance was directly proportional to the concentration of creatinine, in 















Cholesterol is an important in membrane structure as well as being a precursor for the steroid 
hormones and bile acid and is synthesized in the liver from acetyl-CoA. It is categorized as 
low density lipoprotein (LDL) cholesterol which is transported from liver to the cell and high 
density lipoprotein (HDL) cholesterol which is transported from cell to liver. Low density 
lipoprotein cholesterol is also referred to as bad cholesterol because it turns to accumulate in 
the artery when in excess causing atherosclerosis. According to US National Cholesterol 
Education Program (NCEP) the normal values of cholesterol are as follows; total cholesterol = 
<5.1 mmol/L,  LDL = <2.6 mmol/L and HDL = <1.0 mmol/L. Cholesterol levels were 
quantified from serum by use of cholesterol reagent, in conjunction with SYNCHRON CX
®
 
System(s) and SYNCHRON CX MULTI™ Calibrator. Five hundred microlitres (0.5 ml) of 
each freshly drawn serum specimen was pipetted into a cuvette and the SYNCHRON CX
®
 
System(s) automatically proportioned the appropriate sample and reagent volumes in the ratio 
of one part sample to 100 parts reagent. In the reaction, cholesterol esterase (CE) hydrolyzes 
cholesterol esters to free cholesterol and fatty acids which were further oxidized to cholestene-
3-one and hydrogen peroxide by cholesterol oxidase (CO). Furthermore the enzyme 
peroxidase catalysed hydrogen peroxide reaction with 4-aminoantipyrine (4-AAP) and phenol 
to produce a colored quinoneimine product. The change in absorbance at 520 nanometres was 
directly proportional to the concentration of cholesterol in the sample and values were used by 
the system to calculate and express cholesterol concentration. 
 
Triglycerides and another form of lipids produced as end product of fat digesting and break 
down. An increase in triglyceride levels in the body is mostly associated with being 
overweight and may contribute to atherosclerosis. The normal levels for triglycerides 
according to American Heart Association are 1.7 mmol/L. Drugs such as NRTIs have been 
associated with lipid abnormalities [6]. Total serum triglyceride levels were quantified by use 
of triglyceride reagent, in conjunction with SYNCHRON CX
®
 System(s) and SYNCHRON 
CX MULTI™ Calibrator. Triglyceride measurements are used in the diagnosis of stavudine 
associated lipid metabolic disorder. Lipases in reagent hydrolyzed the sample into glycerol 
and free fatty acids. Five hundred microlitres (0.5ml) of each freshly drawn serum specimen 
was pipetted into a cuvette and the SYNCHRON CX
®
 System(s) automatically proportioned 














reagent. In a sequence of three coupled enzymatic steps using glycerol kinase (GK), 
glycerophosphate oxidase (GPO), and horseradish peroxidase (HPO) catalyzed by peroxidase 
caused the oxidative coupling of 3,5-dichloro-2-hydroxybenzenesulfonic acid (DHBS) with 4-
aminoantipyrine to form a red quinoneimine dye. The intensity of the color produced was 
directly proportional to the concentration of triglycerides in the sample when measured at 520 
nanometre. 
 
Glycolysis is a process that involves glucose breakdown to ATP, NADH and pyruvate 
production. Pyruvate is converted to lactic acid under anaerobic conditions, which dissociates 
into lactate molecules and hydrogen H
+
 [7]. An increase in the lactate levels is directly 
proportional to H
+
 (measure of acidosis); therefore, lactate measurement is an indirect indicator 
of acidosis. The normal values of lactate are 0.3 to 1.3 mmol/L [7]. Presence of lactate in the 
blood was measured with the hand-held Lactate ProH (Arkray Europe B.V., Amstelveen, 
Netherlands) at the point-of-care. Patients were rested and checked for dehydration before 
sampling. Lactate levels > 2.5 mmol/L were considered high.  
 
3.1.3.4. Viral Load 
The aim of ART treatment is to reduce HIV viral load and thus stopping progression to AIDS. 
However, there are interindividual variations in the way patients respond to ART. In order to 
determine whether there is treatment success/and or failure in individuals, viral load (number of 
virus per microlitre) is monitored. Treatment success is regarded as decrease in copy number of 
virus to undetectable levels after treatment initiation and failure is defined as continuous increase 
in copy number of virus despite medication a consequence that may lead to disease progression. 
Viral load monitoring was done using the Amplicor HIV Monitor kit version 1.5 (Roche 
Diagnostic
 
Systems, Basel, Switzerland) as adopted by the College of Medicine -Johns Hopkins 
laboratories. The test was an in vitro nucleic acid amplification test for the quantitation of human 
immunodeficiency virus Type – 1 (HIV-) viremia in the plasma with lower limit of
 
detection of 
















The Amplicor HIV-1 monitor test, v 1.5, was based on five major processes:   
1. Specimen preparation 
2. Reverse transcription of target RNA to generate complementary DNA (cDNA) 
3. Polymerase chain reaction (PCR) amplification of target cDNA, using HIV-1 specific 
complementary primers 
4. Hybridization of the amplified products to oligonucleotide probes specific to target(s) 
5. Detection of probe bound amplified products by calorimetric determination. 
 
The test allowed reverse transcription, amplification of HIV-1 and Quantitation Standard (QS) 
RNA reactions to occur simultaneously. The Master Mix reagent contained a biotinylated primer 
pair specific for both HIV-1 and QS target nucleic acid. The quantitation of the virus RNA was 
performed using a Quantitation Standard (QS). The Quantitation Standard was added to each 
specimen at a known copy number and carried throughout the specimen preparation, reverse 
transcription, PCR amplification, hybridization, and detection steps along with the HIV-1 target. 
HIV-1 RNA levels were determined by comparing the absorbance of the specimen to the 
absorbance obtained for the QS. 
 
A. Specimen preparation 
Two hundred microlitres (200 µL) each of patient plasma prepared from blood that had been 
collected into EDTA-containing tubes was added to appropriately labeled tubes containing 600 
µL standard working lysis reagent mixed with quantitation standard (QS). The tubes were 
capped and vortexed for 3-5 seconds. Specimen and control tubes were incubated for 10 
minutes at room temperature. 800 µL of 100% isopropyl alcohol (at room temperature) were 
added to each specimen and control reactions and vortexed for 3-5 seconds. Each tube was 
marked with an orientation mark and micro centrifuged at maximum speed of 12,500 x g for 15 
minutes at room temperature with the orientation marks facing outward, so that the pellets 
aligned with the orientation marks. The supernatant from each tube was discarded and 1.0 mL 
of room temperature 70% ethanol t) was added and tubes vortexed for 3-5 seconds. Tubes were 
micro centrifuged still with the orientation marks facing outward for 5 minutes at maximum 
speed of 12,500 x g at room temperature. The supernatant was discarded, and 400 µL HIV-1 














B. Reverse transcription of target RNA to generate complementary DNA (cDNA) 
Reverse transcription followed within 2 hours of the specimen preparation. It started with master 
mix preparation of 100 μl of AMPLICOR HIV-1 MONITOR manganese solution added to 
AMPLICOR HIV-1 MONITOR Master Mix and the mixture was stored at 2 - 8°C prior and use. 
Using a pipette with aerosol barrier or positive displacement tip, 50 µL of each processed 
specimen and control were added to the reaction tubes containing 50 µL working master mix.  
The tubes were capped and sealed using the MicroAmp cap installing tool. 
 
C. Reverse transcription and amplification – post- amplification/detection  
The samples were amplified by GeneAmp 9600 thermal cycler (Applied Biosystem, California, 
USA) under the following conditions: The initial denaturation step was set at  50°C for 2 
minutes, followed by 60°C incubation for 30 minutes, 8 cycles of incubation at 95°C for 10 
seconds, 52°C for 10 seconds and 72°C at for 10 seconds, further 23 cycles of incubation at 90°C 
for 10 seconds, 55°C for 10 seconds and 72°C for 10 seconds, annealing and extension 
temperatures respectively, with a final extension at 72°C for 5 minutes  
 
D. Hybridization reaction  
In order for the amplicon to form single stranded DNA, 100 µL of monitor denaturation solution 
1 was added to each amplicon tube. Following the denaturation, aliquots were added to separate 
wells of a microwell plate coated with HIV-1 specific (SK102) and QS-specific (CP35) 
oligonucleotide probes. HIV-1 and QS amplicons were bound to microwell plate probes by 
hybridization. The amplicon was left at room temperature for detection within 2hrs.  
 
E. Detection of HIV post amplification  
 The detection stage started with preparation of working wash solution. The 10X wash buffer 
was diluted with distilled water at the ratio of 1:10. One hundred microlitres (100 µL) of 
monitoring hybridization buffer was pipetted into each micro well plate with rows labeled A to 
H. The 25 µL of denatured amplicons to the HIV-1 were added to row A of the detection plate 
which was followed with mixing, and 5-fold serial dilutions were made in the HIV-1 wells in 














with final 25 µL discard.  Twenty-five microlitres (25 µL) of denatured amplicon was added and 
mixed to the quantitative standard wells in row G and 25μl was transfered from row G to row H 
mixed, then same amount was removed from row H and discarded. The plates were washed with 
working wash solution, using an automated ELx50 Microplate Strip Washer, (BioTek; Winooski, 
U.S).  The plates were dried and then 100 µL of avidin horseradish peroxidase (AV-HRP) was 
added, the reactions were incubated for 15 minutes at 37°C. After a second wash, 100μl of 
working substrate solution was added to the amplicons. The working substrate solution was 
prepared by mixing 12 ml substrate A and 3 ml substrate B. Stop solution (100μl) was added to 
the amplicon reaction and measured at optical density (OD) of 450 nm and recorded by Stat 
Fax® 3200 Microplate Reader, (Diagnostic Automation/Cortez Diagnostics, Inc. California, 
USA).  
 
3.2.  Results 
This section will start with a description of the studied opulation, followed by demographic 
characteristics. The next section will describe the medical characteristics of the participants and 
their clinical outcomes. Finally the clinical outcome between groups will be compared. 
 
3.2.1. Population Description and demographics 
Two hundred and fifteen (n = 215) adult participants were enrolled in this study and all were on a 
stavudine containing antiretroviral therapy (ART) regimen. Participants were Malawian Bantu 
speakers from seven ethnic groups (Chewa, Lhomwe, Ngoni, Sena, Tonga, Tumbuka and Yao) 
maternally unrelated (according to family-history information) as shown in Figure 3.1. One 
hundred and thirty two (61%) were women with mean age of 38 years. Participants were grouped 
into young adults (range = 22 - 40 years) and older adults (range = 41- 69 years) with median age 
of 40 (IQR = 32 – 46). Young adults were the most frequent (n = 123; 57%) of participants than 
older adult. Significant differences were observed between ages of women median age of 36 
(IQR = 30 – 46) years and men median age of 39 (IQR = 34 – 48) years P = 0.027. Women were 
shorter (median = 158 cm; IQR = 152 – 158 cm) than men (median = 163 cm; IQR = 159 – 163 
cm) P = 0.001. There was no difference in weight between women (median = 57.2kg; IQR = 














index (BMI) of participants was 23 (IQR = 21 – 25) kg/m
2
 with 20% of them having body mass 
index above the normal range of 25 kg/m
2
. Median BMI for women, (23.2; IQR = 21- 25) kg/m
2
 
was significantly higher (P = 0.006) when compared to that of men (22.2; IQR = 20.57 – 23.75) 
kg/m
2
. There was no difference in BMI between age groups (P = 0.974). Two (1%) patients had 





, respectively. Figure 3.1 shows the ethnic 







  Figure 3.1: Ethnic distribution of the study participants 
 
3.2.2. Participants medical characteristics 
All participants were on stavudine containing antiretroviral therapy regimen for median duration 
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alcoholics respectively. Participants were on cotrimoxazole prophylaxis; 10%, 3%, 2% and 1% 
were also on antihypertensive drugs (nifedipine, hydrochlorothiazide, ACE inhibitors), 
amitriptyline, pyridoxine and fluconazole, respectively. Triglycerides and lactate did not show 
any difference between different women and men. In contrast cholesterol levels were 
significantly higher in women than men (P = 0.013). However, in a separate analysis total 
cholesterol levels (>5mmol/L) were not associated with low BMI (BMI <18.5kg/m
2
 = OR, 1.62, 
95% CI, 0.18 – 19.11; P = 0.699) or high BMI (BMI >25kg/m
2
 = OR, 2.53; 95% CI, 0.81 – 7.87; 
P = 0.109). Accordingly no differences were observed between body mass index with 
triglycerides levels (OR, 4.33; 95% CI, 0.83 – 13.86; P = 0.089). Table 3.1 provides detailed 



































Table 3.1: Patients demographic and clinical characteristics. 
Phenotypes Male (%) Female (%) Total P-Value 
Age     
<40   44 (0.53)   79 (0.60) 123 (0.57) 0.324 
≥40   39 (0.47)   53 (0.40)   92 (0.43)  




    
  68 (0.82) 112 (0.85) 180 (0.84) 0.833 
  10 (0.12)   14 (0.11)   24 (0.11)  
    5 (0.06)     6 (0.04)   11 (0.05)  
CD4 (cells/µL) 292 (157 – 436) 392 (297 – 534) 344 (227 – 489) 0.001 
Missing      4 (0.05)      6 (0.05)    10 (0.05)  
BMI categories     
Underweight (<18.5 kg/m
2
)      5 (0.06)      1 (0.01)      6 (0.03) 0.001 
Normal (18-25 kg/m
2
)     66 (0.79)  100 (0.76)  166 (0.77)   
Overweight (>25 kg/m
2
)    12 (0.14)    30 (0.23)    42 (0.20)  0.089 
eGFR categories (ml/min)     
≥90    77 (.93)  112 (0.85)  189 (0.88) 0.133 
60- 89      1 (0.01)    12 (0.09)    13 (0.06)  
30 - 59      0 (0)      1 (0.01)      1 (0.01)  
15- 29      1 (0.01)      0 (0)      1 (0.01)  
<15      0 (0)      1 (0.01)        1 (0.01)  
Missing      4 ( 0.05)      6 (0.05)    10 (0.055)  




    
    26 (0.70)    48 (0.75)   74 (0.73) 0.534 
      8 (0.22) 
      3 (0.08) 
   13 (0.20) 
     3 (0.05) 
   21 (0.21) 
     6 (0.06) 
 
Cholesterol (IQR) mmol/L 3.55 (3.03 – 4.87) 4.53 (3.52 – 5.06) 4.19 (3.3-5.03) 0.031 
Triglycerides (IQR) mmol/L 0.96 (0.64 – 1.29) 1.05 (0.67 – 1..36) 0.97 (0.65 – 1.35) 0.296 
Current smokers     
Yes       2 (0.02)        0 (0.0)       2 (0.09) 0.788 
No     81 (0.98)    132 (100)   213 (0.99)  
Current alcoholic     
Yes       2 (0.02)       4 (0.03)        6 (0.03) 0.073 
No     81 (0.98)   128 (0.97)    209 (0.97)  
Toxicities     
Peripheral Neuropathy     
Yes      24 (0.29)     29 (0.22)      53 (0.25) 0.250 




    
      6 (0.14)     13 (0.11)      19 (0.16) 0.554 




    
      0 (0)       1 (0.76)        1 (0.47) 0.427 
    83 (100)   131 (99.24)    214 (99.53)  
Pancreatitis       0    0      0  















3.2.3. Participants´ Clinical measurements 
3.2.3.1. Patients’ clinical-immunological outcomes  
The median CD4 cell count for 205 individuals was 344 (IQR = 227 – 489). Men were more 
likely to have lower CD4 cell count compared to women (P = 001).The median CD4 cell count 
for women was 392 (IQR = 297 – 534) cells/µL while median CD4 cell count of men was 292 
(IQR = 157 – 436) cells/µL. Forty seven percent (n = 101) of the participants had CD4 cell count 
above 350 cells/µL; 49% (n = 105) had CD4 cell count of less than 350 cells/µL and 4% (n = 10) 
had missing data. 
 
3.2.3.2. Patients’ clinical-virological outcomes  
The median viral load was 202 copies/ ml (IQR 146 – 268) and virological responses between 
women and men were not different (P = 0.766). The majority of participants had undetectable 
viral load (n = 181; 84%) at a cutoff point of 400 copies/ml while 24 (11%) detectable viral load 
(above 400 copies/ml) at the time of the study. Viral load above 10 000 copies/ml was observed 
in seven (3.26%) of patients. Viral load data was missing on 5% (11/215) of the recruited 
participants. Table 3.2 provides detailed viral distribution of levels among participants. 
 
Table 3.2  Distribution of viral load levels (copies/ml) among patients in our study 
Viral Load (copies/ml) N (%) Frequency (%) Cumulative (%) 95% CI 
2 – 400 181 84.19 84.19 0.050 - 0 .129 
>400 – 1000 5 2.33 86.51 0.008 – 0.053 
>1000 – 5000 7 3.26 89.77 0.013 – 0.066 
>5000 – 10000 4 1.86 91.63 0.005 – 0.047 
>10000 7 3.26 94.88 0.013 – 0.066 
Missed 11 5.12 100  

















3.2.3.3. Participants drug associated toxicities 
Stavudine induced adverse reactions, such as peripheral neuropathy and lipodystrophy, were 
reported in 30% (n = 65) of the patients. The commonest toxicity was peripheral neuropathy 
elicited in 25% (53/215) of the study population, followed by lipodystrophy 16% (19/117). Only 
113 patients had their lactate levels investigated and of these 17% (n = 19) had high lactate levels 
(>2.5 mmol/L). 
 
3.2.3.3.1. Peripheral neuropathy 
Twenty five percent (53/215) of participants presented with peripheral neuropathy and 29 (13%) 
of them were women. There was no significant difference (P = 0.250) observed between men 
and women with regard to peripheral neuropathy. No differences in CD4 cell count between 
those presenting with and without peripheral neuropathy (n = 205; P = 0.880). Likewise 
virologic response (above or below 400 copies/ml) between participants presenting with and 
without peripheral neuropathy was not different. The duration on treatment was not different in 
participants presenting and not presenting peripheral neuropathy. Although being over > 40 years 
of age was associated with increased risk of developing peripheral neuropathy (OR, 1.90; 95%, 
CI 1.01 – 3.55; P = 0.045) in a univariate analysis, this observation was not reflected in the 
multivariate analysis (OR, 1.90, 95%, CI 0.96 – 3.73); P = 0.064). Height (median 159cm) 
showed a trend towards reduced risk of developing peripheral neuropathy (OR, 0.96; 95% CI, 
0.93 -1.00; P = 0.058) in the study. Further results are presented in chapter 5. 
 
3.2.3.3.2. Lipodystrophy 
Only 117 of the 215 participants had their lipodystrophy measured or evaluated, of which 62% 
(n=73) were women. Sixteen percent of the 117 participants (n=19) presented with 
lipodystrophy. There was no difference in the duration time on treatment between participants 
presenting lipodystrophy and those without lipodystrophy (P = 0.229). However older (>40 
years) participants were more likely to present with lipodystrophy compared to those less than 40 
years with significance of (P = 0.017). Total median body mass index (BMI) of participants was 
24 (IQR = 24- 25) kg/m
2
 and no significant differences were observed in BMI between 














further classification of body mass index according WHO categories of underweight, normal and 
above normal, it was observed that 3 (12%) participants with lipodystrophy had  BMI above the 
normal range of 25 kg/m
2
. Triglycerides and cholesterol were not a risk factor to lipodystrophy. 
Markers of disease progression CD4 cell count and viral load were not associated with 
lipodystrophy. In a multivariate analysis, older age was associated with increased risk of 
developing lipodystrophy (OR, 3.73; 95% CI, 1.22 – 11.40; P = 0.021) (Table 3.3). Chapter 6 
provides further results. 
 
Table 3.3: Risk factors for lipodystrophy  
Cholesterol and triglycerides excluded because 26% (n = 30) of the participants did not have the results  
 
3.2.3.3.3. Lactate 
One hundred and thirteen (n = 113, 52%) participants had their lactate levels determined. Using 
Mann Whitney, lactate levels were not different between gender groups. Age was not associated 
with hyperlactatemia (P = 0.480). Metabolic parameters (cholesterol and triglycerides) did not 
show any degree of association with hyperlactatemia with P =0.239 and 0.429 respectively. 
There was no difference in levels of lactate between participants experiencing or not 
experiencing adverse effects such as peripheral neuropathy (P = 0.989), lipodystrophy (P = 
0.627) and hypertension (P = 0.723). Body mass index (BMI) not associated with 
Covariate  Unadjusted  
OR (95% CI) 
P-value Adjusted OR (95% CI) 
 
P-value 
Gender (Female) 1.37 (0.48 – 3.92) 0.484 1.51 (0.46 – 4.96) 0.499 
 















Duration (months) 1.28 (0.86 – 1.91) 0.229 1.17 (0.75 – 1.83) 0.481 
 
Viral Load (CPs/ml) 0.41 (0.0.05 – 3.34) 0.403 0.28 (0.03 – 2.45) 0.253 
 















hyperlactatemia. In addition measure of immunological (P = 0.911) and treatment failure (P = 
0.269) were not associated with increase in lactate levels  
 
3.3.  Discussion  
This part of the study was carried out to evaluate the response of HIV/AIDS participants to 
stavudine containing antiretroviral therapy using immunological markers (CD4 cell count) as 
well as virologic response. We also determined some important, biochemical parameters such as 
cholesterol, triglycerides, lactate levels as well as stavudine associated toxicities including 
peripheral neuropathy and lipodystrophy. 
 
It has been demonstrated in this cross sectional study that stavudine containing antiretroviral 
therapy regimen results in favorable virological and immunological response in a large 
proportion of patients (84% in this case); these outcomes are consistent with findings of other 
studies including our earlier study [1,8,9] . While virological outcomes were similar between 
women and men, it was observed that CD4 cell count was higher in women when compared to 
men with a significant difference of P = 0.001, these results are similar to Kumarasamy et al 
[10]. Women tended to have lower BMIs (< 18.5kg/m
2
) P = 0.001 compared to men.  
 
Stavudine has been associated with metabolic disorder which includes dyslipidemia 
(hypercholesterolemia and/or hypertriglyceridemia), insulin resistance with hyperinsulinaemia 
and hyperlactatemia, kidney failure and liver toxicities [11]. In this cross sectional study we 
found high prevalence of mild hypercholesterolemia especially in women confirming what has 
been shown by others [11], although  the increase in cholesterol levels in this study was mild.  
 
The prevalence of peripheral neuropathy and lipodystrophy in the study, confirms what has been 
established by other studies. Peripheral neuropathy was found in 25% of the study participants 
and was the most common adverse drug effect. This is in line with findings from other studies 
[12,13]. The prevalence of peripheral neuropathy (25%) in the studied population was higher 















Older age has previously been independently associated with peripheral neuropathy [12,16]. 
Although older age appeared significant during univariate analysis, it was not significant in a 
multivariate model after controlling for other clinical parameters. Possibly other confounding 
factors for example height (median height of 159cm) which was observed having a trend towards 
reduced risk of developing peripheral neuropathy could have played a role. Other studies have 
shown that  patients taller than 176cm are at an increased risk of peripheral neuropathy [12,16]. 
In some studies the risk of peripheral neuropathy was associated with malnutrition [17,18], but 
body mass index (BMI) was not associated with risk of developing peripheral neuropathy in this 
study. Good outcome in both CD4 cell counts and viral load suggest that HIV infection itself 
may not be the cause of peripheral neuropathy and strongly point to stavudine-induced toxicity 
as the cause. CD4 counts less than 200 X 10
6
/L and HIV RNA >10,000 copies/mL were found to 
be risk factors for peripheral neuropathy [19,20,21].  
 
The analysis of risk factors for lipodystrophy by gender showed no difference between female 
and male in contrast to a study conducted in Rwanda which showed that the female gender was 
associated with increased risk of stavudine-induced lipodystrophy [8]. Body mass index, CD4 
cell count and viral load parameters were not associated with lipodystrophy. The result could be 
due to the fact that most of the participants had improved clinical response to treatment which 
was indicated by increased CD4 count and low viral load. Metabolic abnormalities such as 
dyslipidemia (increase in triglycerides and cholesterol levels) has been associated with 
lipodystrophy in HIV patients on stavudine containing therapy including our earlier study 
[1,6,11,22], an outcome which was not the same with this study.  
 
Although there was no association between gender and hyperlactatemia, high prevalence of 
hyperlactatemia in women (n = 13; 61%) in this study confirms the previous findings that 
women are more likely to experience hyperlactatemia and lactic acidosis [23]. Unlike our earlier 
study [24] where age, lipodystrophy, higher BMI and peripheral neuropathy, were associated 
with hyperlactatemia in univariate analysis we did not have similar observation in this study. 
Possibly small sample size might have affected the findings as the analysis was based on only 















The findings of this part of the study are limited by its design as well as limited laboratory 
parameters (triglycerides, cholesterol and lactate) as not all participants may have been identified 
in order to establish relationship between clinical parameters and stavudine associated toxicities. 
However, stavudine associated adverse reactions including, peripheral neuropathy, 
lipodystrophy, and lactic acidosis have been associated with mitochondrial dysfunction [25,26]. 
These toxicities are prevalent in specific populations which have specific mutations in the 
mitochondrial DNA. On the other hand, there remains controversy regarding the NRTI 
mitochondrial toxicities in Africans and relatively little is known in regards to polymorphic 
variation of these genes in African population [27]. Detailed information on the stavudine 
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4. CHAPTERS 4:  DIVERSITY OF MTDNA IN THE MALAWIAN POPULATION  
 
Diverse mtDNA subhaplogroups in seven Malawian ethnic groups (submitted to Plos One and 
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 Abstract  
 Introduction: Human population diversity has been characterised mainly on the basis of Y-
chromosome and mitochondrial DNA (mtDNA) variation. With regards to mtDNA variation, 
Sub-Sahara Africa is defined by the mitochondrial lineage L which is further divided into 
haplogroups L0 and L1-6. The distribution of these subhaplogroups is geographically and 
ethnically structured. We aimed to describe the mtDNA variation in seven ethnic groups from 
Malawi, a previously understudied population and draw comparisons with other populations in 
Africa, especially Southern Africa where L0 mtDNA subhaplogroup are deeply-rooted.  
 
Method: Two hundred and fifteen (n=215) Malawian subjects were recruited as part of a study 
that investigated genetic correlates of differential susceptibility and response to highly-reactive 
antiretroviral therapy (HAART) among HIV/AIDS patients. Whole mtDNA coding region was 
sequenced in patients, comprising of Chewa/Nyanja, Lhomwe, Ngoni, Sena, Tonga, Tumbuka 
and Yao and the sequences were aligned with the revised Cambridge reference sequence. A 
phylotree for the seven Malawi ethnic groups was constructed. Molecular indices were measured 
using Arlequin software and the genetic structure of the Malawian ethnic groups was 
investigated using principal component analysis and also compared to other African ethnic 
groups.  
 
Results: The Malawian population presented with 184 haplotypes, resolving into 9 
subhaplogroups with the following frequencies L0a1 (0.06), L0a2 (0.28), L0d (0.07), L0f (0.03), 
L0k (0.04), L1c (0.13), L2a (0.25), L3d (0.02) and L3e (0.12). We report the presence of 
subhaplogroups L0d and L0k that are concentrated in Southern Africa. The Malawian ethnic 
groups correlate well with findings in other Southern African populations with a 48% prevalence 
of haplogroup L0 followed by the L2a (25%), while L3d had the lowest frequency (2%).   
 
Conclusion: This study further confirms the genetic-relatedness of the Bantu linguistic group 
and place Malawian populations more closely with southeast and southern African Bantu 
population groups.  
 















There is no doubt that Sub-Sahara Africa region is home to the earliest lineages of mtDNA. 
Bantu-speaking people migrated from northwestern Cameroon/Southern Nigeria and spread 
throughout Sub-Saharan Africa [1]. Before the Bantu expansion, Sub-Sahara Africa was 
populated by hunting and foraging peoples, such as the Pygmies in central Africa, proto-Khoisan 
around the Kalahari Desert, Hadza and Sandawe in East Africa and Khoe and San in South 
Africa and Namibia [2,3]. The Bantu migration followed two major routes, one group took a 
western route,  travelling south  through what is now the Democratic Republic of Congo (DRC) 
and following the Atlantic coastline [1]. A second group moved eastwards and settled near the 
Great Lakes of East Africa [4,5].  The eastern Bantu went further southwards into two parallel 
directions, one along the Ruvuma river towards the coast, reaching present-day Natal by the end 
of the third century A.D., and another along the shores of Lake Malawi, through what is now 
eastern Zimbabwe, reaching northern Transvaal (current Mpumalanga) around A.D. 500. [5]. 
The Malawian population is believed to have emerged from this last migration.  
 
The Republic of Malawi is located in the southeast of Africa and its 16 million populations is 
made up of eight major ethnic groups comprising the following: Chewa/Nyanja (38%, ~ 6 
million); Lhomwe (18%, ~ 3 million) Yao (13%, ~ 2 million); Ngoni (12%, ~ 2 million); 
Tumbuka (9%, ~ 1.5 million); Sena (3.5%, ~ 700,000); Tonga (2%, ~ 300,000);  and Ngonde 
(1%, ~ 160,000) and other small ethnic groups as well as a few Asians and Europeans (3.5%, ~ 
700,000) [6,7]. Apart from the Asians and Europeans all the ethnic groups belong to the Bantu 
speakers [8]. According to history, the Chewa tribe also known as Nyanja in other countries, 
migrated from the Luba area known as  Malambo in what is now called the Democratic Republic 
of Congo and is one of the tribes which is highly concentrated in the central region [9]. Earlier 
settlement shows that the Chewa were the first Bantu speakers to settle in Malawi where they are 
concentrated in the central region but also show a presence  Chikwawa and in Nkhata-Bay 
districts in southern and northern Malawi, respectively, which are dominated by other ethnic 
groups. Generally people identify themselves by languages of major tribes in their area of 
geographical residence [9]. They follow matrilineality system and their language 
(called Chichewa or Chinyanja) is the official language for Malawi. The Chewa are also found in 














The Lhomwe people migrated into Malawi from Mozambique in the 1930s with the majority 
settling  along the Zambezi province [8]. They are thought to be descendants of the Bantu 
speakers who migrated East from Central Africa [1]. Lhomwe are small scale farmers and 
similar to the Chewa, practice matrilineal kinship. Although the Lhomwe ethnic group 
constitutes the second largest ethnic group in Malawi (18% of the country), their language is 
spoken by a mere 2.4% of the population.  
 
Ngoni is one of the tribes whose distribution is highly dispersed throughout Malawi as shown in 
Figure 1. According to history, the Ngoni ethnic group (also referred to as Nguni) of Malawi, are 
offshoots of  the Zulu-Swazi who emigrated to Natal and Swaziland in Southern Africa [11,12]. 
The name Ngoni was changed from Nguni after crossing Zambezi river and defeating the Shona, 
Thonga and Chewa. They migrated in two groups; one group moving towards the north and 
settling in Mzimba (northern Malawi), while the other group moved southwest and settled in 
Ntcheu (central Malawi) [12]. Later a number of offshoots arose from these groups in the 
nineteenth and early twentieth century and settled in various parts of the country (including 
Dedza, Mchinji, Mwanza, Neno and Thyolo) where their culture and language were assimilated 
by the tribes they found in these areas, for example, the Tumbuka and Chewa [13].  
 
Another ethnic group found in southern Malawi is the Sena whose name derives from a 
Mozambican town of Sena where they are thought to have migrated from. They speak a Bantu 
language referred to as Chisena. The majority of the Sena are found in Nsanje and Chikwawa 
districts and to a lesser extent in parts of Mwanza and Thyolo highlands which are dominated by 
the current the Chewa, Ngoni and Lhomwe [14].  
 
The Tumbuka are part of Bantu people of Malawi and are mainly found in the northern part of 
Malawi [15] and also in neighboring countries such as Zambia and Tanzania [10]. Their primary 
language is called Chitumbuka, and in addition Senga, Fungwe and Yombe of Zambia speak the 
same language as Tumbuka [16]. The Tonga is another tribe which is found in the Northern part 
of Malawi and their language is known as Chitonga. While traditionally the Tumbuka are 
agriculturists, the Tonga are fishermen. Like the northern Ngoni and Sena, Tumbuka and Tonga 














Yao people are widely distributed in the southern part of Malawi, originating from northern 
Mozambique and parts of Tanzania [10]. They established groups of settlements based on fishing 
due to their proximity to the lake and were the first people to be agents of Arabs during slave 
trade. Yao people believe in the matrilineal lineage.  Despite political boundaries, it has proven 
difficult to distinguish the Malawi population by language. 
 
Current efforts to understand population history relies heavily on archaeology and genetic 
characterization of both Y-chromosome and mitochondrial DNA. However, there has been no 
published data and parameter estimation to characterise genetic differences in the mtDNA of the 
Malawian ethnic groups in comparison to other African ethnic groups. Analysis of mtDNA is 
one of the tools available to describe the relatedness, movements and settlements of populations. 
However, populations within Southeast African countries such as Zimbabwe, Malawi and parts 
of Zambia including South Africa and Angola are yet to be fully characterised genetically 
[10,17]. Studies on mitochondrial genetic diversity have until recently been mostly confined to 
East African populations of Uganda, Kenya and Tanzania while from southeast Africa we have 
data only from few studies on Zimbabwean, Mozambican and Zambian ethnic groups 
[1,17,18,19].  
 
The human mtDNA is characterised by distinct lineages or haplogroups. These haplogroups are 
characterised by specific sets of single nucleotide polymorphisms (SNPs) [20]. Many of the 
described haplogroups are characteristic of different populations and/ or ethnic groups [21]. The 
mtDNA L lineage are characteristic of Sub-Sahara African populations [20]. As a result of the 
African population genetic diversity of mtDNA lineage L, it is divided into two branches, L0 and 
L1-6 [22]. These haplogroups are further differentiated into subhaplogroups and the distribution 
and frequency of these subhaplogoups appear to have distinctive patterns in different geographic 
regions or ethnic groups [18,21,23,24]. Furthermore, the L0 haplogroup is divided into L0a, L0d, 
L0f and L0k subhaplogroups with varying frequencies.  For example, over 90% of the Khoisan 
group in South Africa carry the haplogroup L0 with L0k and L0d being dominant while the L0 
haplogroup is found in only 20% of  East Africans [18]. The distribution of  L0 among Southern 
and East African populations  suggest  related origins  and reflects a possible shared migration 














We aimed to describe the phylogenetic relationship, the pattern of diversity and phylogeography 
of seven Malawian ethnic groups with respect to mtDNA variation. Malawi represents an 
important area of the African continent that had not yet been sampled [17]. It is also hoped that a 
better understanding of this diversity could lead to insight into patterns of genetic diseases and 
genetic variations relevant for pharmacokinetic profiles [25].   
 
Materials and Methods 
Participant recruitment and sample collection  
Two hundred and fifteen (n=215) participants comprising of 46 (22%) Chewa (CH), 63(31%) 
Lhomwe (LO), 41(19%) Ngoni (NG), 9(4%) Sena (SE), 10(5%) Tonga (TO), 10(10%) Tumbuka 
(TU), and   36 (16%) Yao (YA) with their origin as indicated on map in Figure 1. All 
participants were unrelated adults recruited from an HIV/AIDS treatment cohort at Queen 
Elizabeth Central Hospital in Blantyre, Malawi, as part of a study to determine factors associated 
with antiretroviral drug toxicities. Participants completed a structured questionnaire that 
collected demographic information, medical history as well as individuals‘ ancestry up to their 
grandparent‘s level. A 5 ml blood sample was collected from each participant for genetic 
analysis. The protocol was approved by the College of Medicine Research Ethics Committee 
(COMREC), University of Malawi and the Human Research Ethics Committee of the University 
of Cape Town (UCT). The participants gave written informed consent.  
 
Whole mitochondrial DNA amplification and sequencing 
Blood samples were collected in EDTA coated tubes and were kept at -20
o
C until DNA 
extraction. DNA was isolated by use of a GenElute Blood Genomic DNA Kit (Sigma-Aldrich, 
ST Louis, US) according to the manufacturer‘s protocol. Whole mitochondrial genome of each 
participant was amplified through a series of  9 partially overlapping fragments using the primers 
according to the method of Ramos et al. [26]. Each time mtDNA templates were amplified in a 
total volume of 25 µl in a reaction mixture that consisted of 1X green GoTaq reaction buffer, 200 
µM of dNTP, 1.0 mM of   MgCl2, 0.4 µmol of each primer, 0.5 U of Taq DNA polymerase and 
20 ng of DNA. The PCR programs each consisted of an initial denaturation step at 94 
o
C for 5 
min, followed by 35 cycles of denaturation at 94
o
C for 1 min, annealing step at 61
 o














extension at 72 
o
C, for 2.5 min respectively, with a final extension step of 5 min at 72 
o
C [26]. 
The quality of the amplified fragments was visualized on a 1.5% agarose gel by electrophoresis. 
PCR products were purified using the Exonuclease and Shrimp Alkaline Phosphatase (ExoSap) 
before sequencing.  The 9 overlapping mtDNA PCR fragmented from each participants, were 
sequenced from position 478 to 15953 (which includes the mtDNA hypervariable segment 3 and 
whole mtDNA coding region) using a series of forward and reverse primers and additional 
internal primers.  The control region of mtDNA was not sequenced.  
 
Mitochondrial DNA variation analysis 
Sequences were aligned with the rCRS for the human mitochondrion NC_012920.1  [27] and 
assembled using Lasergene 10 Core Suite software, DNASTAR package (Madison, Wisconsin 
USA) for mutation scoring [27]. Haplogroups and subhaplogroups were classified according to 
software and data bases developed by of van Oven and Kayser and Accetturo et al [22,28]. 
Network 4.6.1.1[29] was used to construct a phylogenetic network and confirm the grouping of 
haplotypes [30]. Post analysis of median joining network  was carried out using maximum 
parsimony algorithm and the network was redrawn [31] within the software with network 
calculation (epsilon parameter)  set at default 1:1 and transition/transversion ratio of 3:1. The 
parsimony network of haplotypes was reconstructed by hand. Stata® for windows software, 
version SE/11 (Stata corp; Texas, USA) was used to analyze haplogroup and subhaplogroup 
frequencies.  
 
Arlequin 3.5 [32] was used to determine the molecular indices which included gene-diversity, 
haplotype diversity, nucleotide diversity, Tajima‘s D and FU‘s Fs tests within and between 
ethnic groups.  Genetic structure between ethnic groups‘ was calculated based on FST values [33]  
which estimates evolutionary distances between sequences by incorporating information on both 
haplotype frequencies and genetic distances between haplotypes, as the number of nucleotide 
position differences between each pair of sequences and gamma correction of 0.5 using the 
program Arlequin version 3.5 [32]. The distance values were used to construct a Neighbor – 
joining tree using software program in MEGA version 5.2.2 under the Tamura and Nei 














Principal Component Analysis (PCA) was performed with software R foundation for statistical   
package ade4 [35,36] in order to visualize the diversity and relative weight of genetic variables 
among the Malawian ethnic groups and also in comparison to 52 ethnic groups (Table S1) from 
the Sub-Saharan African region using subhaplogroup frequencies (Table S2) . These samples 
were from west, central, southern, southeast and east Africa.  
 
Results 
Mitochondrial subhaplogroup distribution among the 7 Malawi ethnic groups 
All the 215 DNA samples from the participants were successfully sequenced and 184 positions 
showed nucleotide differences when compared with bases on the rCRS [27]. Of these 184 
mutations 175 (95%) have been reported in specific L subhaplogroups before; 7 (4%), m.3579 
A>G (m.3606 A>G, m.5090 T>C , m.647 A>G, m.10463 T>C, m.12192 G>A and m.13104 
A>G  with frequencies of 2%, 2%, 6%, 2%, 1%, 3% and 7%, respectively, are being reported for 
the first time in an African populations although they have been reported in other populations 
before [22,37,38,39], while two, m. 12769 G>A and m.14612 G>A with frequencies of 2% and 
4%, respectively, are novel and have not yet been included on the mtDNA databases 
(MITOMAP or Phylotree). Mutation m.12679 G>A is non-synonymous; while and m.14612 
G>A is synonymous resulting ND5:p.Glu145Lys and ND6:p.Arg154Lys changes, respectively. 
It is well known that the high mutation rate of mtDNA leads to numerous instances of both 
parallel mutations at the same site and of reversion (i.e., homoplasmy) in populations [21]. Of 
Figure 2 shows a maximum parsimony tree of the subhaplogroups in our dataset.   
Haplogroups L0, L1, L2 and L3 were observed in the seven Malawian ethnic groups with 
frequencies of 48%, 13%, 25% and14%, respectively. These haplogroups were further grouped 
into 9 subhaplogroups (L0d, L0k, L0f, L0a1, L0a2, L1c, L2a, L3d and L3e) as shown in Figure 
2. There were both quantitative and qualitative differences in the distribution of the 
subhaplogroups in the Malawian ethnic groups, with the Lhomwe, Ngoni and Yao each having 8 
subhaplogroups whilst the least diverse was the Sena with only four subhaplogroups. The L1c 
(P=0.001) and L2a (P=0.015), were distributed significantly different in the Sena and the Chewa, 
respectively, when compared to other ethnic groups. Figure 3 shows the distribution of the 














L3e were present in all ethnic groups while L0a1 and L0k were observed in only 3 ethnic groups 
each. Among these seven Malawian ethnic groups, L4, L5 and L6 haplogroups were not 
observed.  
 
Evaluating genetic diversity among the Malawi ethnic groups 
Genetic diversity indices for the seven ethnic groups are presented in Table 1. There were 
similarities in genetic diversity with value of 1; haplotype diversity within the population with all 
ethnic groups indicating an excess of rare haplotypes variants compared to the expectation under 
a neutral model of evolution by negative Tajima's D and of Fu's FS values.  Although overall 
diversity was similar among ethnic groups, mean pairwise distances and nucleotide diversity 
were both lowest within the Yao ethnic group as reflected by significant Tajima's D and of 
Fu's FS.  
 
Populations that are closely related are more likely to present with similar frequencies of mtDNA 
haplogroups. Pairwise FST values between ethnic groups ranged from 0.001 to 0.141 (Table 2). 
Comparison between the Sena and other ethnic groups showed highly significant differentiation 
pairwise distances. In contrast the least differentiation was observed between the Lhomwe and 
the Tonga (FST = 0.001) ethnic groups. In addition, to understanding genetic relationship between 
populations a neighbor-joining tree based on genetic distance was constructed (Figure 4) to 
determine the nucleotide diversity between the different ethnic groups using data from Table 
2.The ethnic groups clustered into two distinct groups with the Sena ethnic group completely 
isolated from the other groups and also reflecting the first to diverge.  The inner shorter branches 
separating the Lhomwe and Tonga, Ngoni and Yao, respectively, indicate lack of genetic 
differentiation among these ethnic groups.   
 
Comparison of mtDNA variation in the Malawian population to other African populations  
Characteristics of Southeastern African populations with respect to mtDNA subhaplogroup 
variation are presented in Figure 5. Data on geographical origin, mtDNA subhaplogroup 














African ethnic groups (Table S1). Using database of mtDNA subhaplogroup frequencies (Table 
S2), principal component analysis was performed to check for population stratification in the 
Malawi and other African ethnic groups. PCA axes were plotted basing on the 27% variance 
observed and clearly separated the African populations based on the geographical placement on 
the continent. Ethnic groups from West African were clustered together to the bottom left, 
Central, Southeast and Southern African populations clustered at the centre and East African 
ethnic groups clustered together to the bottom right of the PCA (Figure 6). The Malawi ethnic 
groups were clustered between ethnic groups from Southeast and Southern Africa. It was also 
observed that clustering of ethnic groups followed a pattern dependent on language, with Bantu 
speakers (including the Malawian ethnic groups) clustered away from Afro-asiatic, Nilotic and 
Click speakers (Figure 6). The Bantu speakers were clustered to the left while Afro-asiatic, 
Nilotic and Click speakers to the right of the PCA. The Malawi population was clustered with 
the Bantu speakers to the left.  
 
Discussion 
Very little genomics research has been carried out among populations of Malawi [10] including 
mtDNA variation. We characterised mtDNA variation in seven Malawian ethnic groups and 
compared the observed haplogroups and subhaplogroups to those reported from other ethnic 
groups in Africa. The Malawi population is characterised with the L haplogroups, L0, L1, L2, 
and L3, which define African populations and further support the observation that sub-Saharan 
mtDNA gene pool is mixture of L subhaplogroups occurring at varying frequencies throughout 
the continent [40]. L4, L5 and L6 were not observed, confirming earlier reports of their 
confinement to West and East African populations and their absence in Southeast African 
populations [1,19]. High prevalent of L0a (34%) subhaplogroup among the Malawi population is 
consistent with earlier studies, which have reported the subhaplogroup as the most common in 
Southeast African populations [1,19]. Presence of L0d and L0k subhaplogroups in Southeast 
African population which was previously reported [17] is further confirmed here, pointing to 
possible population admixture with the Khoisan. Subhaplogroup distribution within the ethnic 
groups showed variations with Chewa and Sena being associated more with L2a (n = 22, P = 
0.029) and L1c (n = 6, P = 0.001), respectively, suggesting that haplotypes are not randomly 














to the other six Malawian ethnic groups could be attributed to the unique culture of patrilineal 
kinship which prevents them from marrying among surrounding ethnic groups with different 
cultures. In contrast Lhomwe, Ngoni, Tonga, Tumbuka and Yao, showed a lot of genetic 
admixture such that they could not be assigned with specific subhaplogroups, possibly due to 
their migration history as well as shared common languages [41] which makes it difficult to 
establish their real ethnicity.  For example, intermarriages are very common between Tumbuka 
and Ngoni from the Northern part of Malawi such that most Ngoni are masked under the 
Tumbuka and these groups have patriarchal culture where ethnicity is defined by the male 
lineage.  In addition, industrialization in the southern region of Malawi an area which is mainly 
dominated by Yao and Lhomwe might have also contributed to the failure to assign the tribes 
into specific haplogroups because more people of different ethnic groups moved and settled in 
the Lhomwe and Yao settlements.  
 
Comparing the subhaplogroup frequencies among Malawi, Zimbabwean and Mozambican 
populations, all from Southeast Africa shows, show differences in the distribution of most of the 
subhaplogroups. A comparison of the distribution of L0a, L2a and L3e subhaplogroups among 
Malawian and Zimbabwean populations reveals a possible genetic relatedness that needs further 
investigations.   The clustering of African ethnic groups on PCA was based on geographical 
origin similar to what was also observed  in Coelho‘s study [42] suggesting variability in the 
genetic structure within ethnic groups in the Sub Sahara African region. Furthermore, the 
analysis also shows that the Malawi Yao and Kaskazi Yao of Mozambique are very similar, 
supporting their common maternal ethnic origin or influence [43]. Alves et al [44] described that 
the Mozambican Yao are linguistically closer to Bantu people from Tanzania and Kenya 
suggesting relationships to ethnic groups in an extended geographical area. There is need for a 
comprehensive molecular evolutionary analysis of the ethnic groups in Southeast Africa focusing 
on more markers including Y-chromosome DNA. The Ngoni, Tonga and Tumbuka and from 
Malawi are scattered between the Southern African Bantus speakers (i.e. Zulu/Xhosa from South 
Africa, Swazi from Swaziland, Sotho from South Africa and Makonde of Mozambique). Taking 
into account gene variation, these ethnic groups share similarities in the distribution of the L0 














 Interestingly, there seems to be less genetic relatedness between Lhomwe ethnic group of 
Malawi and the Lhomwe from Mozambique possibly suggesting population  admixture in 
support of the ethnologue information [43]. This observation defeats the use of language to 
solely characterise populations. Using PCA, clear separation is observed between Malawi Sena 
and Nyasa speakers of Mozambique (Sena and Nyungu). However the Sena is an umbrella term 
for sub-ethnic groups of the major Kusi-speaking groups of  Makua, Shona, Rabu and Phodzo 
and other Southeast Bantu [14,44]. Therefore the separation from the cluster of the Kusi-
speakers as observed on PCA may reflect genetic variation still to be explained. Nonetheless, 
further work to be carried in order to investigate the relationship of the Malawi Sena ethnic 
group with the Kusi-speaking ethnic groups. One must however take precaution when predicting 
genetic similarity from language because during population dispersal there were tribal wars and 
conquering victors often imposed their language on the losers.    
 
MtDNA variation has been used in human phylogeography and also in studies trying to define 
the risk mtDNA variants in common disease [21,46]. The presence of mtDNA variants which 
have not been reported in L subhaplogroups could suggest population admixture possibly due to 
colonisation, slavetrade and exploration [41,47,48,49] which could have increased admixture. 
Data on the mtDNA landscape of Malawi has not been available up to this point and this is a 
contribution towards unraveling the deep-rootedness of mtDNA lineages in Southern African 
populations. However, one of the limitations of this study was small sample sizes for ethnic 
groups because participants were primarily recruited to investigate the pharmacogenetics 
correlates of differential response to stavudine-containing antiretroviral therapy and evaluating 
population history was a secondary. However, still our sample sizes for the ethnic groups are 
comparable to other current studies [50]. In addition, mtDNA variation, may not completely 
explain the population characteristics of Malawian ethnic groups because of the focus on 
matrilineality, thus, need to be complemented with studies looking at Y-chromosome variation. 
For future studies, we recommend focused sampling  for an in depth  population history study of 
the Malawian ethnic groups in their respective geographical areas than the current study which 
relied on participants presenting themselves for HIV/AIDS treatment at Queen Elizabeth 














However, our study gives a glimpse into the population history of the Malawian people.  
 
Conclusion 
The results presented here reveal the genetic characteristics of the of Malawi population with 
respect to mtDNA variation. The majority of subhaplogroup distribution patterns in the 7 
Malawian ethnic groups bear resemblance to that of Southern and Southeastern African 
populations. The observation of L0d and L0k in the Malawi population further suggests that 
there could maternal relationship of the Malawi Bantu speakers to L0d and L0K lineages of 
Khoisan. It is now well recognized that mutations of mtDNA are an important cause of inherited 
neuromuscular disorders in man [51]. A great deal of work has been done to identify and classify 
these mutations in Caucasian European populations [52,53] and efforts in Asian populations 
have been growing for a number of years [54,55].  However, progress in populations of African 
origin has been limited, what has been deduced is that the spectrum of mutations responsible for 
clinically-manifesting mtDNA are likely to have some important differences in African 
populations when compared to others [56]. This suggests that haplogroup context is playing an 
important role in the penetrance of mutations, and this is something that we have seen illustrated 
before by the variable penetrance of Leber‘s hereditary optic neuropathy (LHON) in different 
haplogroups in both European and Asian populations [57,58].  Furthermore, clinically 
manifesting mutations such as those that can result in the LHON are thought by many to be only 
one facet of the role played by mtDNA variants in human disease, with many studies suggesting 
a role for common mtDNA variants in common complex disease either affecting likelihood of 
disease [59] or course of disease [60].  Therefore observation from this data makes it imperative 
for studies to investigate the clinical significances of the common mtDNA haplogroups in 
Southern and southeast African populations that bears such a huge burden of common diseases. 
 
The effective identification of clinically manifesting mutations and construction of association 
studies alike requires a detailed and accurate understanding of phylogeny [61], and for many 
African populations this has been lacking. While there has been much needed growth in the 














variation in Malawi is as yet unexplored, as such we offer here a tentative first exploration of the 
mtDNA diversity of the ethnic groups of this nation.        
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Titles and legends for figures 
 
Figure 1:   Map of Malawi showing ethnic groups in the study and their settlement pattern.  
Malawi is bordered by Tanzania, Mozambique and Zambia. CH = Chewa/Nyanja; LO = Lomwe; 
 NG = Ngoni; SE = Sena; TO = Tonga; TU = Tumbuka; YA = Yao. The participants were  
recruited from Queen Elizabeth central Hospital in Blantyre as part of a pharmacogenetics study  















Figure 2: Maximum parsimony network of haplotypes for mtDNA of Malawian samples. 
The network was reconstructed from maximum parsimony phylogenetic tree. It is showing subhaplogroup diversity 
in Malawian population. Numbers refer to nucleotide (haplotype) position with respect to revised Cambridge 
Reference Sequence. Positions of nucleotides in red board are reported for the first time in the mtDNA L lineage. 

















Figure 3: Subhaplogroup distributions among Malawian ethnic groups.  
CH = Chewa; LO = Lomwe; NG = Ngoni; SE = Sena; TO = Tonga; TU = Tumbuka; YA = Yao. The 
most diverse ethnic groups in terms of mtDNA subhaplogroups were Lhomwe, Ngoni and Yao, while the 





















Figure 4:  Neighbor joining tree based on genetic distances between seven Malawi ethnic 
groups.  
The tree is drawn to scale, with branch lengths in the same units as those of the evolutionary distances that were 
used to infer the phylogeny tree (scale bar, 0.01 nucleotide substitutions per site). CH = Chewa; LO = Lomwe; NG = 

















Figure 5: Comparison of mtDNA subhaplogroup distribution within Southeast African 
(Malawi, Mozambique and Zimbabwe) populations. 
 Presence of L0f, L0k, L1b, L2b, L2c, L3b and L4g is population dependent. L0a, L0d, L1c, L2a, L3d and L3e are 
present in all the populations. Mal = Malawi; Moz = Mozambique; Zim = Zimbabwe; pop = population. When 
haplogroups frequencies Malawi population were compared to Mozambican population significant differences P – 
















Figure 6: Principal component analysis showing genetic affinities between 60 ethnic groups  
in Sub-Sahara Africa. 
The ethnic groups are classified as of Niger-Congo, Nilo-Saharan and Khoisan speakers from West, Central, Southwest, 
Southeast, Southern Africa and East Africa. The codes in red are representing the Malawi population and the codes in blue, bright 
turquoise, purple, dark green, brown, bright maroon are representing the other African population in the west, west central, 
central, southeast, east and southern Africa respectively. Codes bottom left of the PCA are for Bantu population from West 
Africa and bottom right is for population from East Africa. The population from central and southeast Africa is clustered to the 
upper left centre of the PCA. The Southern African Click speakers are to upper right of the diagram. Populations are abbreviated 
as follows:  CH = Chewa; LO = Lomwe; NG = Ngoni; SE = Sena; TO = Tonga; TU = Tumbuka; YA = Yao; CHO = 5 Chopi; 
CHW =  Chwabo; LOM = Lomwe; MAK = Makhuwa; MAD =  Makonde; MOZP = Mozambicans; NDA =  Ndau; NGU =  
Ngoni; NYA =  Nyanja; NYU = Nyungwe; RON = Ronga; SEA= Sena; SHA = Shangaan; SHO =  Shona; TON  = Tonga; TSW  
= Tswa; YAO =  Yao; SHON =  Shona; KIK = Kikuyu; HUT = Hutu; SUK = Sukuma; ANG = Mbundu; CAB = Cabinda; HER 
= Herero; BAM = Bamileke; BUB = Bubi; EWO = Ewondo; FAN = Fang; BAK = Bakaka; BAS = Bassa; STM =  Sa˜o TomeM; 
STT = Sa˜o TomeT; TAL = Tali; FUL = Fulbe; MAN = Mandenka; SEN = Senegal; SER = Serer; WOL = Woloff; YOR = 
Yoruba; Hadz II = Hadza II; Sanda = Sandawe; Hadz I = Hadza I; X/Khwe = Xun/Khwe; Xun = Xun; Kun = Kung; Manyanga = 














Table 1: Intrapopulation diversity indices in the Malawi population 
 
N, number of sequences; NH, number of different haplotypes; H, haplotype diversity (defined as H = (1-∑x
2
i) N/(N-
1), where x is the frequency of haplotype; π, nucleotide diversity (average over loci); MNPD, mean pairwise 













Population N NH H (SD) MNPD (SD) π (SD) Tajima‘s D (P) Fu‘s Fs (P) 
Chewa 46 135 1.00 ± 
(0.022) 
22.15 (9.94) 0.127 (0.063) -1.14 (0.119) -24.16 (0.001) 
Lhomwe 63 134 1.00± 
(0.016) 
20.20 (9.04) 0.116 (0.057) -1.24 (0.075) -24.11 (0.001) 
Ngoni 41 124 1.00 ± 
(0.024) 
17.68 (8.02) 0.102 (0.051) -1.39 (0.062) -24.22 (0.001) 
Sena 9 54 1.00 ± 
(0.111) 
15.38 (7.60) 0.088 (0.049) -1.15 (0.134) -1.85  (0.099) 
Tonga 10 71 1.00 ± 
(0.100) 
16.49 (8.03) 0.095 (0.052) -1.48 (0.058) -2.21 (0.072) 
Tumbuka 10 82 1.00 ± 
(0.100) 
19.87 (9.61) 0.115 0.0620 -1.52 (0.059) -1.88 (0.104) 
Yao 36 96 1.00 ± 
(0.028) 















Table 2: Pairwise differences ( FST ) between the 7 ethnic groups 
 Chewa Lhomwe Ngoni Sena Tonga Tumbuka Yao 
Chewa - - - - - - - 
Lhomwe 0.0288*  - - - - - 
Ngoni 0.016 0.018  - - - - 
Sena 0.081* 0.152* 0.107*  - - - 
Tonga 0.0436 0.001 0.029 0.132*  - - 
Tumbuka 0.007 0.012 0.013 0.072* 0.004   





Table 3: P-values for Pairwise differences ( FST ) between the 7 ethnic groups 
 Chewa Lhomwe Ngoni Sena Tonga Tumbuka Yao 
Chewa - 0.018 0.968 0.022 0.994 0.377 0.142 
Lhomwe -  0.055 0.004 0.380 0.276 0.016 
Ngoni - -  0.006 0.866 0.241 0.430 
Sena - - -  0.002 0.041 0.001 
Tonga - - - -  0.540 0.069 
Tumbuka - - - - -   























Table S1: Population groups, geographical origin, language classification sample size, and 








Population Study West Africa 
Fulbe FUL Niger 
Niger- Congo, Atlantic, North 
Senegambian 57 
{Watson E, 1996 
#234} 
Mandenka MAN Senegal Niger- Congo, Mande, Central 117 
{Graven L, 1995 
#226} 
Senegal SEN Senegal Niger- Congo, Atlantic, mixed 50 
{Rando JC, 1998 
#231} 
 
Serer SER Senegal 
Niger- Congo, Atlantic, North 
Senegambian 23 
{Rando JC, 1998 
#231} 
 
Woloff WOL Senegal 
Niger- Congo, Atlantic, North 
Senegambian 48 
{Rando JC, 1998 
#231} 
 
Yoruba YOR Nigeria 
Niger- Congo, Volta-Congo, 
Defoid 34 
{Watson E, 1996 
#234} 
Gabon GAB Gabon Niger- Congo, Mixed 489 
{Quintana-Murci L, 
2008 #216} 





   
Bamileke BAM Cameroon 
Niger- Congo, Bantoid, Narrow 
Grassfields 48 
{Destro-Bisol G, 2004 
#225} 
Bubi BUB Bioko 
Niger- Congo, Narrow Bantu, 
Northwest, B 45 {Mateu E, 1997 #228} 
Ewondo EWO Cameroon 
Niger- Congo, Narrow Bantu, 
Northwest, A 53 
Destro-Bisol G and 
others 2004) 
Fang FAN Guinea 
Niger- Congo, Narrow Bantu, 
Northwest, A 11 {Pinto F, 1996  #229} 
Bakaka BAK Cameroon 
Niger- Congo, Narrow Bantu, 
Northwest, A 50 {Coia V, 2005 #224} 
Bassa BAS Cameroon 
Niger- Congo, Narrow Bantu, 
Northwest, A 47 {Coia V, 2005 #224} 
São ToméM STM São Tomé 
Niger- Congo, Narrow Bantu, 
mixed 50 {Mateu E, 1997 #228} 
São ToméT STT São Tomé 
Niger- Congo, Narrow Bantu, 
mixed 103 
{Trovoada MJ, 2004 
#233} 
Tali TAL Cameroon 
Niger- Congo, Volta Congo, 
Adamawa 20 {Coia V, 2005 #224} 




















Cabinda CAB Angola 
Niger- Congo, Narrow Bantu, 
Central, H 110 {Beleza S, 2005 #200} 
Herero HER Namibia 
Niger- Congo, Narrow Bantu, 
Central, R 27 
{Soodyall H, 1996 
#232} 





   
Chewa CH Malawi 
Niger- Congo, Narrow Bantu, 
Central N 46 present study 
Lomwe LO Malawi 
Niger - Congo, Mixed (Makhua-
Nyanja) 63 present study 
Ngoni NG Malawi 
Niger - Congo, Narrow Bantu, 
Central S 41 present study 
Sena SE Malawi 
Niger - Congo, Narrow Bantu, 
Central N 9 present study 
Tonga TO Malawi 
Niger - Congo, Narrow Bantu, 
Central N 10 present study 
Tumbuka TU Malawi 
Niger - Congo, Narrow Bantu, 
Central N 10 present study 
Yao YA Malawi 
Niger - Congo, Narrow Bantu, 
Central P 36 present study 
Chopi CHO Mozambique 
Niger- Congo, Narrow Bantu, 
Central, S 27 
{Salas  Antonio, 2002 
#184} 
Chwabo CHW Mozambique 
Niger- Congo, Narrow Bantu, 
Central, P 20 
{Salas  Antonio, 2002 
#184} 
Lomwe LOM Mozambique 
Niger- Congo, Narrow Bantu, 
Central, P 20 
{Salas  Antonio, 2002 
#184} 
Makhuwa MAK Mozambique 
Niger- Congo, Narrow Bantu, 
Central, P 20 
{Salas  Antonio, 2002 
#184} 
Makonde MAD Mozambique 
Niger- Congo, Narrow Bantu, 
Central, P 19 
{Salas  Antonio, 2002 
#184} 
Mozambicans MOZP Mozambique 
Niger- Congo, Narrow Bantu, 
Central, mixed 107 {Pereira, 2001 #2} 
Ndau NDA Mozambique 
Niger- Congo, Narrow Bantu, 
Central, S 19 
{Salas  Antonio, 2002 
#184} 
Nguni NGU Mozambique 
Niger- Congo, Narrow Bantu, 
Central, N 11 
{Salas  Antonio, 2002 
#184} 
Nyanja NYA Mozambique 
Niger- Congo, Narrow Bantu, 
Central, N 20 
{Salas  Antonio, 2002 
#184} 
Nyungwe NYU Mozambique 
Niger- Congo, Narrow Bantu, 
Central, N 20 
{Salas  Antonio, 2002 
#184} 
Ronga RON Mozambique 
Niger- Congo, Narrow Bantu, 
Central, S 22 
{Salas  Antonio, 2002 
#184} 
Sena SEA Mozambique 
Niger- Congo, Narrow Bantu, 
Central, N 21 
{Salas  Antonio, 2002 
#184} 
Shangaan SHA Mozambique 
Niger- Congo, Narrow Bantu, 
Central, S 22 
{Salas  Antonio, 2002 
#184} 
Shona Moz SHO Mozambique 
Niger- Congo, Narrow Bantu, 
Central, S 17 
{Salas  Antonio, 2002 
#184} 
Tonga TON Mozambique 
Niger- Congo, Narrow Bantu, 
Central, S 20 
{Salas  Antonio, 2002 
#184} 
Tswa TSW Mozambique 
Niger- Congo, Narrow Bantu, 
Central, S 19 
{Salas  Antonio, 2002 
#184} 
Yao YAO Mozambique 
Niger- Congo, Narrow Bantu, 
Central, P 10 






















Shona Zim SHON Zimbabwe 
Niger- Congo, Narrow Bantu, 
Central, S 59 {Castrì, 2009 #221} 
      Khoisan 
 
Southern Africa / East Africa 
  Hadza II Hadz II Tanzania Khoisan, Hatsa 79 {Gonder, 2007 #147} 
sandawe Sanda Tanzania Khoisan, Sandawe 82 {Gonder, 2007 #147} 
Hadza I Hadz I Tanzania Khoisan, Hatsa 12 
{Knight A, 2003 
#227} 
Xun/Khwe X/Khwe South Africa 
Khoisan, Southern Africa, 
Central 18 {Gonder, 2007 #147} 
Xun Xun Namibia 
Khoisan, Southern Africa, 
Southern  43 
{Vigilant L, 1991 
#235} 
Kung Kun Botswana 
Khoisan, Southern Africa, 
Northern 26 
{Vigilant L, 1991 
#235} 
      Bantu  
 
Southern Africa         
Zulu/Xhosa ZUX South Africa  
Niger-Congo, Atlantic-Congo, 
Volta-Congo, Southern, Narrow 
Bantu, Central, S 36 
{Schlebusch, 2009 
#194} 
Swazi SWAZ South Africa 
Niger-Congo, Atlantic-Congo, 
Volta-Congo,  Narrow Bantu, 
Central, S, 5 
{Schlebusch, 2009 
#194} 
Sotho SOT South Africa 
Niger-Congo, Atlantic-Congo, 
Narrow Bantu, Central, S 22 
{Schlebusch, 2009 
#194} 
      Bantu 
 
East Africa 
   
Kikuyu KIK Kenya 
Niger- Congo, Narrow Bantu, 
Central, E 25 
{Watson E, 1996 
#234} 
Hutu HUT Rwanda 
Niger- Congo, Narrow Bantu, 
Central, J 42 {Castrì, 2009 #221} 
Sukuma SUK Tanzania 
Niger- Congo, Narrow Bantu, 
Central, F 21 
{Knight A, 2003 
#227} 
Turu TURU Tanzania 
Niger- Congo, Narrow Bantu, 
Central, F 29 {Tishkoff, 2007 #183} 
      Nilo - Saharan East Africa 
   
Datoga DAT Tanzania 
Nilo - Sahara, Eastern Sudanic, 
Nilotic, Southern 39 {Tishkoff, 2007 #183} 
      Afro - Asiatic East Africa 











Table S2: Mitochondria Haplogroup frequencies in different population in Sub-Sahara 
Africa 
L0a L0a1 L0a2 L0d L0f L0k L1b L1c L2 L2a L2b L2c L2d L3 L3b L3d L3e L3f L3x1 L4g L5 Other 
CH 0 0 26 11 0 0 0 11 0 37 0 0 0 0 0 2 13 0 0 0 0 0 
LO 0 11 35 8 3 6 0 10 0 19 0 0 0 0 0 0 8 0 0 0 0 0 
NG 0 5 27 7 0 7 0 10 0 27 0 0 0 0 0 2 15 0 0 0 0 0 
SE 0 0 0 0 11 11 0 67 0 0 0 0 0 0 0 0 11 0 0 0 0 0 
TO 0 0 30 0 10 0 0 20 0 30 0 0 0 0 0 0 10 0 0 0 0 0 
TU 0 0 30 20 0 0 0 20 0 20 0 0 0 0 0 0 10 0 0 0 0 0 
YA 0 11 27 0 0 3 0 6 0 22 0 0 0 0 0 8 17 0 0 0 0 0 
CHO 0 4 11 0 0 0 4 7 0 30 0 0 0 7 0 15 11 7 0 0 0 0 
CHW 0 10 5 0 0 0 5 5 0 40 0 0 5 0 10 10 5 0 0 0 0 0 
LOM 0 20 35 0 0 0 0 10 0 25 4 0 5 0 0 0 5 0 0 0 0 0 
MAK 15 0 30 0 0 0 0 10 0 20 0 0 0 0 0 5 20 0 0 0 0 0 
MAD 0 0 16 5 0 0 0 11 21 0 0 0 0 0 11 0 37 0 0 0 0 0 
MOZP 15 0 0 7 0 0 1 6 0 43 0 1 0 2 4 2 17 0 0 0 0 0 
NDA 0 6 33 17 0 0 0 6 0 28 0 0 0 8 6 6 0 0 0 0 0 0 
NGU 8.33 25 17 0 0 0 0 0 0 17 2 0 0 0 0 8 17 0 0 0 0 0 
NYA 0 5 25 0 0 0 0 0 0 45 0 0 0 0 0 15 10 0 0 0 0 0 
NYU 0 30 0 0 0 0 0 10 0 20 0 0 0 0 0 10 15 0 0 0 0 0 
RON 0 10 10 19 0 0 0 0 0 24 0 5 0 0 0 0 19 10 0 0 0 0 
SEA 0 5 32 0 0 0 0 5 0 36 0 0 0 0 0 14 5 5 0 0 0 0 
SHA 0 14 14 5 0 0 5 9 0 27 5 0 0 0 0 9 14 0 0 0 0 0 
SHO 0 13 13 0 0 0 6 0 0 44 0 6 0 0 0 0 13 6 0 0 0 0 
TON 0 5 10 5 0 0 0 10 0 35 5 0 0 0 0 0 30 0 0 0 0 0 
TSW 0 11 0 16 0 0 0 0 0 37 0 0 5 0 11 11 11 0 0 0 0 0 
YAO 0 10 30 0 0 0 0 0 0 10 0 0 0 10 0 40 0 0 0 0 0 0 
SHON 0 7 20 2 0 2 3 8 0 20 2 0 0 7 7 1 0 0 0 2 0 0 
KIK 0 8 4 0 0 0 0 0 0 12 0 0 20 0 0 19 0 0 0 4 8 4 
HUT 0 12 5 0 17 0 0 2 0 7 2 2 10 17 2 20 0 2 0 7 5 2 
SUK 0 14 10 0 0 0 0 14 0 5 0 0 0 5 5 7 0 0 0 24 5 14 
ANG 0 7 7 0 0 0 5 16 0 26 5 0 0 2 5 5 2 0 0 0 2 0 
CAB 0 10 3 0 0 0 3 25 0 5 6 0 0 4 5 21 13 0 0 1 0 3 
HER 0 0 0 0 0 0 0 0 0 0 0 0 0 81 0 7 0 0 0 0 0 7 
BAM 6 4 4 0 0 0 2 6 0 29 4 4 0 4 13 10 10 0 0 0 0 0 
BUB 0 0 9 0 0 0 0 22 0 18 2 16 0 0 0 33 0 0 0 0 0 0 
EWO 0 8 2 0 0 0 6 20 0 18 0 8 0 6 0 8 4 0 0 8 0 4 
FAN 0 8 0 0 0 0 8 17 0 0 0 0 0 0 0 0 25 0 0 0 0 25 
BAK 0 10 10 0 0 0 6 14 2 10 2 0 12 2 0 26 4 0 0 2 0 0 
BAS 4 0 0 0 0 0 7 24 2 15 0 4 13 2 2 13 11 0 0 2 0 0 
STM 0 6 2 0 0 0 18 8 0 20 0 0 0 4 0 28 6 0 0 0 0 4 
STT 0 6 1 0 0 0 14 3 16 14 3 1 0 4 6 27 4 0 0 0 0 2 
TAL 0 0 0 0 0 0 5 5 5 26 0 0 11 11 0 21 16 0 0 0 0 0 
FUL 0 0 0 0 0 0 16 0 0 16 0 0 0 14 11 9 9 0 0 2 0 14 
MAN 0 2 0 0 0 0 20 0 0 12 3 1 0 5 9 7 1 0 0 0 0 5 
SEN 0 0 0 0 0 0 8 4 0 20 8 0 0 14 10 6 8 0 0 0 0 8 
SER 0 0 0 0 0 0 22 0 0 26 17 0 0 17 4 0 0 0 0 0 0 0 
WOL 0 0 0 0 0 0 23 0 0 25 15 6 0 2 4 8 0 0 0 0 0 0 
YOR 0 3 0 0 0 0 18 6 0 21 3 0 0 9 6 21 3 0 0 3 0 6 
GAB 0 7 3 0 0 0 0 36 0 14 2 2 1 2 3 4 15 6 0 1 0 0 
TURU 10 0 0 0 14 0 0 3 0 7 0 0 8 10 7 3 3 3 0 28 0 12 
DAT 28 0 0 0 5 0 0 0 0 0 0 0 0 27 0 0 0 0 0 13 0 19 
BURU 25 0 0 3 30 0 0 0 3 0 0 0 0 18 0 3 0 8 0 8 0 6 
Hadz_II 5 0 0 3 0 0 0 0 1 10 0 0 0 8 4 1 0 5 0 60 1 3 
Sanda 17 0 0 5 4 0 0 0 0 1 0 0 0 0 0 0 13 2 0 48 5 4 
0Hadz_I 0 0 0 0 0 0 0 0 17 0 0 0 0 0 0 0 0 0 0 83 0 0 
X/Khwe 0 0 0 61 0 22 0 0 17 0 0 0 0 0 0 0 0 0 0 0 0 0 
Xun 2 0 0 51 0 26 0 0 16 0 0 0 0 0 0 0 5 0 0 0 0 0 
Kun 0 0 0 96 0 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
DRC 7 0 0 0 0 0 14 0 0 7 0 7 0 0 7 7 29 21 0 0 0 0 
ZUX 8 0 0 44 0 3 0 6 0 14 0 3 0 0 0 8 8 3 0 0 2.8 0 
Swaz 0 0 0 40 0 0 0 0 0 0 0 0 0 0 0 0 60 0 0 0 0 0 














5. Chapter 5: MITOCHONDRIAL DNA VARIATION AND SUSCEPTIBILITY TO 
PERIPHERAL NEUROPATHY 
 
Mitochondrial DNA subhaplogroups L0a2 and L2a modify susceptibility to peripheral 
neuropathy in Malawian adults on stavudine containing highly active antiretroviral 
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Introduction: Peripheral neuropathy is one of the main toxicities associated with stavudine. 
Genetic variants in mitochondrial DNA haplogroups have been associated with increased risk of 
developing peripheral neuropathy in European non-Hispanic and black patients on stavudine 
containing antiretroviral therapy (ART). We investigated mtDNA haplogroups and their role in 
susceptibility to stavudine induced peripheral in Malawian patients on antiretroviral therapy. 
 
Method: Two hundred and fifteen (n = 215) adults on stavudine containing regimens were 
recruited from the ART clinic at Queen Elizabeth Central Hospital, Blantyre, into a cross 
sectional study to investigate the effects of genetic variants in mitochondrial DNA of individuals 
in relation to response to treatment.  Patients were categorized according to whether or not they 
had developed peripheral neuropathy after a minimum of six months on stavudine containing 
ART. Whole mitochondrial DNA coding regions of each patient were sequenced, CD4 count, 
viral load and creatinine were determined. Mitochondrial DNA variation was correlated with 
clinical characteristics. 
 
Results: Fifty three (25%) of the participants developed peripheral neuropathy after starting 
stavudine containing antiretroviral therapy. Mitochondrial DNA subhaplogroup L0a2 
 
 was 
independetly associated with increased risk of peripheral neuropathy in a multivariate model (OR 
2.23; 95% CI, 1.14 – 4.39; p = 0.019) and subhaplogroup L2a was independently associated with 
reduced risk of peripheral neuropathy (OR 0.39; 95% CI, 0.16 – 0.94; p = 0.036).  
 
Conclusion: Genetic variation in mtDNA confers differential risk of developing peripheral 
neuropathy in patients on stavudine containing ART among Malawians. 
 
 



















Peripheral neuropathy (PN) is one of the most common neurological complication  associated 
with HIV infection, occurring in up to 35% of the patients  
1, 2
.  Peripheral neuropathy may result 
from HIV infection itself or from the neurotoxic side effects of antiretroviral drugs, especially 
nucleoside reverse transcriptase inhibitors (NRTIs) 
1, 3
.  Among NRTIs, stavudine and 
didanosine have the highest propensity to cause peripheral neuropathy. Cui et al.
4
  showed that 
stavudine inhibits neurite regeneration; however the mechanism of neurotoxicity is not fully 
established.  Phosphorylated molecules of NRTIs in the mitochondrial matrix inhibit the activity 
of mitochondrial polymerase gamma by competing with deoxyribonucleotide triphosphates  
(dNTPs) for the binding site and then as they incorporate into the growing mitochondrial DNA 
(mtDNA) strands by causing inhibition in the synthesis of mtDNA thus prematurely terminating 
chain elongation 
5, 6
. In addition to mitochondrial DNA polymerase gamma inhibition, 
mitochondria dysfunction could be the a result of increased mtDNA  polymorphisms as well as 
oxidative stress caused by NRTI which may have adverse effect on mitochondrial structure and 
function 
7
. It has recently been suggested that polymorphisms in mitochondrial genes may 
explain variations in the response to ART between individuals 
8
.    
 
The evolution of the human mtDNA is characterised by the emergence of distinct lineages or 
haplogroups. These haplogroups are characterised by specific sets of haplotypes or single 
nucleotide   polymorphisms (SNPs) 
9
. For example, the mutations m.5147 G>A, m.5711 A>G, 
m.6257 G>A and m.8460 A>G describe subhaplogroup L0a2. Many of the described 





lineage L characteristically defines African populations and is divided into two branches, L0 and 
L1-6 
12
 see Figure 1.  The distribution and frequency of these mtDNA L subhaplogoups within 
Africa appear to have distinctive patterns in different geographic regions or ethnic groups 
11, 13-15
. 
For example, over 90% of Khoisan group of South Africa carry the haplogroup L0 while this 




Analysis of mitochondrial subhaplogroups among European patients enrolled in AIDS clinical 
Trials Group (ACTG) studies showed that individuals in haplogroup T had increased risk of 
developing peripheral neuropathy during ART 
8, 16














subhaplogroups in Africa varies widely between geographic regions and ethnic groups 
11, 15
. 
Although some genetic studies on African have focused on mtDNA, this has mainly been aimed 
at unraveling demographic phenomena related to the settlement of populations and ethnic groups 
on the continent, while information on the association of subhaplogroups with risk of drug 
toxicities is very sparse and completely lacking among Malawians and other African 
populations. Our aim was therefore to investigate the association of mtDNA subhaplogroups 
with development of peripheral neuropathy among adult Malawians on stavudine containing 
ART. 
 
Materials and methods 
Participants 
Unrelated HIV/AIDS patients from an ART cohort at Queen Elizabeth Central Hospital in 
Blantyre, Malawi were recruited into a cross sectional study. The patients completed a structured 
questionnaire that collected demographic information, medical history as well as ancestry of 
each participant up to their grandparent‘s level. Pregnant women, patients on tuberculosis 
treatment, persons who experienced peripheral neuropathy prior to ART initiation and those who 
had missed their medication in the past 3 days were excluded from participation. Participants had 
to be on stavudine containing regimen for at least 6 months. The protocol was approved by the 
College of Medicine Research Ethics Committee of the University of Malawi and the Human 
Research Ethics Committee of the University of Cape Town (UCT). All participants gave written 
informed consent. The study conformed to the declarations of Helsinki 2008. 
 
Clinical and laboratory measurements 
History and physical examinations were performed at enrolment. Stavudine associated peripheral 
neuropathy was defined as a history of characteristic symptoms of numbness, dysesthesia and 
pain in the feet and legs that had started after initiation of ART 
2
. The glomerular filtrate rate was 
estimated with the US K-DOQI group method 
17
. A sample for CD4 cell count (FACSCount 
flow cytometer, Beckton Dickinson, New Jersey, USA) and HIV-1 RNA (Amplicor HIV 















Blood samples for DNA extraction were collected in EDTA coated tubes and were kept at -20
o
C 
until DNA extraction. DNA was isolated by use of a GenElute Blood Genomic DNA Kit (Sigma-
Aldrich, ST Louis, US) according to the manufacturer‘s protocol. Mitochondrial DNA for each 
of the 215 samples was amplified in 9 partially overlapping fragments using the primers reported 
by Ramos et al. 
18, 19
. Each time mtDNA templates were amplified in a total volume of 25µl in a 
reaction that consisted of 1X green GoTaq reaction buffer, 200µM of dNTP, 1.0mM of MgCl2, 
0.4µmol of each primer, 0.5U of Taq DNA polymerase and 20ng of DNA were performed in 
GeneAmp® PCR System 9700 by Life technologies (New York, USA). The PCR programmes 
each consisted of an initial denaturation step at 94
o
C for 5 min, followed by 35 cycles of 
denaturation at 94
o




C for 40s 




. PCR products were 
purified using the exonuclease and shrimp alkaline phosphatase (ExoSap).  
 
Sequence analysis and quality control 
Instead of targeting confirmed informative SNPs, we sequenced whole mtDNA coding region in 
order to search for any novel SNPs in this Malawian population because of the known genetic 
diversity in African populations.  Through the series of 9 PCR fragments and use of forward and 
reverse primers and additional internal primers all samples (n=215) were sequenced from 
nucleotide position 577 – 15953 of the mtDNA according the revised Cambridge reference 
sequence Locus NC_012920.1. Capillary electrophoresis for sequencing reactions was run on an 
ABI PRISM® 3130xl Genetic Analyzer (Applied Biosystems, USA).  Sequences were aligned to 
the revised Cambridge Reference Sequence for the human mitochondrion Locus NC_012920.1 
and assembled using Lasergene 10 Core Suite software supplied by DNASTAR package 
(Madison, Wisconsin USA). After assembly of the sequences, mutations (polymorphisms) were 
determined as nucleotide differences when compared to the Cambridge reference sequence.  
   
Subhaplogroup Analysis and Statistical Analysis 
We classified mtDNA mutations into haplogroups according to the data bases of van Oven and 
Kayser 
12
 www.phylotree.org/ and Accetturo et al 
20
. Stata for windows software (version SE/11; 














compared between participants presenting with and without peripheral neuropathy using Fisher‘s 
exact tests.  
 
 In order to assess the relationship between independent variables (sex, BMI, age, duration on 
ART, CD4 count, viral load, eGFR and subhaplogroups) and the presence of peripheral 
neuropathy, univariate logistic regression model was performed. Variables which showed a 
degree of association with peripheral neuropathy (P<0.1) were included in multivariate logistic 
regression models, where one subhaplogroup was included in the absence of other 
subhaplogroups. Odds ratios are reported with 95% confidence intervals and a p-value of <0.05 
was considered significant. 
 
Results 
We enrolled 215 maternally unrelated adult (according to family-history information) ART 
patients. All were Malawian Bantu speakers, 132 (61%) were women and all were on stavudine 
and lamivudine containing first-line antiretroviral therapy for at least 23 months, median 
duration  of 25 months (range 23 -29). Two (1%) patients had severely elevated serum creatinine 





, respectively. One percent (1%) and 3% of patients were current smokers and 
alcoholics respectively. Fifty-three (25%) patients had peripheral neuropathy. Table 1 provides 
further details of patient characteristics. 
 
Mitochondrial variation and haplogroup analysis 
All 215 samples were successfully sequenced  and 143 positions showed nucleotide differences 
when compared with bases on the revised Cambridge Reference Sequence (rCRS) 
21
. Of these 
143 mutations 134 (94%) have been reported in specific L subhaplogroups before; 7 (5%) of the 
mutations,  m.3579 A>G, m.3606 A>G, m.5090 T>C , m.10463 T>C, m.12192 G>A, m.13104 
A>G and m.15038 G>A  with frequencies of 2%, 2%, 6%, 1%, 3%, 7% and 9% respectively, are 
being reported in an African population for the first time but have been observed previously in  
non-African populations 
12, 22, 23
. Of the few remaining changes two (1%); m. 12769 G>A with a 
frequency of 2% and m.14612 G>A at a frequency of 4% were novel and are not on either 














haplogroups and subhaplogroups according to software provided by van Oven and Kayser 
12
. 
Major L haplogroups (L0-L3) were identified in the study population and were further 
characterised into 9 subhaplogroups, namely; L0a1, L0a2, L0d, L0f, L0k, L1c, L2a, L3d and L3e 
(Table 2).  Subhaplogroup L0a2 had the highest frequency (28%) while L3d (2%) was the least 
common. We did not observe haplogroups L4,  L5 and L6 as well as subhaplogroup L1b which 
have been reported in other African populations 
14, 24
.  Two mitochondrial subhaplogroups were 
associated with the presence of peripheral neuropathy (see Table 2). In a multivariate logistic 
regression model, the L0a2 subhaplogroup was an independent risk factor for peripheral 
neuropathy (OR, 2.23; 95% CI, 1.14 – 4.39; p = 0.019) (Table 3). On the other hand, the 
presence of the L2a subhaplogroup was associated with reduced risk for peripheral neuropathy 
(OR, 0.39; 95% CI, 0.16 – 0.94; p = 0.036). The mutations m.5147 G>A, m.5711 A>G, m.6257 
G>A and m.8460 A>G described subhaplogroup L0a2 
 
Discussion 
The study was undertaken to investigate the role of mtDNA subhaplogroups in the susceptibility 
to stavudine induced peripheral neuropathy in HIV/AIDS patients from Malawi. We observed 
that there was no relationship between gender and the risk of peripheral neuropathy. The role of 
age on peripheral neuropathy is in contrast to our earlier findings that reported there was 
association between age and risk of peripheral neuropathy 
2
. Unlike in other studies where height 
has been associated with increased risk for peripheral neuropathy, this was not the case in the 
Malawi cohort  
25
.  In antiretroviral naïve patients, peripheral neuropathy has been reported to be 
more common with CD4 counts <200 cells/µL and HIV-1 RNA >10,000 copies/mL 
26, 27
. In our 
study all patients were on ART for at least 23 months and the vast majority showed good control 
of HIV replication, which likely explains why we did not observe an association of CD4 and 
HIV-1 RNA with peripheral neuropathy.  
 
In some studies the risk of PN was associated with malnutrition 
28, 29
, therefore our finding that 




with borderline significance ( P-value = 0.055)  in 
patients experiencing peripheral neuropathy could be remarkable. One possibility is that we 
overlooked the diagnosis of type II diabetes in many obese patients, however in a cohort that 
















. Another explanation is that the studies that found an association low BMI with PN 
mainly included patients who were not on ART 
28, 30
. After starting ART, the prevalence of 
malnutrition steadily decreased and the pathogenesis and risk factors of PN are likely to be 
different.  In ART patients, high BMI has been identified as a risk factor for high lactate 




MtDNA variation has been used in human phylogeography in association with population 
genealogy and also in studies trying to define the risk mtDNA polymorphisms in human disease 
11, 20, 31, 32
. Prevous studies have demonstrated that European polulations with haplogroup T are 
more susciptible to developing stavudine associated peripheral neuropathy compared to other 
haplogroups 
8, 33
. A study conducted in blacks of African origin showed that subhaplogroup L1c  
was associated with increased susceptibility to developing stavudine associated peripheral 
neuropathy 
34
 , while in this Malawi population, two subhaplotypes, that L0a2 and L2a, seem to 
be the important markers. 
 
This is the first study to be carried out within the indigenous Africans with known demographic 
information. However, our study has several limitations which include  a small sample size 
which makes it difficult to determine the effects of subhaplogroups with low frequencies (e.g. 
L3d with 2%), a weakness in the objective assessment of peripheral neuropathy (for example, 
clinical findings including nerve conduction velocity and/or intraepidermal nerve fiber density) , 
possibility of undiagnosed pre-ART neuropathy and lack of information on the role of other 






We report a significant association between L02a with increased risk of peripheral neuropathy 
and a protective effect of L2a in Malawians on stavudine based ART. Although it is unlikely that 
in our setting subhaplogroups can be introduced as biomarkers for tailoring antiretroviral drugs 
to individual patients in the near future, our findings help better understand the mitochondrial 
toxico-pathology of NRTI‘s and if confirmed by other studies may improve drug selection for 
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Data is expressed as N (%) except for age, BMI, CD4 count, viral load, duration on ART and eGFR (median, 
  IQR); 
ϮϮ
 IQR, inter-quartile range; BMI, body mass index; ART, antiretroviral therapy; eGFR, estimated 
glomerular filtrate Rate; PN, peripheral neuropathy; 
‡ 
BMI (calculated as weight in kilograms divided by meters 
squared); 
‡‡
 eGFR (calculated using US K-DOQI group  method); * 11 samples (7 without PN and 4 with PN did 








Characteristic No PN  
 
PN  Total (n = 215) P-Values 
Gender (Female)  103 (63)    29 (56) 132 (61) 0.251 
Median age (IQR), (years)   37 (31– 46)    41 (36 –  48)   38 (32 – 46) 0.063 
Age Categories 
Age < 40 years 
Age ≥ 40 years 
 
  99 (61) 
  63 (38) 
 
  24 (45) 
  29 (55) 
 
123 (57) 




Height (Cm) 160 (155 – 165) 159 (154 – 165) 159 (154 -165) 0.198 
Median BMI (IQR), kg/m
2












    5 (3) 
130 (80)   
  27 (17) 
 
    1 (  2) 
  37 (70) 
  15 (28) 
 
    6 (2.8) 
167 (78) 





Median CD4 (IQR)  
(cells/µL) 
 
344 (212 – 495) 
 
344 (281 – 486) 
 
344 (227 -489) 
 
0.805 
CD4 Categories (cells/µL) 
0 - 199 




  35 (22) 
  44 (28)  
  76 (49) 
     
 
    8 (16) 
  17 (35) 
  24 (49) 
     
 
  43 (21) 











  20 (13) 
 
  45 (92) 
    4 (8) 
 
180 (88) 




Duration on ART(IQR) 
(months) 
  
25 (23 – 28) 
 
25 (23 – 32) 
   
25 (23 -29) 
 
0.883 
Median eGFR (IQR) 
(ml/min) 














Table 2: The association of mtDNA subhaplogroup with peripheral neuropathy among 


























Subhaplogroups   Total (%)   no PN (%)    PN (%) P-Value 
L0a1   13 (6.0)   11 (7.0)   2 (4.0) 0.527 
L0a2   61 (28.0)   39 (24.0) 22 (42.0) 0.022 
L0d   15 (7.0)   11 (7.0)   4 (8.0) 0.766 
L0f    6 (3.0)    5 (3.0)   1 (2.0) 1.00 
L0k  9 (4.0)   8 (5.0)   1 (2.0) 0.458 
L1c  27 (13.0) 21 (13.0)   6 (11.0) 1.00 
L2a  53 (25.0) 46 (28.0)   7 (13.0) 0.028 
L3d    5 (2.0)   2 (1.0)   3 (6.0) 0.097 
L3e  26 (12.0) 19 (12.0)   7 (13.0) 0.809 














Table 3: Multivariate logistic regression analyses of factors associated with peripheral  


























Model 1 Model 2 
Covariate Adjusted  
OR (95% CI) 
L2a group 
P-Value Adjusted  



















18.5 – 25  
>25  
 
0.93 (0.10 – 8.43) 
 






0.80 (0.08 – 7.33) 
 





     
L2a(vs all L 
subhaplogroups) 
 



























Figure 1. Phylotree describing the mtDNA haplogroup L and its subhaplogroup.  
The haplogroups are differentiated by mutations at specific positions.  Numbers refer to nucleotide (mutation) 
position with respect to revised Cambridge Reference Sequence. The letter to the left side of the number refers to 
ancestor allele and the letter to the right side refers to derived allele. Haplogroups are found at varying frequencies 
























6. CHAPTER 6: MITOCHONDRIAL DNA VARIATION AND SUSCEPTIBILITY TO 
LIPODYSTROPHY 
 
Mitochondrial subhaplogroups and differential risk of stavudine induced lipodystrophy in 
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Introduction: Lipodystrophy remains a significant problem in HIV/AIDS patients especially 
those on regimens containing either protease inhibitors or thymidine analogues (stavudine or 
zidovudine).  Many of the manifestations of lipodystrophy have been linked to mitochondrial 
dysfunction. We set out to investigate if mitochondrial DNA variation is associated with 
development of stavudine induced lipodystrophy among adult Malawian HIV/AIDS patients on 
antiretroviral therapy that included stavudine.   
 
Method: One hundred and seventeen (n = 117) adult HIV/AIDS patients on stavudine 
containing ART were recruited from the antiretroviral therapy (ART) clinic at Queen Elizabeth 
Central Hospital, Blantyre.  The patients were categorized according to whether or not they had 
developed lipodystrophy after being on stavudine containing ART regimen for at least 6 months. 
Whole mitochondrial DNA coding region of each patient was sequenced and correlated to 
clinical characteristics. 
 
Results: Lipodystrophy was apparent in 16% (n=19) of the participants.  In multivariate 
analysis, Age >40 years (OR, 4.43; 95% CI, 1.36 – 14.47; P = 0.014) was significantly 
associated with presence of lipodystrophy. The mtDNA subhaplogroup L3e appeared to be 
protective against lipodystrophy as none of 11 subjects with this subhaplogroup presented with 
lipodystrophy. 
  
Conclusion: mtDNA subhaplogroups seem to differentially affect susceptibility to 
lipodystrophy. More research is required to identify patients who are more or less likely to 






















Lipodystrophy is one of the metabolic disorders associated with HIV infection and antiretroviral 
therapy (ART).  Lipodystrophy is characterised by peripheral fat loss of the limbs, cheeks, and/or 
buttocks (lipoatrophy), and by accumulation of fat in the abdomen, neck and/or breasts (fat 
accumulation)  as reviewed by  Cossarizza et al [1]. In many cases, lipodystrophy is 
accompanied by metabolic features such as hypertriglyceridemia, hypercholesterolemia, low 
high-density lipoprotein cholesterol levels, insulin resistance, type 2 diabetes mellitus, and 
steatosis of the liver [2, 3]. These conditions may elevate the risk of cardiovascular disease in 
ART patients [4]. Although lipoatrophy and lipohypertrophy may have different pathogenic 
components and can occur independently from each other, they often coexist [5]. Risk factors for 
lipodystrophy that have been identified in ART patients include the use of stavudine and 
didanosine, protease inhibitors (PIs), longer duration of ART, age over 40 years, female gender, 
lower baseline CD4 cell count and BMI >25 kg/m
2
  [6-9] 
 
Lipodystrophy occurs in 12% - 34% of HIV/AIDS patients in sub-Saharan Africa, and the risk is 
especially high in patients on stavudine containing ART [2, 10]. Despite having an extensive pattern 
of toxicities, stavudine is still widely used in low and medium income countries (LMIC), mainly 
because of its efficacy and low price. Rather than a complete ban of stavudine, it can be argued 
that if biomarkers of poor response to and toxicity of stavudine could be identified, only certain 
patients may be excluded from its use. Mitochondrial dysfunction together with effects from 
variation in mitochondrial polymerase-γ have been suggested as effectors of  stavudine  induced 
lipodystrophy as reviewed in Lewis et al [11]. In addition, genetic variation in HLA genes has 
been shown to play a role in the pathogenesis of lipodystrophy. For example, HLA A01, B08 or 
DQ2 supertype alleles  were protective against development of  lipoatrophy among Australians, 
while in the Thai population,  the HLA-B*4001 allele was associated with increased risk of  
stavudine associated lipodystrophy [12, 13]. It was also observed that  lipodystrophy is 
overrepresented in patients carrying the m.9055 G>A single nucleotide polymorphism (SNP) in 
mitochondrial DNA (mtDNA) which was associated with disruption of the normal functions of 
the mitochondrial ATP6 enzyme [14]. In two European studies, patients carrying the  mtDNA 
haplogroup K presented with increased risk of lipoatrophy while those carrying haplogroup T 














various populations worldwide, and it is therefore important to investigate if there is a role for 
mtDNA subhaplogroups specific for Africans, premised under the L haplogroup, in the 
susceptibility to stavudine toxicity.  Particularly few data still exist about  the effects of L 
subhaplogroups on the development of lipodystrophy [16], and the aim of this project therefore 
was to investigate the association of mtDNA subhaplogroups with lipodystrophy in adult 
Malawian HIV/AIDS patients on stavudine containing ART. 
 
Materials and methods  
Participants  
The participants in this study were recruited from the ART clinic of Queen Elizabeth Central 
Hospital, in Blantyre, Malawi and were part of an earlier longitudinal study that reported on 
stavudine toxicities [2]. To be eligible for the study, participants had to be on the standard first 
line ART regimen (stavudine, lamivudine and nevirapine), be maternally unrelated and willing to 
provide blood samples for genetic analysis. The exclusion criteria were pregnancy, being on 
tuberculosis treatment, being on ART treatment for less than 6 months and having missed 
medication for the past 3 days. The protocol conformed to the declarations of Helsinki 2008 and 
was approved by the College of Medicine Research Ethics Committee of the University of 
Malawi and the University of Cape Town, Faculty of Health Sciences, Research Ethics 
Committee. All participants gave written informed consent. 
 
Clinical and laboratory measurements  
Lipodystrophy was diagnosed with a validated questionnaire that uses a combination of patient 
self-assessment and inspection of seven body areas (face, neck, chest, abdomen, arms, legs and 
buttocks) by clinician as outlined by Carr et al [17]. An experienced ART clinician was trained 
in the use of the tool before the study by one of the investigators. CD4 cell counts were done 
with a FACSCount flow cytometer (Beckton Dickinson, New Jersey, USA), HIV-1 RNA with 
the Amplicor HIV Monitor version 1.5 (Roche Diagnostic Systems, Basel, Switzerland). 
Creatinine levels were measured using the end point Jaffe method [18] and the glomerular filtrate 















Total DNA was isolated from peripheral blood samples collected in EDTA coated tubes and used 
for mtDNA genotyping. MtDNA from each patient was amplified in 9 partially overlapping 
fragments to cover the whole mtDNA sequence using the primers reported by Ramos et al. [20, 
21]. Total volumes of 25 µl in a reaction mixture that consisted of 1X green GoTaq reaction 
buffer, 200 µM of dNTP, 1.0 mM of MgCl2, 0.4 µmol of each primer, 0.5 U of Taq DNA 
polymerase and 20 ng of DNA were amplified in the GeneAmp® PCR System 9700 by Life 
technologies (New York, USA). The PCR programs each consisted of an initial denaturation step 
at 94 
o
C for 5 min, followed by 35 cycles of denaturation at 94 
o
C for 1 min, annealing at 57 - 
64.4
 o
C  for 40s and extension at 72
o
C 2.5 min, with a final extension step of 5 min at 72
o
C [20]. 
PCR products were purified to remove excess primers and dNTP using exonuclease and shrimp 
alkaline phosphatase (ExoSap).  
 
Following polymerase chain reaction of 9 overlapping fragments sequencing reactions were 
performed using forward and reverse primers and additional internal primers. Mitochondrial 
DNA coding region was sequenced from nucleotide position 577 – 15953 according the revised 
mtDNA Cambridge reference sequence Locus NC_012920.1. ABI PRISM® 3130xl Genetic 
Analyzer (Applied Biosystems, California, USA) was used for capillary electrophoresis and  
Lasergene 10 Core Suite software (DNASTAR, Wisconsin, USA) to align and assemble 
sequences. Mutations (polymorphisms) were determined as nucleotide differences when 
compared to the Cambridge reference sequence.  
 
Subhaplogroup Analysis and Statistical Analysis 
Stata for windows software version SE/11 (Stata Corp; Texas, USA) was used for statistical 
analysis. We assessed the association of independent variables (sex, BMI, age, duration on ART, 
CD4 count, viral load and eGFR) with lipodystrophy, as well as the subhaplogroup distribution 
between patients presenting with and those without lipodystrophy with univariate logistic 
regression modelling. Multivariate logistic regression analysis was performed with those patient 
characteristics and subhaplogroups that had shown some degree of association (P <0.12) with 
lipodystrophy in univariate analysis. Odds ratios are reported with 95% confidence intervals and 
















A total of 117 participants on the standard first-line stavudine containing regimen were recruited 
and sixty-two per cent of the participants (n = 73) were female. The median age was 37 (IQR = 
31 - 46) years.  The median duration of ART at enrolment was 24 months (range 24 -25). The 
median body mass index (BMI) was 23 kg/m
2
 and 21% had a BMI above the normal range (>25 
kg/m
2
). Lipodystrophy was diagnosed in 16% (n = 19). Two (1%) patients presented with 
severely elevated serum creatinine levels of 5.4 mg/dl and 6.0 mg/dl (normal range = 0.5 – 1.5 
mg/dL). One percent (n = 1) and 2% (n = 2) were current smokers and consumed alcohol, 
respectively.  Table 1 gives a summary of the demographic and clinical characteristics of the 
study participants‘ time point at first lipodystrophy diagnosis. A significantly larger proportion 
of patients with lipodystrophy were above 40 years of age compared to those without 
lipodystrophy. 
 
Mitochondrial variation and haplogroup analysis  
After sequencing and alignment, 184 positions  exhibited polymorphisms that were used to 
groups the participants into four mitochondrial haplogroups  L0, L1, L2 and L3 were identified 
and further classified into  subhaplogroup L0a1, L0a2, L0d, L0f, L0k, L1c, L2a, L3d and L3e 
with L0a2 being the most frequent (27%) and L3d (3%) the least. None of the individuals 
carrying the mtDNA L3e subhaplogroup had lipodystrophy (table 2). No subhaplogroups were 
significantly associated with presence of lipodystrophy in univariate analysis. 
 
In multivariate logistic regression models, age >40 years was independently associated with 
lipodystrophy (Table 3).  Subhaplogroup L2a which had shown a degree of association with 
lipodystrophy in the univariate analysis however this was no longer significant after multivariate 
analysis. Heteroplasmy was observed in 19 mtDNA positions with the 5 positions, 6917, 7055, 
7274, 10589 and 10792, each being reported in 2 different samples, while the rest of the 
heteroplasmic positions were only observed once. Only one patient with lipodystrophy exhibited  

















Discussion   
The study was undertaken to explore the role of mtDNA subhaplogroups in susceptibility to 
develop lipodystrophy in HIV/AIDS patients on stavudine from Malawi. Subhaplogroup L3e 
appeared to protect patients against lipodystrophy. Variation in susceptibility to lipodystrophy 
observed with respect to mtDNA subhaplogroups could point to effects of subhaplogroup 
specific mutations on the structure of mitochondria and associated proteins.  Studies conducted 
in HIV/AIDS patients of Caucasian origin by Hendrickson et al [15] showed that the 
mitochondrial haplogroup K was a risk factor for lipodystrophy.   The absence of lipodystrophy 
in our patients with the mtDNA subhaplogroup L3e confirms earlier observations in South 
African HIV/AIDS patients [16]. Our findings and those of others show that each population 
group may have specific subhaplogroups that are associated with differential susceptibility to 
side effects of drugs. This notion has implications for the study of bi markers of the response to 
medication, stressing the need to include all population groups in such studies to determine 
population and group specific biomarkers.  
 
Of other characteristics that were studied, only age above 40 years was significantly associated 
with the presence of lipodystrophy. Our observation about age is comparable to other reports [10, 
15]. A study in South Africa found that males were at increased risk of lipodystrophy [22], 
however we observed no gender bias. In our study, lipodystrophy was not associated with 
markers of disease progression (viral load and CD4 cell count), although others indicated that the 
risk was greater in patients with lower CD4 cell count and lower BMI during early stages of 
ART treatment [23]. This is mainly determined by the fact that our measurements were done at a 
time that patients had been on ART for 2 years.   
 
Our study in the genetically underresearched  Malawian population [24] has several limitations. 
These include the cross sectional study design, which only considered variables at the point of 
enrolment and strongly limits conclusions about causality. The study was insufficiently powered, 
due to a small sample size, to detect associations of multiple haplogroups with lipodystrophy.  
Therefore we recommend larger prospective studies in Malawi to further investigate mtDNA 
patterns and ART responses. Secondly, lipodystrophy was diagnosed clinically, without using 














objective and we may not have separated lipo-atrophy from fat accumulation accurately. In 
addition, other genetic factors that may be associated with stavudine-induced lipodystrophy, such 
as levels of cytokines including TNF-α, IL-6; proteins such as leptin and adiponectin and 
polymorphisms in major histocompatibility complex genes [12, 25] were not considered.  
 
Conclusion 
Our study provides indications that susceptibility to lipodystrophy in HIV/AIDS patients on 
stavudine containing ART is mtDNA subhaplogroup and population specific.  
 
Future perspective 
Knowledge about the genetic variation in mtDNA should be integrated with information about 
variation in other genes especially those coding for drug metabolising enzymes, receptors and 
transporters, to get a clearer picture of the response to stavudine containing ART.  
Executive Summary 
 Genomics research especially with respect to pharmacogenetics, promises to reveal 
genetic biomarkers associated with differential susceptibility and response to treatment.   
 Recently, variation in mtDNA has been associated with risk of developing antiretroviral 
induced metabolic disorders in a subhaplogroup specific manner. 
 In addition to the traditional studies evaluating variation in drug metabolising enzyme 
genes, receptors and transporters,  variation that affects mitochondrial function should be 
studied as it affects both susceptibility to development of metabolic disorders and 
response to treatment 
 More African populations need to be studied in order to capture the breadth of the genetic 
diversity among its people.  
 In this study, we report the association of L3e with decreased risk of developing 
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Table 1: Clinical characteristic of the participants in relation to lipodystrophy  
 
Data is expressed as N (%) except for CD4 count and duration on ART  
IQR =, inter-quartile range 
BMI = body mass index (calculated as weight in kilograms divided by meters squared) 
LD = Lipodystrophy 
Freq = Frequency 
*10 samples (1 with LD and 9 without LD) did not have CD4  
**11 samples (1 with LD and 10 without LD) did not have viral load data 
eGFR =   estimated glomerular filtrate rate 
Black bold significant association 
 
 
Table 2: Association of mtDNA haplogroup with lipodystrophy in Malawian ART patients 
Subhaplogroups   Total 
(Freq) 
  LD (Freq)    No LD (Freq) Unadjusted OR (95%CI)  P-
Value 
L0a1   13 (0.06)   2 (0.10)    11 (0.06) 1.75 (0.17 – 8.94) 0.481 
L0a2   61 (0.28)   4 (0.19)    57 (0.29) 0.56 (0.13 – 1.84) 0.318 
L0d   15 (0.07)   2 (0.10)    13 (0.07) 1.46 (0.15 – 7.26) 0.630 
L0f     6 (0.03)   2 (0.10)      4 (0.02) 5.00 (0.42 – 37.12) 0.049 
L0k     9 (0.04)   3 (0.14)      6 (0.03) 5.22 (0.77 – 26.67) 0.015 
L1c   27 (0.13)   4 (0.19)    23 (0.12) 1.75 (0.39 – 6.01) 0.345 
L2a   53 (0.25)   2 (0.10)    51 (0.26) 0.29 (0.032 – 1.30) 0.090 
L3d     5 (0.02)   2 (0.10)      3 (0.02) 6.70 (0.52 – 61.35) 0.021 
L3e   26 (0.12)   0 (0.0)    26 (0.13)             - - 
Total 215 (100) 21 (100)  195 (100)   
 
Black bold significant association 
Characteristic LD (Freq) 
 
No LD (Freq) Total (N = 215) Odds Ratio P-
Value 
Female gender (%)   15 (0.71)  117 (0.60) 132 (0.61)  1.64 (0.57 – 5.39) 0.320 
 
Age Categories      
Age < 40 years     7 (0.33) 116 (0.60) 123 (0.57) 1.00  
Age ≥ 40 years   14 (0.67)   78 (0.40)   92 (0.43)  2.97 (1.06 – 9.07) 0.02 
 
BMI categories           
Normal (18-25 kg/m
2
)   17 (0.81)   150 (0.77) 167 (0.78)  1.00 1.00 
Underweight (<18.5 kg/m
2
)     0 (0.0)       6 (0. 3)      6 (0.3)         - - 
Overweight (>25 kg/m
2
)     4 (0.19)   38 (0.20)   42 (0.19)  0.93 (0.29 – 2.92) 0.899 
 
*CD4 count (cells/µL)  340 (228 - 451) 344 (227 – 494) 344 (227 – 489) 1.00 (0.99 – 1.01) 0.543 
**Viral Load (CPs/ml)          
<400   19 (0.95) 161 (0.87)  180 (0.88)   1.00 1.00 
≥400     1 (0.05)   23 (0.13)    24 (0.12) 0.368 (0.01 -2.56) 0.323 
 
Duration on ART(IQR) 
(months) 
  
  25 (24 – 26) 
 
  25 (23 – 31) 
   
   25 (23 -29) 
 
  1.00 (0.95 – 1.04) 
 
0.845 
Median eGFR (IQR) 
(ml/min) 















Table 3: Multivariate logistic regression analyses of factors associated with lipodystrophy   
Phenotype data including gender, age, BMI, duration on treatment, viral load, CD4 cell count) were analysed in the 
multivariable analysis with either L0k (model 1) or L2a (model). Black and bold significant association. L0f and 
L3d although their P-value were <0.1 but were not considered in the multivariate analysis because of wide variation 















Covariate Model 1  
(L0k versus all other L 
subhaplogroups)  
OR (95% CI) 
P-value Model 2 




Gender (Female) 1.69 (0.55 – 5.15) 0.356 1.94 (0.64 – 5.79) 0.236 
Age (yrs) ≥40 3.70 (1.30 – 10.58) 0.014 3.09 (1.14 – 8.38) 0.027 
BMI (kg/m
2
) >25 0.91 (0.27 – 3.10) 0.270 0.86 (0.26 – 2.85) 0.802 
Duration on ART (months) 1.00 (0.95 – 1.05) 0.927 1.00 (0.95 – 1.05) 0.926 
Viral Load (CPs/ml) 
≥400 
 




0.32 (0.04 – 2.63) 
 
0.291 
CD4 count (cells/µL) 1.00 (0.99 – 1.00) 0.346 1.00 (0.99 – 1.00) 0.395 
L0k(vs all L subhaplogroups) 7.45 (1.45 – 38.24) 0.016   














7. CHAPTER 7: EFFECTS OF STAVUDINE-CONTAINING ART ON 
MITOCHONDRIA LEVELS  
 
Decreased mitochondrial DNA content in HIV-infected Malawian patients on stavudine 
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Mitochondrial toxicity is a major concern related to nucleoside reverse transcriptase inhibitors 
and manifests through peripheral neuropathy, lipodystrophy, lactic acidosis and hyperlactatemia. 
Depletion of mitochondria has been associated with mitochondrial dysfunction. We investigated 
whether mtDNA levels in peripheral blood can be used as a biomarker of mitochondrial 
depletion due to stavudine associated toxicity. A cross sectional study of 203 HIV- infected 
patients on stavudine containing therapy and 64 healthy controls conducted. Peripheral 
neuropathy was present in 21% (43/203), while lipodystrophy measurement were present in 18%  
(n = 20) of 112 investigated and out of 113 patients high lactate levels were present in 17% (n = 
19) and those with no adverse events group (n = 142). Total DNA was extracted from whole 
blood and relative mtDNA/nuclear DNA ratio was determined.    
 
The healthy controls had higher relative mtDNA/nDNA ratios compared to patients on ART with 
board line statistical significance (P = 0.05). Compared to healthy controls, the following groups 
had statistically significantly decreased relative mtDNA/nDNA ratios; patients on ART 
presenting with peripheral neuropathy (P=0.039) and patients presenting with high lactate levels 
(P = 0.024). Comparison between groups significant differences in mtDNA/nDNA ratios were 
observed between patients with high lactate levels to patients with normal lactate levels (P = 
0.018). Significant mtDNA/nDNA ratios (P = 0.01) were observed when subhaplogroup L0a2 
was compared with L2a. Stavudine is associated with decreased mitochondrial content in HIV-























The amount of mitochondrial DNA (mtDNA) varies among healthy individuals of different ages 
and in different tissues within the same individual from 100 to 1000 copies mtDNA per cell (Bai 
et al., 2004; Pezeshkpour et al., 1987). The quantity of mtDNA in an organ can also have 
pathological relevance as depletion is associated with respiratory chain defects (Bai et al., 2004). 
Mitochondrial diseases are characterised by molecular defects in mtDNA or in nuclear genes that 
code for mitochondrial components. These defects can be acquired or inherited (Mazunin et al., 
2010; Naviaux RK, 2003). Certain infections, for example human immunodefiency virus (HIV), 
and adverse effects of drugs such as nucleoside reverse transcriptase inhibitors (NRTIs), may 
result in mitochondrial dysfunction (Carrozzo and Lucioli, 2005; Mazunin et al., 2010; Naviaux 
RK, 2003; van der Watt et al., 2011).   
 
 Stavudine is a NRTI used in combination with other antiretroviral drugs for the treatment of 
HIV infected individuals. It is effective in suppressing HIV replication and affordable in low and 
medium income countries.  However, common and severe adverse drug effects have led to calls 
for its withdrawal. Most of the adverse drug effects of stavudine resemble patterns found in 
inherited mitochondrial diseases for instance hepatic steatosis, lactic acidosis, myopathy, 
nephrotoxicity, peripheral neuropathy, and pancreatitis (Keswani et al., 2002; Nicholas et al., 
2007). The proposed mechanism by which mitochondria are affected by stavudine can be 
described as direct, through inhibition of mtDNA transcription, or indirect, through impact on the 
activity of mitochondrial polymerase gamma, an enzyme required for mtDNA replication and 
repair. In both scenarios, mitochondrial DNA becomes depleted, and if this reaches a critical 
threshold, insufficient energy generation ensues (Casula et al., 2005; White, 2001). Low ATP 
production results into tissue or organ dysfunction. Stavudine induced mitochondrial dysfunction 
can be the result of effects on adenylate kinase, by inducing mtDNA mutations as well as by 
exerting oxidative stress; this has been suggested to trigger the onset of peripheral neuropathy 
(Lewis et al., 2003; Tozzi, 2010). Histologic evidence demonstrates abnormal mtDNA structure 
















There is great inter-individual variation in the presentation of stavudine toxicities and also within 
the same individual marked differences in organ susceptibility can exist. The molecular 
mechanisms underlying these differences are not fully understood. One possible explanation is a 
differential effect of mtDNA variants on treatment response and susceptibility of toxicity in 
different populations (Canter et al., 2010; Grady et al., 2011; Kampira et al., 2013) 
 
Mitochondrial determinants may predict the risk of developing drug associated toxicities in 
individuals as they can be determined before initiation on ART. However determination of 
mtDNA variants as a measure of risk for drug toxicities is expensive in resource poor countries. 
We aimed at investigating whether mitochondrial levels in peripheral blood can be used as 
markers of stavudine-associated toxicities in addition to genotyping for mtDNA variants.  
 
Laboratory measurements 
 Lactate levels were measured with the hand-held Lactate Pro (Arkray Europe B.V., Amstelveen, 
the Netherlands) at the point-of-care. Lactate levels above 2.5 mmol/L were considered to be 
elevated. CD4 cell count and HIV-1 RNA  were determined  by FACSCount flow cytometer  
(Beckton Dickinson, New Jersey, USA) and  Amplicor HIV Monitor version 1.5 (Roche 
Diagnostic Systems, Basel, Switzerland) respectively.  
 
Whole blood was kept at -20
o
C until DNA extraction as described earlier (Kampira et al., 2013). 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) nuclear control and ATP synthase 
(ATPase) 8 mitochondrial DNA gene were quantified by real-time quantitative PCR with use of 
Light Cycler II Roche (Roche Diagnostic Coorperation, Indianapolis, USA). Primers for RT Q-
PCR analysis for GAPDH were: forward: 5'-CCCCACACACATGCACTTACC-3´ and reverse: 
5'-CCTAGTCCCAGGGCTTTGATT-3´ while those for mtDNA ATPase 8 were: forward: 5'-
AATATTAAACACAAACTACCACCTACC-3´ and reverse: 5'-TGGTTCTCAGGGTTTGTT 
ATA-3´ (Xia et al., 2009). GAPDH and mtDNA ATPase templates were amplified separately in 
total volume of 25µl in a reaction that consisted of 12.5 μl KAPA SYBR green qPCR master 
mix, 0.4 µmol of each primer of 200nM concentration, 2 μl DNA and 9.5 μl water. The RT- PCR 
amplification consisted of a single denaturation–enzyme-activation step of 10 minutes at 95°C, 














temperature-transition rate of 20°C per second. The real-time PCR reactions were performed in 
duplicate for each gene.  
 
The mean threshold cycle number (Ct) values from real time PCR were obtained to compare the 
level of expression of GAPDH (nDNA) and ATPase 8 (mtDNA) in healthy controls and HIV-
infected patients on ART. According to Gibson et al (Gibson et al., 1996) the Ct value is the 
lowest cycle number at which the fluorescence detected crosses a threshold level deemed to be 
significantly higher than background. Therefore the fewer cycles it takes to reach a detectable 
level of fluorescence, the greater the initial DNA concentration, meaning that  low Ct values are 
detected in samples with high initial DNA template (Bustin, 2000). Threshold cycle values of 
nDNA and mtDNA were compared using the delta Ct (∆Ct) which is the difference of the 
average of two measurements Ct of nDNA and of mtDNA (∆Ct = CtnDNA- CtmtDNA) in the 
same sample. Mitochondrial DNA and nDNA standard dilution curves generated from total 
genomic DNA with the following concentrations: 5000, 500, 50 and 5pg/ µL. Nuclear DNA and 
mtDNA concentrations were estimated from a standard efficiency curve using the delta Ct (∆Ct) 
of average Ct of the same sample versus log DNA concentration. Furthermore, the mtDNA 
content of the cells was expressed relative to concentration of nDNA (mtDNA/nDNA ratio).  
 
Mitochondrial DNA was isolated from peripheral blood samples collected in EDTA coated tubes 
and used for mtDNA genotyping. Mitochondrial DNA from each of the 203 patients was 
amplified in 9 partially overlapping fragments to cover the whole mtDNA sequence using the 
primers reported by Ramos et al. (Ramos et al., 2009; Ramos et al., 2011). A total volume of 25 
µl in a reaction mixture that consisted of 1X green GoTaq reaction buffer, 200 µM of dNTP, 1.0 
mM of MgCl2, 0.4 µmol of each primer, 0.5 U of Taq DNA polymerase and 20 ng of DNA were 
amplified in GeneAmp® PCR System 9700 by Life technologies (New York, USA). The PCR 
programs each consisted of an initial denaturation step at 94 
o
C for 5 min, followed by 35 cycles 
of denaturation at 94 
o
C for 1 min, annealing at 57 - 64.4
 o
C  for 40s and extension at 72
o
C 2.5 
min, with a final extension step of 5 min at 72
o
C (Ramos et al., 2009). PCR products were 
















Following polymerase chain reaction of 9 overlapping fragments sequencing reactions were 
performed using forward and reverse primers and additional internal primers. Mitochondrial 
DNA coding region was sequenced from nucleotide position 577 – 15953 according the revised 
mtDNA Cambridge reference sequence Locus NC_012920.1. ABI PRISM® 3130xl Genetic 
Analyzer (Applied Biosystems, California, USA) was used for capillary electrophoresis.  
Lasergene 10 Core Suite software (DNASTAR, Wisconsin, USA) was used to align and 
assemble sequences. Mutations (polymorphisms) were determined as nucleotide differences 
when compared to the Cambridge reference sequence.  
 
Statistical analysis 
Both mtDNA and nDNA threshold cycle values and concentration were analyzed as median, 
interquartile ranges (1QRs) range and differences in levels between health controls and patients 
on ART were determined. Spearman rank correlation was used to determine the relationship 
between mtDNA Ct and nDNA CT values of healthy and patients on ART. Using Graph Pad 
Prism® 5 software (GraphPad Software Inc., San Diego Canada) we compared the 
mtDNA/nDNA ratio in blood between healthy controls and patients on ART with or without 
toxicities with the Mann Whitney U- test.  We used MANOVA analysis to determine the 
association of age, gender, and duration on ART, BMI, CD4 and viral load with mtDNA content. 
Associations were considered significant when p < 0.05 was observed. Stata for windows 
software version SE/11 (Stata Corp, Texas, USA) was used for statistical analysis of age, gender, 
duration on ART, BMI, CD4 and viral load with mtDNA content. Kruskal Wallis test was used 
to compare the content of mtDNA in blood between mtDNA subhaplogroups. 
 
Results 
Out of the 215 ART patients that were recruited, 203 had their mitochondrial content 
successfully analyzed, the other 12 (6%) were excluded from the analysis. Six (9%) of 70 
healthy controls were excluded for the same reason. Patients were on stavudine containing first 
line ART for a median duration of 25 months (range 23 -29). There was a female preponderance 
(n= 132, 61%) and the mean age was 40 years. Cotrimoxazole prophylaxis was used by all 














participants examined for lipodystrophy, of which 18% (20/112) presented with lipodystrophy. 
Lactate levels were available from investigated 113 patients and of these 17% (n = 19) presented 
with elevated levels (>2.5 mmol/L).  Healthy controls were determined by physical examination 
and no information on HIV status was available.  
  
Mitochondrial DNA level  
The median Ct values of GAPDH (indicative of nuclear DNA) of healthy controls and of 
HIV/AIDS patients; were not significantly different (23.58 vs. 23.43; P= 0.998). However, the 
median Ct value of the ATPase gene (indicative of mtDNA) of healthy controls was significantly 
lower than that of HIV/AIDS patients (17.88 vs.18.75; P = 0.005). Significant differences were 
also observed between the relative nDNA Ct levels and mtDNA Ct level of healthy controls and 
HIV/AIDS patients as illustrated in Table 1. There was no significant correlation between nDNA 
Ct values and mtDNA Ct values in healthy controls while a significant correlation existed 
(r=0.232; P = 0.0009) ART patients as illustrated in Figure 1. The standard curves generated 
from total DNA showed good correlation with threshold Ct values, r
2 
= 0.9966 for GAPDH and 
r
2
 = 0.9419 for ATPase (Figure S1) versus log DNA concentration.  
 
Healthy controls had a significantly higher mtDNA/nDNA ratio than patients on ART, (6.64 vs. 
5.08; P = 0.05), as indicated in Figure 2. It was observed patients on ART presenting with 
peripheral neuropathy had significantly lower (6.64 vs 3.4, P = 0.039) mtDNA/nDNA ratio when 
compared to healthy controls and no significant differences (P = 0,207) were observed between 
patients experiencing peripheral neuropathy and those not experiencing peripheral neuropathy.  
mtDNA/nDNA ratios of patients on ART with elevated lactate levels were much lower than in 
healthy controls (6.64 vs 0.68, P = 0.024) and also lower in patients with elevated lactate (0.68 vs 
5.88, P = 0.018) when compared to the group with normal lactate levels. None of the patient 
characteristics (age, gender, duration on ART, BMI, viral load, CD4 count and viral load) were 
associated with peripheral blood mtDNA/nDNA ratio (Table 2).  
 
Nine mtDNA L lineage subhaplogroups L0a1, L0a2, L0d, L0f, L0k, L1c, L2a, L3d and L3e were 
identified with frequencies of  6%, 29%, 8%, 3%, 4%, 12%, 24%, 2% and 12% respectively. 














had were significantly lower levels  (0.62 vs 8.50, P = 0.01) when compared to subhaplogroup 
L2a (figure 3).  
 
Discussion 
Previous studies have associated NRTIs with development of ART associated toxicities such as 
peripheral neuropathy, lipodystrophy, lactic acidosis and hypertension (Anderson et al., 2004; 
Domingo et al., 2010; Hulgan et al., 2005; Menezes et al., 2011). However these findings have 
been tissue specific and there are no established standard laboratory markers to predict the risk of 
developing/or the onset of mitochondrial toxicity. Therefore, we set out to investigate the effects 
of stavudine containing ART on mitochondrial levels in peripheral blood. We report no 
differences in the GAPDH Ct levels between healthy control and patients on ART indicating that 
the HIV/AIDS condition does not substantially affect GAPDH levels in agreement with earlier 
observations (Barber et al., 2005).  
 
There was a trend towards low level (P = 0.05) mitochondrial in HIV/AIDS patients on ART 
when compared to healthy controls an observation that may reflect possible stavudine effects on 
mitochondrial that  may interfere with mtDNA replication processes (White, 2001). In addition, 
significantly low mitochondrial levels were associated with peripheral neuropathy suggesting 
that mitochondrial dysfunction may have casual relationship with peripheral neuropathy.  These 
findings are in support of earlier reports which identified decreased mitochondria in patients with 
peripheral neuropathy on stavudine containing therapy (Casula et al., 2005; Dalakas et al., 2001; 
Kakuda, 2000). Lack of evidence of decreased mitochondrial content in the group with 
lipodystrophy could suggest that drug effect on mitochondrial in relation to this adverse event is 
cell, tissue and organ specific supporting finding of other studies (Feng et al., 2001; Morse et al., 
2012). However, other factors such as sample size could be considered since this study was cross 
sectional. 
 
Decrease in mitochondrial content in HIV/AIDS patients on ART with elevated that lactate 
levels (>2.5U/L) are in agreement with previous studies which reported elevated lactate levels 














(stavudine) inhibition effect on mtDNA proliferation (Montaner et al., 2004). Results of this 
study support the hypothesis that mitochondrial levels in blood are associated with 
hyperlactatemia  and confirm previous observations (Montaner et al., 2004). Accordingly, 
elevated lactate levels are indirectly a sign of mitochondrial dysfunction. Abnormal functioning 
of the mitochondria will result a shift towards anaerobic oxidation of pyruvate by pyruvate 
dehydrogenase and the formation of lactate dehydrogenase and lactate (Claessens et al., 2003; 
Côté et al., 2002; Miller et al., 2000). Hyperlactatemia has been reported to be associated with 
peripheral neuropathy and lipodystrophy (Brew B et al., 2001; Simpson D et al., 2004), although 
hyperlactatemia was  common among patients with peripheral neuropathy and lipodystrophy but 
we could not establish this relationship in this study possibly because of  the study design. 
However in our earlier study it was postulated suggested that elevated lactate levels may reflect a 
common underlying pathophysiology of peripheral neuropathy and lipodystrophy (Chagoma et 
al., 2013). Therefore we further suggest that lactate and mitochondrial levels can be used to 
predict onset of mitochondrial associated toxicities. Differences observed in mtDNA/nDNA ratio 
between  subhaplogroups L02a and L2a could possibly support our earlier findings (Kampira et 
al., 2013) that susceptibility to stavudine associated toxicities is subhaplogroup specific.  
 
However our study has limitations which include lack of corresponding information on 
morphology of cells to confirm observed relationships between abnormalities and toxicities. We 
propose further investigations on the relationship between hypertension and stavudine associated 
mitochondrial depletion, lipodystrophy and dyslipidemia. Another factor to be considered is that 
our controls although being Bantu speakers as patients, they were not from the same population. 
There was no data on mitochondrial content in specific tissues in order to compare with our 
results in to establish if there is relationship between mitochondrial content in the blood and 
other tissues. A bigger sample size for each of the toxicity groups is needed to further confirm 
our findings.   
 
Conclusion 
Large numbers of patients in resource limited settings are still receiving stavudine containing 
regimen. Quantitative evaluation of mitochondrial levels in the peripheral blood of individual on 














mitochondrial toxicities (peripheral neuropathy and hyperlactatemia which may lead to 
irreversible lactic acidosis). Further studies need to be conducted to confirm if peripheral blood 
mitochondrial levels could be used in monitoring events associated to stavudine induced 
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Table 1: mtDNA content in peripheral blood of healthy controls and patients on stavudine 
 Healthy 
Controls 
 (n = 64) 
On stavudine 




∆Ct (CtnDNA – CtmtDNA)     
Median 5.73 4.62 1.11 0.003 
Range 3.08 – 7.71 2.77 – 5.12   
nDNA content (pg/µL)     
Median 1225 1352  0.998 
Range 229 - 2698 979 - 1892   
mtDNA content 
(pg/µL) 
    
Median 15812 6368  0.005 
Range 482 – 506991 514 – 17458   
Correlation     
(Ct nDNA vs CtmtDNA) r
2
  = 0.083 r
2
  = 0.232   
 P = 0.513 P = 0.0009   



















Table 2: Patients’ characteristics in relation to relative mtDNA/nDNA ratio 
  mtDNA/nDNA ratio 
Median (range) 
Overall relative mtDNA/nDNA 




   
Female 5.26 (0.47 – 11.70) 5.08 (0.37 – 12.34) 0.999 





Age Categories    
Age < 40 years 5.20 (0.37 -13.14) 5.08 (0.37 – 12.34) 0.154 
Age ≥ 40 years 4.70 (0.34 – 11.66) 
 
  





6.81 (2.16 – 17.72) 5.08 (0.37 – 12.34) 0.129 
Normal (18-25 kg/m
2
) 4.99 (0.31 -12.34)   
Overweight (>25 kg/m
2





   
0 - 199 5.30 (0.37 – 13.89) 5.14 (0.39 – 13.14) 0.908 
200 - 349 5.51 (0.60 -11.62)   
≥350 4.09 (0.29 – 14.27) 
 
  
Viral Load (CPs/ml)    
<400 5.15 (0.37 – 10.93) 5.12 (0.39 – 13.14) 0.501 





   
< 24 5.12 (0.44 – 13. 14) 5.08 (0.37 – 12.34) 0.730 






















 Figure 1: Correlation of nDNA and mtDNA Ct levels in peripheral blood 
A: In healthy controls, nDNA and mtDNA Ct values were not significantly correlated (R
2
  = 0.043; P = 0.738).B: In 
patients on stavudine containing ART, nDNA and mtDNA Ct values were significantly correlated  R2 = 0.232; P = 

































































Figure 2: mtDNA/nDNA ratios in healthy controls and ART patients with and without 
toxicities 
1. HC, healthy controls; Patients on ART; 3 PN, peripheral neuropathy; 4 LD, lipodystrophy; 5 LAC, lactate 

























































Figure 3: mtDNA/nDNA ratios in ART patients categorized in different mtDNA 
Subhaplogroups 
























Figure S1: Standard curve plotted from regression analysis of threshold cycle and serial 
dilution of total genomic amplified DNA.     










y = -3.587x + 34.655
R² = 0.9966
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8.1.1. Mitochondrial polymerase amplification and sequencing analysis 
Mutations in mitochondrial polymerase gamma have been associated with stavudine induced 
toxicities but distribution of polymerase gamma variants are population specific [1,2]. In order to 
investigate the reported variants and possible novel mutations  in mitochondrial polymerase 
gamma, a section of the polymerase gamma domain from exon15 to exon 18, (Figure 8.1) a 1450 
base pair region was amplified using the primers according to van Goethem [3] and these were 
exon 15 forward primer: 5´-ATG GTG GGATGT GGG ATA GATT-3´  and exon 18reverse 
primer: 5´-GTA ATG GGC AGG AGA TAG AAC AGA-3´. Pol γ DNA template was amplified 
in total volume of 25 µl in a reaction that consisted of 1X green GoTaq reaction buffer, 200µM 
of dNTP, 2.0 mM of MgCl2, 0.4 µmol of each primer, 0.5 U of Taq DNA polymerase and 20 ng 
of DNA in a GeneAmp® PCR System 9700 (Life technologies, New York, USA). The PCR 
conditions involved an initial denaturation step at 95 
o
C for 5 min, followed by 30 cycles of 
denaturation at 94 
o
C for 30 seconds, annealing and extension temperatures of 60 
o
C and 72 
o
C 
for 30 seconds and for 1.0 minute, respectively, with a final extension step of 10 minutes at 72 
o
C. PCR amplification products were confirmed by electrophoresis on 1.5% agarose gel stained 
with ethidium bromide. The separated DNA fragments were visualized under UV light using a 
UV transilluminator (Nucleotech, California, USA) and images were captured using the 
Nucleovision system and its associated Gel Expert software (Nucleotech, CA,USA).  
 
PCR templates were cleaned-up by using exonuclease 1 in order to remove excess primers and 
shrimp alkaline phosphatase to degrade the dNTPs in the reaction. Each reaction mixture 
contained 2 U of exonuclease, 1 U shrimp alkaline phosphatase (Fermentas), 13.9 µl water and 5 
µl of PCR product. The samples were then incubated at 37 °C for 15 minutes and at 75 °C for 














8.1.2. Mitochondrial polymerase gamma genotyping 
Using the cleaned PCR product, sequencing was performed using 0.5 µM of exon 17 forward 
primer: 5´-CAG GAA TGG GGT AGG AAG AGT C-3´, 1µl of Big Dye Terminator mix Cycle 
Sequencing Kit (ABI PRISM Big Dye Terminator v3.1 mix (Applied Biosystems, California, 
USA) in the presence of deoxynucleoside triphosphates, fluorescence-tagged terminating 
analogues, DNA polymerase, MgCl2 and the appropriate buffer , 2 µl of 5X sequencing buffer, 2 
µl cleaned PCR product and 4 µl was electrophoresed on GeneAmp 9700 sequencing machine 
(Applied Biosystems, California, USA) .The sequencing temperatures conditions were 96 
o
C for 
5 minutes,  and 96
 o
C for 30 seconds, 55 
o
C for 15 seconds and 60 
o
C for 4 seconds
  
for 30 cycles.  
Exon 18 reverse primer: 5´-GTA ATG GGC AGG AGA TAG AAC AGA-3´ was used to 
confirm the mutations. PCR templates were cleaned-up inorder to remove excess nucleotides and 
primers from PCR reactions by using exonuclease 1 to removes primers and shrimp alkaline 
phosphatase (ExoSap) degraded the dNTPs in the reaction. Each reaction mixture contained 2 U 
of exonuclease, 1 U shrimp alkaline phosphatase (Fermentas), 13.9 µl water and 5µl of PCR 
product. The samples were then incubated at 37 °C for 15 minutes and at 75°C for 1hour in 
GeneAmp® PCR System 9700 (Life technologies New York, USA).  
 
Cleaned PCR product were sequenced with reaction contained 0.5 µM primer, 1 µl of 
Terminator mix Cycle Sequencing Kit (ABI PRISM Big Dye Terminator v3.1 Cycle Sequencing 
Kit, Applied Biosystems, California, USA) containing optimized concentrations of 
deoxynucleoside triphosphates, fluorescence-tagged terminating analogues, DNA polymerase, 
MgCl2 and the appropriate buffer , 2 µl of 5X sequencing buffer, 2 µl cleaned PCR product and 4 
µl water run on GeneAmp 9700 sequencing machine (Applied Biosystems) with temperature 
conditions 96 
o
C for 5 min, followed by 30 cycles at 96 
o
C for 30 seconds, 55 
o
C for 15 seconds 
and 60
 o
C for 4 minutes.  Sequencing reaction cleanup was performed using ethanol/sodium 
acetate (NaAc). Capillary electrophoresis for sequencing reactions were run on an ABI PRISM® 
3130xl Genetic Analyzer (Applied Biosystems) and analyzed using sequencing Analysis 






















           
                                         649bp (sequenced)                         
       
                                                                                             
                                                                                                       
                                                                                             18939 C>T (R964C)                                                                                              
 
Figure 8.1: Schematic representation of human mitochondrial polymerase gamma gene on     
chromosome 15q25. 
(A) Shows 22 exons (2-23) with corresponding introns and their positions (numbers below). Red and grey markers 
 indicate positions of reported dominant and recessive mutations respectively (B) A schematic representation of  
polymerase gamma showing sequenced region. Figure adapted from Hudson and Chinnery [4] 
 
8.1.3. Data analysis  
The partially sequenced fragm nts of POLG-γ from position 18487 – 19136 (649bps) were 
assembled and aligned to NC_000015.9 reference gene using Lasergene 10 Core Suite software 
(DNASTAR, Wisconsin, USA). Sequences were compared and mutations (polymorphisms) were 
determined as nucleotide differences with the reference sequence gene. Using Stata software 
version SE/11 (Stata Corp; Texas, USA) and Shesis software [5] were used to determine 
genotype and allele frequencies. Linkage disequilibrium (LD) analysis for determined mutations 
was calculated and furthermore LD was measured by Lewontin‘s coefficient (D‘) and squared 
correlation coefficient (r
2
) with range from zero from independence to 1for complete co-
inheritance were carried using SHEsis [5]. Hardy Weinberg Equilibrium (HWE) analysis of 















Mann Whitney test was used to compare allele frequencies between Malawi population and other 
populations (Sub-Sahara Africa, European and Asian). Chi-square was used to determine 
whether the frequencies of genotypes were associated with demographic information and clinical 
parameters (peripheral neuropathy, lipodystrophy, lactate, CD4 cell count, viral load, gender, 
age, body mass index and duration on treatment). Furthermore, genotypes were compared with 
mtDNA levels.  
 
8.2.  Results  
8.2.1. POL-γ genotype frequencies 
Results on the patient‘s characteristic have been detailed in chapter 3. Of 215 patients‘ DNA 
samples available, 166 (77%) samples were successfully sequenced for the polymerase gamma 
amplicon. A total of 4 positions showed polymorphic variation, rs2307431 (19011 C>T) in exon 
18 and rs58584025 (18709 indel AGGT), rs41544115 3 (18773 C>T) and rs2307449 (19103 
A>C) in intron 17 and intron 18 with the reference sequence NC_000015.9. The frequencies of 
the minor alleles were as follows; 19011T (24%), 18709 indel (5%), 18773T ( 4%) and 19103C 
(18%). The distribution pattern of the variants in the studied population was as indicated in Table 
8.1. The genotypes for all the SNPs conformed to Hardy Weinberg equilibrium. Allele and 
genotype frequencies were compared to other populations in Sub-Sahara Africa (Yoruba), 
European and, Asian taking the data from HapMap and dbSNP databases (Table 8.2). No 
differences were observed with respect to allele frequencies within Sub-Sahara African 
populations.  However, rs2307431 (19011 C>T) mutation among Malawians was significantly 
different when compared to those for European and Asian populations (P = 0.001; P = 0.0003, 
respectively). We observed a high prevalence of the rs2307449 (19103 C/C) genotype in our 


















Table 8.1: Distribution of alleles in the Malawi population. 
Genotype Frequencies = (%) 
 
18709 indel AGGT 
 
-/- 8 (0.048) 





C/ C 153 (0.956) 
C /T 7 (0.0438) 
T/T  - 
19011 C>T  
C/ C 100 (0.758) 
C /T 27 (0.204) 










Table 8.2: Comparison of allele frequencies between our study (Malawi) population and 
other world populations  




Asians  N(P) 
18709 indel AGGT 
(rs58584025) 
           - 





NA NA NA 
18773 C>T (rs41544115) 
           C 













19011C>T (rs2307431)   
          C 













19103 A>C  (rs2307449)       
          A 






























8.2.2. Linkage disequilibrium and haplotype analysis 
Linkage disequilibrium (LD) analysis for the POLG-γ 4 SNPs obtained in our study population 
was performed in order to determine the pattern of inheritance by correlation coefficient r
2
 using 
SHEsis software [5]. The strongest pairwise linkage disequilibrium (D‘) and coefficient (r
2
) were 
observed between 18709insA, 18710G, 18711G and 18712T (D‘= 0.99, r
2
 = 1) see Linkage 





Figure 8.2: Linkage disequilibrium (LD) plot of POLG variants. 
Correlation coefficient (r
2

















8.2.3. POLG mutations in association with mitochondrial toxicities 
None of the demographic parameters was associated with any of the genotypes (Table 8.3)  The 
distribution of mutations in individuals with different levels of CD4 cell count was not different. 
Viral suppression was not associated with any of the identified mutations. Heterozygous minor 
alleles identified on the mitochondrial polymerase gamma were not associated with peripheral 
neuropathy, lipodystrophy and hyperlactatemia in samples. In a separate analysis homozygous 
19011T/T was not significantly associated with mitochondrial associated toxicities. 
 
Table 8.3: POL-γ genotypes and association with patient features 




                                                    Genotypes (MAF) 
18709-/-   18773T 19011 T 19103 A 
N (freq) P-value N (freq) P-value N (freq) P-value N (freq) P-value 
Gender         
Female 5 (0.63) 0964 6 (0.86) 0.205 12 (0.37) 0.797 19 (0.83) 0.068 
Male 3 (0.37)  1 (0.14)  20 (0.63)   4 (0.17)  
Age categories 
 
        
<40 years 6 (0.75) 0.282 3 (0.43) 0.465 16 (0.50) 0.371 10 (0.43) 0.976 
>40 years 2 (0.25)  4 (0.57)  16 (0.50)  13 (0.56)  
BMI categories         
Underweight  
(<18.5 kg/m2) 
1 (0.15) 0.065 0 (0) 0.315 0 (0) 0.559 0 (0) 0.737 
Normal  
(18-25 kg/m2) 
7 (0.87  3 (0.43)  27 (0.84)  19 (0.83)  
Overweight  
(>25 kg/m2) 
0 (0)  4 (0.57)  5 (0.16)  4 (0.17)  
CD4 (IQR) 
cells/µL 
290 (191 - 435) 0.334 451 (167 – 484) 0.861 384 (317 – 503) 0.305 412 (276 – 534) 0.566 
Viral Load  
(CPs/ml) 
        
<400 5 (0.63) 0.061 7 (1.00) 0.255 28 (0.87) 0.969 16 (0.76) 0.084 




25 (23 – 29) 0.753 24 (12 – 46) 0.958 24 (23 – 29) 0.472 25 (23 – 33) 0.333 
PN         
Yes 0 (0.0) 0.102 3 (0.43) 0.244 8 (0.25) 0.724 5 (0.22) 0.986 
No 8 (1.00)  4 (0.57)  24 (0.75)  18 (0.78)  
LD         
Yes 1 (0.13) 0.779 1 (0.14) 0.699 4 (0.13) 0.226 0 ( 0.0) 0.117 
No 7 (0.87)  6 (0.86)  28 (0.87)  23 (1.00)  
LAC >2.5U/L          
Yes 2 (0.33) 0.543 1 (0.33) 0.674 2 (0.20) 0.791 2 (0.20) 0.765 














8.2.4. POL-γ mutations and mtDNA depletion 
Relative mtDNA/nDNA ratios between the wildtype genotype and variants were compared and 
results were as shown in Figure 8.3. Mitochondrial DNA/nDNA ratios‘ between samples with 
variant 18709 indel AGGT and those without an insertion were not significantly different (P = 
0.1556).  Although mtDNA/nDNA ratio were higher in the samples with genotype 18773 T/T 
compared to 18773 C/C this was not statistically significant (P = 0.2791). Comparison of 
mtDNA/nDNA ratios between genotypes 19011C/C with the heterozygous genotype, 19011C/T 
and homozygous 19011T/T were not statistically significant (P = 0.8496; P= 1.00 respectively). 
Low mtDNA/nDNA ratios were observed in the individuals with 19103 A/A genotype when 
compared to individual with the19103C/C genotype, however this difference was not statistically 
significant (P = 0.5364).   
 
 
Figure 8.3: POLG-γ variants in association with mtDNA/nDNA ratio.  
 















Partially sequenced region in the active domain of polymerase gamma was selected based on the 
fact that it consists of highly conserved O helix that directly interacts with bound nucleotides. 
Secondly previous studies had shown that the selected region is highly polymorphic 
(http://tools.niehs.nih.gov/polg/) encompassing the mutation R964 which has been associated 
with stavudine associated lactic acidosis [1]. Secondly whole polymerase gamma was sequenced 
on 10 samples from the study where no known pathogenic mutations were identified [6] 
Prevalence of variant 18709 indel AGGT has not been reported in other populations according to 
HapMAp, and we report it for the first time with highest prevalence of 95% in our population. 
Further analysis of the mutation in African population may provide information on the 
distribution and base composition. Allele frequencies for 18773T (2.2%) and 19011T (14%) in 
our study population were not different from frequencies in Sub-Sahara African populations , 
although differences were observed with other populations from other regions suggesting genetic 
drift could have played a role. The variation observed with respect to 19103A allele frequencies 
when the Malawian population is compared to other populations is further testimony of the 
genetic diversity of African populations [7].   
 
 
Mutations in POLG have been associated with stavudine induced mitochondrial toxicities. In 
separate studies among French  And Thai  [8,9] mutations in the polymerase gamma active 
domain, 2890 T>C and 3428 A>G,  were associated with susceptibility to lactic acidosis and 
lipodystrophy,  respectively, whilst 2684 A>G (E895) and 2864 A>G (Y955C) amino acid 
substitutions have been reported to induce a higher discrimination against triphosphoralyted - 
d4T that prevents their incorporation into DNA [10]. Analysis of genotypes with anthropometric 
measurements and clinical manifestations such as peripheral neuropathy, lipodystrophy and 
hyperlactatemia in HIV/AIDs patients on stavudine did not show any association. In spite of 
having one patient who presented with lactic acidosis we did not find any of the mutations 
reported before to be associated with lactic acidosis to support the report by Chinnery et al [7] 
who suggest that variation to response to stavudine basing on mutations is differential. The 
identified mutations 18709ins AGGT, 18773 C>T, 19011C>T and 19103A>C have been 
reported to be nonpathogenic according to the PubMed database 














mutations are similar to our earlier study results [6].  A change at position 19103T>G 
(rs2307449 ) has been reported to be associated with  aging in women of other populations of 
Chinese origin [11,12]. No T/G base pair substitution was observed at this position in our 
samples.   
 
Polymerase gamma‘s main role is to replicate and repair damaged mitochondrial DNA [13] and   
mutations such as the R964C have been associated with decreased  activities of POLG which 
may result in decreased mtDNA content [1,8]. No significant difference in mitochondrial level 
between individuals with identified variants and those without was observed possibly suggesting 
that these mutations may not have effects the amount of mitochondria in the cell but function. 
Although in a separate analysis we observed that clinical parameters such as peripheral 
neuropathy and hyperlactatemia were associated with decreases in mitochondrial levels, none of 
these adverse effects was identified with the known polymerase gamma pathogen mutation. 
These findings, may support a role for d4T in mtDNA depletion by inhibition of mitochondrial 
DNA replication [8] and this could be either through POLG activity inhibition or directly 
[8,14,15]. We however acknowledge that our study has several limitations and these include the 
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9. CHAPTER 9: DISCUSSION AND CONCLUSION 
This section gives a summary of the overall findings, recommendations emerging from the study, 
limitations and conclusions. Demographic parameters of the HIV/AIDS patients as well as ethnic 
groups were correlated with genetic variation in mtDNA and polymerase gamma. The 
observations in this Malawi population were compared to other world populations. The 
availability of highly active antiretroviral therapy (HAART) for HIV-1 infection has led to 
significant decrease in mortality and disease progression, a situation that has converted 
HIV/AIDS from a death sentence into a chronic disease. Favorable HAART-associated 
virological and immunological successes observed in this study (Outlined in chapter 3) are 
consistent with findings from other studies  [1,2], which have demonstrated how HAART has led 
to decreased disease progression.  
 
Variations observed in patients in their response to stavudine-containing therapy in this study 
support the hypothesis that different individuals respond to the same treatment differently. 
Observation of  higher CD4 cell counts in females compared to males is a confirmation of  
earlier reports in the Malawi population [3] which may point to gender differences in the 
handling of ARV drugs and CD4 recovery. The gender differences in CD4 cell counts have been 
observed in other populations within Sub-Sahara Africa, [4] and it has been suggested that 
women may naturally have high CD4 counts despite HIV status. Factors such as BMI and age 
>40 years have proven to be associated with risk of stavudine associated adverse effects 
[2,5,6,7,8,9]. The most possible mechanisms could be through increased reactive oxygen species 
production due to synergistic effect of both age and NRTIs [10,11].  Besides nucleoside analogue 
reverse-transcriptase inhibitors (NRTIs) being part of the backbone of HAART, their 
effectiveness is hampered by side effects [12] .  
 
In this study observed stavudine- associated toxicities included were peripheral neuropathy and 
lipodystrophy in confirmation of earlier reports [13]. Although some studies have suggested that 
host mtDNA haplogroups and polymorphisms in the poly – γ influence the risk of stavudine 
associated toxicities during antiretroviral therapy treatment [14,15]; we did not observe much 
influence from polymerase gamma gene variation. However, this could be due to the fact that we 














could be in the unsequenced region. We postulate that mutations in polymerase gamma could 
result in reduced mtDNA replication efficiency. This would result the dysfunction of 
mitochondrial DNA leading to insufficient ATP production, a factor that causes tissue and organ 
malfunctioning and ultimately present as mitochondrial toxicity [10]. That is why we 
investigated variation in mtDNA and polymerase gamma and their role on the response of adult 
Malawian HIV/AIDS patients to stavudine- containing ARTs. 
 
Genetic diversity of the Malawi population 
The genetic characteristics of the Malawi population based on the matrilineal inherited 
mitochondrial DNA had not been characterised before. Generally, studies on mtDNA have 
helped in demonstrating the African origin of humans and the relationship between various 
populations. Most studies on African mtDNA haplogroup lineages and their phylogenetic 
relationships have been based on polymerase chain reaction restriction fragment length 
polymorphisms (PCR-RFLP) haplotyping of mtDNA control regions only and recently have 
started incorporating whole-mtDNA sequencing. For example, the current study is one of the few 
that have sequenced almost whole mtDNA in search of variation among African populations. 
Haplotyping only control region raises a problem when one wants to compare findings across 
different studies as the genotyped regions often do not overlap. The PCR-RFLP method focuses 
on known mutations (mutation hotspots) whilst sequencing gives you a glimpse of the variation 
across the sequenced region  [16]. Rosa and Brehm [17] indicated that most mtDNA haplogroups 
on African populations show variations in distribution and sub-structuring when geographical 
and ethnolinguistic affiliations are considered. We investigated the mtDNA variation in the 
seven Malawi ethnic groups by sequencing the whole mtDNA coding region, leaving out a small 
portion of the control region.  
 
We report on 184 mtDNA mutations in the Malawian population (As described in Chapter 4) 
and these mutations were used to construct a phylogenetic tree. The constructed phylogenetic 
network of haplotypes represents mtDNA L lineage haplogroups (L0, L1, L2, L3) and is similar 
to what is expected in Sub-Sahara African populations (Appendix D). The structure shows the 
relationship between different subhaplogroups and haplogroups. The observation is in support of 














subhaplogroups found at varying frequencies throughout the continent [18].The grouping 
together of sequences with similar haplotypes in the network points to a possible same maternal 
ancestor. 
  
Furthermore, the absence of haplogroup L4, L5 and L6, in the Malawi population confirms 
earlier reports of these haplogroups being confined to West and East African populations 
[19,20]. The observed subhaplogroup variations between the Malawi population with other 
African populations confirms what earlier observations of subhaplogroups co-segregating 
geographically as reported by Gonder et al  [16]. Earlier studies reported of high prevalence of 
haplogroup L0 and subhaplogroup L0a in Southern and Southeast African populations 
(especially Mozambique) when compared to North and West Africa [19,20], and this is  
consistent with our observations with haplogroup L0 having frequencies of as high as 48% in the 
Malawian population group. While earlier studies have reported the subhaplogroups L0d and 
L0k to be found almost exclusively among southern African Khoisan (SAK) speakers, apart from 
L0d being present among the Turkana of Kenya and populations in Mozambique [20,21,22]  
presence of these subhaplogroups in the Malawian ethnic groups point to possible population 
admixture with the Khoisan and possibly through a dispersal wave from East to Southern Africa 
during which some pre-Bantu speaker remnants could have settled within the country [18]. The 
L0f subhaplogroup in the Malawian population could be compared to that of East Africa 
populations of North Sudan, Ethiopia, Kenya, and Tanzania with Uganda presenting with highest 
frequencies different to what is observed among populations of Zimbabwe and Mozambique, 
where the subhaplogroup is rarely reported. Presence of the L0f subhaplogroup among Malawian 
ethnic groups could be due to intermarriages between different ethnic groups from east Africa.  
 
Presence of subhaplogroup L2a which has been reported to be the most frequent in Central 
Africa occurs at frequency of 25% , in the Malawi population which supports the thinking that 
the subhaplogroup has undergone dramatic demographic expansion in the Southeastern African 
region [20,23]. Although studies have postulated L1c subhaplogroup to have originated in 
Central Africa, this subhaplogroup was observed to be present in the Malawi population at 














western Bantu migration towards Southeast Africa. However, there is need to further investigate 
the genetic characteristics of L1c identified in Malawi population wand compare it with that of 
other African populations in order to establish its originality. Whilst the most common 
subhaplogroup in Africa is L3e, its presence among the Malawi population could point to 
possible have maternal links between the Malawians with other Bantu speakers both in the 
Central and east Africa.  
 
Distribution of subhaplogroups within the Malawi ethnic groups could suggest population 
admixture, with the Chewa and Sena being the only ethnic groups specifically associated with 
subhaplogroup L2a and L1c respectively, while Lhomwe, Ngoni, Tonga, Tumbuka and Yao 
could not be differentiated into specific subhaplogroups. Genetic differences observed between 
the Sena and Chewa could be a result of different cultural practices which could have prevented 
them from intermarriages. The genetic admixture observed among the Lhomwe, Ngoni, Tonga, 
Tumbuka and Yao, could possibly be due to their culture similarities as well common shared 
languages [24] which could have made it difficult for participants to indicate their real 
ethnicities. For example, the Tumbuka language is common and spoken by over 60% percent of 
people in the Northern region of Malawi, thereby, masking other ethnicities whose languages are 
least spoken making it difficult to differentiate different ethnic groups.   
 
Secondly intermarriages are very common between Tumbuka and Ngoni from the Northern parts 
of Malawi such that most Ngoni are masked under the Tumbuka and these groups both have 
patriarchal cultures where ethnicity is defined by the male lineage.  Migration and demographic 
factors (urbanization due industrialization) in the Southern Region of Malawi, an area which is 
mainly dominated by Yao and Lhomwe, might have also contributed to genetic admixture which 
might have contributed to failure to assign the tribes into specific haplogroups because more 
people of different ethnic groups moved and settled in the Lhomwe and Yao settlements when 
early industrialization was taking place. The slave trade is also thought to have contributed to 
some ethnic admixture with the Yao tribe acting as the intermediary between inhabitant worker 















African populations have been associated with high genetic-diversity and our study results 
further confirm these findings [20,26,27]. The observed intra- and interpopulation sequence 
divergences within  and between ethnic groups with lower FST estimates (FST = 0.001– 0.152) 
compared to global FST estimates based on variation in mtDNA (FST = 0.24–0.27)  [28] 
indicates low genetic differentiation between Malawian ethnic groups  in support of close genetic 
relatedness as depicted by the neighbor-joining tree. However, clustering of Chewa, Yao, 
Tumbuka, Tonga, Lhomwe and Ngoni, may support the population admixture phenomenal where 
populations descended from recent mixture of groups that have long been separated with short 
branches and  observed to be located centrally in inferred neighbor-joining trees [29].   
 
Genetic structure relationship between Malawi ethnic groups and other Sub-Sahara Africa 
ethnic groups  
Current studies on evolutionary relationships based on uniparental transmitted polymorphisms 
have primarily focused on the mtDNA genes and not on population history [17]. However 
complex African ethno-linguistic context must be taken into account, considering where societies 
are deeply structured by cultural beliefs and patterns of admixture which strongly influence 
genetic inheritance pattern [17]. Therefore, we further investigated the genetic structure of 
Malawi ethnic groups in comparison to those of other Sub-Sahara African ethnics groups (see 
chapter 4). Comparing the subhaplogroup frequencies among Malawi populations with 
populations from Mozambique and Zimbabwe which are all in Southeast Africa shows variation 
in the distribution of most of these subhaplogroups. Although three of the largest  ethnic groups 
in Malawi (Lhomwe, Sena, Yao) migrated from Mozambique and share language similarities, a 
comparison of the distribution of major subhaplogroups L0a, L1c, L2a and L3e at country 
population level, the Malawian population gladiates more towards similarities with the  
Zimbabwe population  while sort of drifting away from the Mozambican population.  This could 
be due to the fact that we are looking at mtDNA which does not give a complete genetic picture. 
It could be possible if we were to investigate Y-chromosome DNA variation, the Malawian and 
Mozambican populations would share more resemblance and the Zimbabwean population be a 















On the other hand, the similarities between Malawians and Zimbabweans could be a recent 
phenomenon, being a reflection of colonialism and the slave trade [23,30,31].  Mozambique was 
colonized by the Portuguese, whereas both Zimbabwe and Malawi were under British rule, thus 
their inhabitants were more likely to mix under the Federation of Rhodesia and Nyasaland. In 
terms of slave trade, Mozambique provided the link to the ocean, thus, inland countries mostly 
affected by slave trade are likely to have contributed to the genetic admixture in Mozambique. 
Therefore, further work to determine how genetically these populations are structured is needed. 
Unlike non-African populations, African populations are characterised by greater levels of 
genetic diversity, population substructure variations, and less linkage disequilibrium (LD) among 
loci [32]. Using haplogroups frequencies to determine the genetic structure of different ethnic 
groups in Sub-Sahara Africa, a principal component analysis (PCA) demonstrated clustering of 
ethnic groups according to geographical region an observation also demonstrated by other 
studies [19,33]. This observation is supported by hypothesis that distribution pattern of mtDNA 
subhaplogroups is geographical-area and ethnic-group structured [34,35].   
 
The Malawi ethnic groups genetically appear to be more closely related to Southeastern and 
Southern African ethnic groups. Clustering of the Malawi Yao and Kaskazi-speaking 
Mozambique Yao is consistent with language, these ethnic groups speak same language and also 
could support their common origins [36,37]. However, further analysis should be considered in 
order to investigate their genetic relatedness as well as to groups from East Africa who speak 
similar languages [37]. Similarly, the Chewa ethnic group speaks the same language as the 
Nyanja of Mozambique and is very close to other Bantu speakers of Southeastern and Central 
Africa than East Africa possibly signifying closeness in their genetic relationship but further 
studies are required to determine the true genetic relatedness. Interestingly, the Ngoni, Tonga, 
Tumbuka from Malawi cluster close to the Southern African Bantus, especially the Zulu/Xhosa, 
Swazi, Sotho and Makonde of South Africa, Swaziland and Mozambique.  
 
Taking into the account gene variation, presence of the haplogroup L0 among Southeastern 
African ethnic groups may signify their genetic closeness to the Southern African ethnic groups 
[16,20,38]. Population admixture could have occurred in some ethnic groups for example the 














ethnologue information [36]. This observation defeats the use of language to solely characterise 
populations, but calls for a comprehensive molecular evolutionary analysis of the ethnic groups 
in Southeast Africa focusing on more markers including Y-chromosome DNA. While most 
Malawi ethnic groups seem close to each other using our mtDNA variation data, exceptions are 
observed with the Sena who appear to be closer to East African ethnic groups as depicted in the 
PCA (See Chapter 4). The Malawi Sena ethnic group which is believed to have originated from 
Mozambique was also clearly separated from Mozambican Sena who belongs to Kusi-speaking 
and are scattered across Southeast Africa. Historically, Sena is an umbrella name for sub-ethnic 
groups of the major Kusi-speaking groups of  Makua, some Shona groups, Rabu and Phodzo and 
other Southeast Bantu [37,24]. Therefore, future studies should consider investigating the 
evolutionary relatedness between Malawi Sena with Kusi-speakers who are distributed 
throughout Southeast Africa [37] and their East African counterparts.  
 
On the other hand, it is suggested that one must take precaution when predicting genetic 
similarity from language because during population dispersal there were tribal wars and 
conquering victors often imposed their language on the losers.  Clustering of ethnic groups on 
PCA may support the hypothesis of the split been West and East Africa populations suggesting  
co-evolution of L0-L6 lineages in a African populations Behar et al [18]. Unlike other 
populations within the region, data on the mtDNA landscape of Malawi has not been available 
up to this point and this is a contribution towards unraveling the deep-rootedness of mtDNA 
lineages in Southeastern African populations. However, a full understanding of the genetic 
landscape and demography of the Malawian ethnic groups in relation to other Sub-Sahara Africa 
ethnic groups should be considered especially once other populations start also to have whole 
mtDNA sequence data as opposed to the current targeted SNP data. A part from population 
studies, mtDNA variation has been used in predicting susceptibility to drug induced toxicities 
[39]. Variations in mtDNA has been associated with differential susceptibility to neurodegerative 
and metabolic diseases as well as progression to diseases state[39] as will be discussed in the 
















Mitochondrial DNA haplogroups and susceptibility to stavudine induced adverse effects  
Susceptibility to diseases shows interindividual and interethnic differences and this has been 
mapped to both the nuclear and mitochondrial genome. For example, the mtDNA mutation 
m.3243 A>G in the tRNA (Leu(uur) gene has been associated with dysfunctional β cells in the 
pancreas leading to impaired insulin secretion a situation which is associated hyperglycemia 
[40,41]. However, in some individuals, the same mutation, m.3243 A>G has been associated 
with myopathy when occurring at certain high mutation loads in the skeletal muscle compared to 
blood  [42]. The differential outcome could also be at population level, such that, different 
populations characterised by different mitochondrial lineage (haplogroups) may exhibit different 
phenotypes. This has been observed in some studies that populations characterised with 
haplogroup J of European descent carrying mutation m.10398 A>G are associated with 
longevity, while the same mutation has been associated with increased ROS and insulin 
resistance,  a risk factor for type 2 diabetes in Northern Indians [43,44]. Also, the 9-bp deletion 
found in COII/tRNA
Ly
 has been reported to be associated with MELAS or MERRF in 
individuals of Taiwanese origin [45] while this mutation has been identified at high prevalence in 
subhaplogroup L0a2 in Africans [20,46] as well as in this study 45% but not reported in 
association to disease. Furthermore, many mitochondrial dysfunction symptoms manifest when 
the bearer is exposed to environmental toxins. For example, studies have shown that 
mitochondrial subhaplogroup L1c is associated with peripheral neuropathy in HIV/AIDS patients 
on stavudine containing regimen [14]. Using SNPs and subhaplogroups, we report on the 
association of L3e with reduced risk for lipodystrophy, the association of L0a2 with increased 
risk of developing peripheral neuropathy and L2a with reduced risk of developing peripheral 
neuropathy (As described in Chapters 5 and 6)  
 
Among the Malawians ethnic groups, subhaplohagroups L0a2 and L2a seem to be the important 
markers in susceptiblity to peripheral neuropathy  which is contrary to observations among other 
African population group[47] where subhaplogroup L1c  was reported among  blacks of African 
origin to associate with increased susceptibility of developing stavudine associated peripheral 
neuropathy. These findings are a clear indication that African subhaplogroups could be viewed 














investigations on environmental factors and mtDNA  dysfunction in the genetically diverse 
African population should be carried out 
 
It has been postulated that mtDNA haplotypes may modulate oxidative phosphorylation, thus 
influencing the overall physiology of individuals thereby predisposing them to, or protecting 
them from, certain diseases [49]. The possible ways through which subhaplohagroup L0a2 
associates with peripheral neuropathy could be through changes in the protein structure because 
of non-synonymous mutations. Within L0a2 subhaplogroup, the most significant mt DNA 
mutation to be associated with peripheral neuorpathy is m.5711 A>G (OR = 2.59, CI 95% = 1.15 
– 5.85, P = 0.021) . This mutation is found in the mitochondrial tRNA asparagine gene which 
transfers the amino acid asparagine to a growing polypeptide chain at the ribosome site of 
protein synthesis in the mitochondria. The mutation m.5711 A>G is non-synonymous and result 
in amino acid change, tRNAAsn: p.Asn18Ser. It is possible that the changes may affect the 
structure and functional activity of the mitochondrial encoded tRNA asparagine which could 
result in an improper balance of amino acids in nerve tissue resulting in the development of 
peripheral neuropathy.  Another mutation in the mitochondrial tRNA asparagine (m.5669 G>A) 
has been associated with myopathy [50]. The mechanisms by which stavudine alters the 
functional activity of mitochondrial tRNA asparagine due to the m.5711 A>G mutation is not 
known. It has been reported that mitochondrial mutations can be protective as well, therefore, 
significant reduced risk of peripheral neuropathy in subhaplogroup L2a  supports that mtDNA 
mutations may play protective roles in certain individuals and this is confirmation of the findings 
by Wallace et al [11] among Europeans where the mutation  m.14798 C>T in cytochrome b was 
associated with neuro-protection among haplogroups J1 and Uk  carriers. This could be 
applicable to subhaplogroup L2a, with mutations m.7175 T>C and m.7274 C>T in the 
cytochrome c oxidase subunit I which are associated with reduced risk of developing peripheral 
neuropathy (OR = 0.074, CI 95% = 0.01 – 0.55, P = 0.011; OR = 0.06, CI 95% = 0.01 – 0.04, P 
= 0.007), respectively.  
 
Variation in response to stavudine associated lipodystrophy dictated by subhaplogroups in our 














between population subhaplogroups and may influence the susceptibility to environmental toxins 
such as drugs. The absence of lipodystrophy in subhaplogroup L3e  is further proof that mtDNA  
variation can predispose individuals to differential susceptibility to toxicity which is in 
agreement to the observations in a South African cohort [51]. These differences in responses 
have been also observed in other populations of European origin, for example haplogroup T 
appeared protective against lipodystrophy [39,52]. This suggests that individuals in the same 
population will respond to same treatment differently, therefore it is important have more 
pharmacogenomics studies hence supporting precision medicine [53], at the same time 
increasing the health and safety of individuals of at risk [54]. Mutations in the mitochondrial 
respiratory genes though synonymous could as well have altered functional role of mitochondrial 
encoded genes by either increasing or reducing expression, through a phenomenon commonly 
referred to as codon-usage. Therefore the effect of these synonymous mitochondrial DNA 
mutations with regard to the functional structure of the gene should be evaluated.  
 
Our study support the long observed association between age and developing lipodystrophy [55]. 
Age is associated with reduced expression of mtDNA as well as accumulation of ROS in 
muscles and brain. Therefore, a decline in mitochondria due to age may contribute to 
subcutaneous adipocytes tissue apoptosis and chronic mitochondrial dysfunction in adipose 
tissue which may induce adipocyte metabolic dysfunction which are characterised by decreased 
capacity for triglyceride storage and synthesis [56]. Antiretroviral therapy triggers mitochondrial 
dysfunction and oxidative stress, which leads to cellular senescence more in aged people 
compared to the young [57] a factor that may influence lipodystrophy. The decline in mtDNA 
expression affects fuctions of mitochondria a circumstance that may result in increased 
lipodystrophy.  Mitochondrial DNA mutations have been associated with longevity and disease 
in certain populations [11]. However mitochondrial diseases have been related to molecular 
defects in both mtDNA and nuclear genes that code for mitochondrial components [58,59] 
 
While the mitochondrial haplogroup/haplotypes are associated with the risk of developing 














gamma may also influence the activity of the enzyme in presence of NRTIs. For example, it has 
been reported that the mutation R964C in the polymerase gamma, decreases the selectivity 
natural dNTP over d4TP an effect which has been associated with lactic acidosis [60]  . 
According to literature, most polymerase gamma mutations are population specific and 
environmentally influenced [53] hence the reason for us to pursue this study among Malawian 
participants on  stavudine.  
 
In the sequencing of a portion of the polymerase gamma gene, non-pathological mutations were 
observed, further supporting the hypothesis that presence of POL- γ mutations are geographically 
and population structured [61]. For those mutations we observed among Malawian population, 
their frequencies were not statistically significantly different to Sub-Sahara African populations 
but significant differences were observed when compared to those in other world population 
(chapter 8). For the observed mutations, we also correlated them to mtDNA/nDNA levels and no 
significant results were observed. However, our study has the limitation that only a portion of the 
polymerase gamma was sequenced, thus, causative mutations could still be in the unsequenced 
region. 
 
Effect of stavudine containing ART on mitochondrial levels 
The distribution of mitochondrial varies among individuals and between different organs, tissues 
and cells depending on each‘s energy needs [62,63]. Mitochondrial DNA replication failure 
affects the quantity of mitochondria in an organ and may have pathological relevance as it is 
associated with respiratory chain defects [62]. Our observations of significantly decreased 
mitochondrial content in patients on ART when compared health controls is in agreement to 
observations from other studies which have shown that NRTIs are associated with mitochondria 
depletion [64]. Observed low mtDNA levels in patients on ART presenting peripheral 
neuropathy in this study confirms earlier reports of decreased mitochondria in patients with 















Age which was associated with the risk of developing lipodystrophy in this study it was not 
associated with low mitochondrial levels.  Pathophysiology of aging has been linked with 
increase in the reactive oxygen species which increases cell loss as well as depletes 
mitochondrial, a mechanism which is similar to effects of stavudine resulting in drug induced 
toxicities [66,67]. 
 
Previous studies which reported elevated lactate levels (asymptomatic hyperlactatemia) in 
association with low mtDNA/nDNA ratios due to NRTI (stavudine) inhibition effect on mtDNA 
proliferation [68] are in agreement with present study. In addition, when compared within 
groups, patients with elevated lactate levels (>2.5U/L) presented with significantly lower 
mtDNA content when compared to patients with normal lactate levels, further confirming 
previous observations [68]. Accordingly, abnormal functioning of the mitochondria will result in 
a shift towards anaerobic oxidation of pyruvate and the formation of lactate [69,70,71]. Although 
in our analysis hyperlactatemia could not be associated with peripheral neuropathy and 
lipodystrophy (see chapter 3), this seems to be conflicting with earlier studies including one in 
the same population. However, many studies including our earlier study [72,73,74], have 
identified that there is  a relationship and further suggest that hyperlactatemia may reflect the 
underlying pathophysiology of peripheral neuropathy and lipodystrophy. Therefore, mtDNA 
subhaplogroups and levels of lactate could be used as markers for patients who are at risk of 
developing stavudine associated toxicities such as peripheral neuropathy and hypertension and 
lipodystrophy.   
 
However, a large numbers of patients in resource limited settings are still receiving stavudine 
containing regimen despite WHO recommendations of withdraw of the drug. Therefore 
quantitative evaluation of mtDNA in the peripheral blood of individual on stavudine may be a 
useful first step in identifying patients that may develop stavudine induced-metabolic disorders. 
However, it will be important to establish the expected normal mtDNA levels between different 
age groups and gender within the specified population to improve our understanding of the 


















Stavudine containing therapy has proven to be effective as evidenced in this study when one 
considers virological success and increased immunological response in participants. Despite its 
effectiveness stavudine still remains an unsafe drug manifested by its increased rate of toxicities 
which include peripheral neuropathy, lipodystrophy and hyperlactatemia. Older age appears to 
be the common risk factor to susceptibility to stavudine associated toxicities; therefore it will be 
important in future to further consider looking at the drug metabolism profiles basing on 
categories of adult age groups when carrying up clinical trials. In addition we recommend close 
monitoring of long term toxicities in patients at high risk (>40 years) with NRTIs. 
 
Drug associated toxicities presented by patients on stavudine containing therapy are 
characteristically associated with mitochondrial dysfunction. Differences observed in response to 
treatment by different individuals groups from this study demonstrate that mtDNA 
subhaplogroup may be an important factor in the development of stavudine associated toxicities 
for example peripheral neuropathy and lipodystrophy. Therefore, it is important to begin to 
understand the genetic structure of each population in order to effectively tailor prescription of 
drugs. Differences in mtDNA genetic variation observed within the Malawian ethnic groups and 
between Malawians and other African populations further strengthen the call for genetic 
characterization of all African populations in order to come up with specific biomarkers of both 
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GTGCAAGAATAGGAGGTGGAGT 1872 60 
 
The primer name is primers‘ starting binding position according to Cambridge Reference Sequence. Primers adapted 



















Appendix B:  Table of forward and reverse sequencing primers for mtDNA coding region 
Primer 
Name 
Sequencing Primer  (5’ - 3’) Annealing 
temperature (0C)  
Confirmatory 
Primer Name 











































































8910for CTTACCACAAGGCACACCTACA 50 9647rev AGCTCAGGTGATTGATACTCC 
9393for CGAGAAAGCACATACCAAGGC 50 10154rev TTCTATGTAGCCGTTGAGTTG 
9874for TAATATTTCACTTTACATCCA 50 10648rev GGCACAATATTGGCTAAGAGGG 
10360for GTCTGGCCTATGAGTGACTACA 50 11163rev CGGGTGATGATAGCCAAGGTG 
10892for ATCAACAACAACCTATTTAGC 50 11673rev GTTTGGATGAGAATGGCTGTT 
11461for ACTCTTAAAACTAGGCGGCTA 50 12226rev CAGTTCTTGTGAGCTTTCTCGG 
11977for CTCCCTCTACATATTTACCACAAC 50 12763rev CGATGAACAGTTGGAATAGGT 
12500for TGTGCCTAGACCAAGAAGTTA 50 13297rev GGTTGATGCCGATTGTAACTA 
12988for CTAGCAGCAGCAGGCAAATCA 50 13830rev 
AAGTCCTAGGAAAGTGACAGC
GA 
13477for GCAGGAATACCTTTCCTCACAG 50 14325REV AACTTTAATAGTGTAGGAAGC 










































~ T ranslate ~ Consensus 
~ G08 - D4T356 - 411F-052 . ab1 (19)776) 
~ G09-D4T186-411F 067 . ab1(28)718) 
~ G09 )4T364 - 411F=067 . ab1 (27)777) 
"" G10_D4T028_ 411F_068 . ab1 (25)709) 
~O 640 650 











~ G10 D4T204 411F_068 . ab1 (26)715) 
~ G10 - D4T377 - 411F 068 . ab1 (21)665) 
~ Gll)4T070 - 411F=083 . ab1 (25)785) 
')70 3580 3590 3 
It! I I I I II I I I I I I I I I I I I I I I tI I I I 
~ Translate ~ Consensus CCTCCCCATACCCAACCCCCTGGTTAACC' 
Mitochondrial ... gene . s (1)16569) --.. cctccccatacccaaccccctggtcaacc' 
~ D4T321.abl (13)523) .................. --.. CCTCC CATACCCAACCCCCTGGTCAACC' 
~ D4T378 . ab1 (11)603) ..... .. .. .. ...... --.. CCTCCCCATACCCAACCCCCTGGTCAACC' 
... D4T310 . ab1 (13) 650) ... .. .. .. ...... --.. 
~ D4T337 . ab1 (13)537) .......... --.. CCTCCCCATACCCAACCCCCTGGTCAACC' 
~ D4T322 . ab1 (14)452) .................. --.. CCTCCCCATACCCAACCCCCTGGTTAACC' 
~ D4T324 . ab1 (11)592) .................. --.. CCTCCCCATACCCAACCCCCTGGTTAACC' 
~ Tr-anslate • Consensus 
~ D4T142. ab1 (20 )5 40) .................. ---; 
~ D4T375 . ab1 (21 ) 596) .................. ---; 
~ D4T 3 1 3 . ab1(17)600) .................. ---; 
... D4T1 32 . ab1 (20)530) ... ... .• .... . . .... ---; 
3610 3620 






, ,, , IIf, ." 
~CCTGGGCCTCCTATTTATTCTAGC( 
• D4T 33 5.abl (20) 544) ............ ----+ AACCTAGGCCTCCTATTTATTCTAGC( 
~ D4T354. ab1 (21 ) 597) .... . .... . ........ ---; AACCTAGGCCTCCTATTTATTCTAGC( 
~ D4T411 . ab1 (20)60 1) .... . ..... . .... .---; AACCTAGGCCTCCTATTTATTCTAGC( 



























• Translate • Consensus 
• D4T121.ab1(120)40S) 
• D4T326 .ab1(l19>S73) 
• D4T052 . ab1 (122)400) 
~ D4T217 . ab1(126)S10) ...•...... 
5090 51 00 
II , I , , II I , " , I " , , I , " , I 
TTAACTATTTATATTATCCTAACT. 
. --.. TTAACTATTTATATTATCCTAACT. 
.. --.. TTAACTATCTATATTATCCTAACT. 
.. --.. TTAACTATTTATATTATCCTAACT. 
.. --.. 
TAACTATCTATATTATCCTAACT. 
• D4T226 . ab1 ( 119)797) .. . .... • ...... --.. TTAACTATTTATATTATCCTAACT. 
• D4T411 . ab1 (122)S 7 4) .. . .......... --.. TTAACTATTTATATTATCCTAACT. 
• D4T330 . ab1 (127)726) ... • ........... --.. TTAACTATTTATATTATCCTAACT. 
• D4T247 . ab1 (116)792) .. --.. TTAACTATCTATATTATCCTAACT. 
• D4T415 . ab1(l1S>404) .... --.. TTAACTATTTATATTATCCTAACT. 
• Translate • Consensus 
.D4T090 .ab1(12) 487) ........... <-
• D4T169 . ab1 (17)492) ........... <-
• D4T411. ab1 (81)444) ....•.. . .... . ..... <-
• D4T028 . ab1 (21)350) ....• .. •...• . ..... <-
~ D4T421. ab1 (22)346) .................. <-
'0460 10470 1 






• D4T4S0.ab1(13)347) ....... • ......... <- ATATTTACCAAATGCCCCTC 
• D4T321. ab1 (79)317) ................. <- ATATTTACCAAATGCCCCTC 
• D4T148.ab1(63)3 45) ....•. . ..... . .... <- ATATTTACCAAATGCCCCTC 
C Relerence CoooilaIes 12180 12190 12200 
II III! ! I ! " ! I " ! ! I I " ! It" 1 I 
• Translate • Consensus CAACAGAGGCTTACGACCCCTTATTTAC 
• 2012-03-071D4T220 . ab1 (79)834) ....... --l CAACAGAGGCTTACGACCCCTTATTTAC 
• 2012-03-071D4T320. ab1 (78)520) ....... --l CAACAGAGGCTTACGACCCCTTATTTAC 
• 2012-03- 071D4T323 . ab1 (62)608) ....... --l CAACAGAGGCTTACGACCCCTTATTTAC 
T 2012-03-071D4T357 . ab1 (77) 403 ) ....... --l 
m.5090T>C 
m.l0463 T>C 
r.:c:m'!l..1'i..u::w~iSt!!!ttftt!:'i:f.-- m.12192 G>A 
AACAGAGGCTTACAACCCCTTATTTAC 
• 2012-03-081D4T222. ab1 (77)825) ....... --l CAACAGAGGCTTACGACCCCTTATTTAC 























      
 










                                                                                                                               
o Reference Coormaes 13100 13110 13120 
I ! I ! II ! I ! ! ! ! I ! ! ! I I ! I ! ! I 11 
~ T ranslate ~ Consensus AGCAGGARTCTTCTTACTCATCCGC 
. . 
... D4T1l4.ab1(22)758) ........ ... . .. ... .. . ---1 
i.H+t-ih-rlt-crh<-r.ocr-- m.13104 A>G 
AGCAGGGGTCTTCTTACTTATCCGC 
~ D4TllS. ab1 (21)730) ........ . . .. ... .. .... ---1 AGCAGGAATCTTCTTACTCATCCGC 
~ D4Tll7. ab1 (14) 759) .................... . ---1 AGCAGGGGTCTTCTTACTTAT CCGC 
~ D4Tll8. ab1 (17)65 4) ...........•......... ---1 AGCAGGAGTCTTCTTACTCATCCGC 
~ nJll'!l11C ... h1 {1)"7 ,&;nn, ... . ..... . ... . ....... ---4 ",..,.."f'"rll f" ml""mmf"mml\rom .... l\m,..,..,..,.. 
Ref"""",,, CooIdilaIes 
~ Translate ~ Consensus 
~ 2012-04-131D4T459. ab1 (89)834) ....... ---. 
~ 2012-04-141D4T041. ab1 (29)748) ... . ... ---. 
~ 2012-04-141D4T101. ab1 (22)741) . .... .. ---. 
~ 2012-04-141D4T126. ab1 (158)687) ...... ---. 
"'" 2012-04-141D4T127. ab1 (96)818) ....... ---. 
14610 14620 






6rn-I\"A~~-- G>A 14612 
, 
~ 2012-04-141D4T167. ab1 (121)755) ...... ---. AAGGCTTAGAAGAAAACCCC 
~ 2012-04-141D4Tl71. ab1 (131)660) ...... ---. AAGGCTTAGAAGAAAACCCC 














              
       
 
 
Sequence showing        
known 9 base pair 
deletion on COX II 





m.3579 A>G (m.3606 A>G, m.5090 T>C , m.647 A>G, m.10463 T>C, m.12192 G>A and  
m.13104 A>G have been reported in other populations of non Africans while known mutations while m.14612 G>A 






























Appendix D: Phylogenetic  tree 
 
Median joining network representing L subhaplogroups of the 7 ethnic groups of Malawi.  




















Appendix E: List of haplotypes and haplogroups in 215 individuals from 7 Malawi ethnic  
                      groups 
 
L0a1a A2245G C3594T T4586C T5096C C5603T T6185C C7256T C9042T G10589A C10664T
 G10688A T10810C T10915C G11176A G11914A G12007A T14308C    
            
L0a1b1 A2245G C3594T T4586C T5442C C5603T C5911T T6185C A7146G C7256T A8191G C9042T
 A9347G G10589A G11176A G12007A A13105G       
           
L0a1b1 C1048T G2758A T2885C C3516A C3594T T4586C G5231A C5911T T6185C A7146G C7256T
 C10664T G10688A T10810C T10915C G12007A A13105G C13506T 
   
L0a1a A2245G C3594T T4586C T5096C G9755A C9818T G10688A T10810C 
    
L0a1b1 C1048T A2245G G2758A T2885C C3516A C3594T T4586C T6185C A7146G C7256T C9042T
 A11641G G11914A G12007A A13105G C13506T A14007G G15431A 
   
L0a1b1a A2245G G2758A T2885C C3516A C3594T T4586C A7146G C7256T A8191G C9042T
 C10664T G10688A T10810C T10915C G11176A A11641G G12007A G12127A  
  
L0a1b1 C3594T T5442C C5603T C5911T A11641G G11914A A12720G A13105G A13276G
 C13506T T14308C G15431A  
        
L0a1b1 G2758A T2885C C3594T T5442C C7256T A8191G A9347G G10589A G12007A  
  
L0a1b1 C1048T T2885C C3594T C5911T G11914A G12192A A13105G A13276G C13506T A11641G 
 
L0a1b1a G2758A T2885C C3594T T4586C G5231A T5442C G5460A C5603T C5911T A7146G C7256T
 C8428T C9042T G9755A C9818T A11641G G12007A G12127A A12720G A13105G T14308C  
               C15136T G15431A          
     
L0a1b1a C3516A C3594T T5096C C7256T A8191G C9042T G9755A C9818T A11641G G11914A
 G12007A G12127A A12720G A13105G A13276G C13506T A14007G T14308C C15136T
 G15431A 
           
L0a1b1 A2245G T4586C C5603T C5911T T6185C C7256T C9042T A9347G G9755A C9818T A11641G
 G12007A A12720G A13105G A14007G G14612A 
      
L0a1b1a A2245G G5147A A8191G C8428T C8468T C9042T G9755A C9818T G10589A G11176A
 A11641G G12007A G12127A A14007G T14308C  
      
L0a2a2 C1048T A2245G G2758A T2885C C3594T C5603T A5711G T6185C C7256T C8281 - 8289d C8428T
 A8460G A8566G C9042T A9347G G10589A C10664T G10688A T10810C A11641G
 G11914A G12007A A12720G A13105G C13116T T14308C 
     
L0a2A2 T2885C T4586C G5147A C5603T A5711G A7146G C7256T A8566G G9554A G10589A














          
L0a2a C1048T G2758A T2885C C3516A C3594T G5147A G5231A A7146G C7256T C8281 - 8289d C8428T
 A8566G C9042T G10589A T10915C C11143T A11172G G11176A  A11641G G11914A G12007A  
               G15431A 
         
L0a2a2 C1048T T4586C G5147A G5231A G5460A C5603T A5711G T6185C A7146G C7256T C8428T
 C8468T C9042T A9347G G9554A G10589A C10664T G10688A T10915C A11172GG11176A  
               A11641G A13105G  
        
L0a2 A2245G T4586C G5147A A7146G C7256T C8281 - 8289d C8428T A8460G C9042T A9347G 
 G10589A C10664T G10688A T10810C T10915C A11641G G11914A G12007A A13105G A13276G  
               C13506T T14308C  
       
L0a2a2 C1048T T4586C G5147A G5231A A7146G C7256T C8281 -8289d C9042T A9347G A9545G 
  G9554A G9755A C9818T G10589A C10664T G10688A G12007A A12720G A13105G C13116T  
                C13506T  
        
L0a2a2 C1048T C3594T A5711G A7146G C7256T C8281 -8289d C8428T A8460G A8566G C9042T
 A9347G A9545G G9554A G10589A C10664T G10688A T10810C T10915C C11143T A11172G
 G11176A A11641G G12007A A12720G A13105G C13116T A13276G C13506T T14308C
 C15136T G15431A  
      
L0a2a C1048T A2245G G2758A T6185C G6257A C9042T G10589A G10688A T10810C C11143T
 A11641G G11914A A12720G A13105G A13276G C13506T 
     
L0a2a2 C1048T A2245G C3516A C3594T T4586C G5147A G5231A T5442C G5460A C5603T A5711G 
  T6185C G6257A A7146G C7256T C8281 - 8289d C8428T A8460G A8566G C9042T A9545G 
  G9554A G10589A T10915C C11143T A11172G G11176A A11641G G11914A G12007A A12720G  
                A13105G C13116T A13276G C13506T T14308C G14612A 
 
L0a2 C1048T C3594T C5603T A5711G T6185C C7256T C9042T G10688A T10810C G11176A 
               A13105G C15136T G15431A         
            
L0a2a C1048T G2758A T2885C C3516A C3594T T4586C G5147A G5231A C5603T A5711G T6185C
 G6257A A7146G C7256T C8281 -8289d C8428T A8460G C9042T A9347G G10589A C10664T
 G10688A T10810C T10915C C11143T A11172G G11176A A11641G G12007A A13105G  
               T14308C C15136T G15431A  
    
L0a2a C1048T G2758A T2885C C3516A C3594T T4586C C5603T A5711G T6185C G6257A C7256T  
               C8281 - 8289d C8428T A8460G A9347G G10589A C10664T G10688A T10810C T10915C
 C11143T A11172G G11176A A11641G G11914A G12007A A12720G A13276G C13506T
 T14308C C15136T G15431A 
      
L0a2a2 C1048T G2758A T2885C C3516A C3594T T4586C G5147A G5231A T5442C G5460A C5603T
 A5711G C7256T C8281 - 8289d C8428T A8460G C9042T A9347G C9818T G10688A T10810C
 T10915C A11641G G11914A A13105G C13116T A13276G C13506T T14308C C15136T 
 G15431A 














L0a2 C3594T T5090C G5147A G5231A T5442C G5460A C5603T A5711G A7146G C7256T A13105G 
 
L0a2 C1048T G2758A T2885C C3516A C3594T T4586C G5147A G5231A C5603T A5711G A7146G
 C9042T A9347G G9554A G9755A C9818T G10589A A11641G G11914A G12007A  A13276G
 C13506T T14308C C15136T G15431A  
       
L0a2a2 C1048T G2758A T2885C C3516A C3594T T4586C A5711G A7146G C7256T C8281 -8289d A8460G 
  A9347G A9545G G9554A G9755A G10589A C10664T G10688A T10810C T10915C
 C11143T A11172G G11176A G12007A A12720G A13104G C13116T C13506T T14308C
 C15136T  
       
L0a2a2 C1048T G2758A T2885C C3516A C3594T T4586C A7146G C7256T C8281 - 8289d C9042T A9347G 
  G9554A G10589A C10664T G10688A T10810C A11641G G12007A A12720G  A13104G A13105G  
               C13116T A13276G T14308C C15136T G15431A       
     
L0a2 C1048T G2758A T2885C C3516A C3594T T4586C C5603T A5711G A7146G C7256T G10589A
 G10688A T10810C T10915C A11641G G11914A   
     
L0a2 C1048T G2758A T2885C C3516A C3594T T5442C G5460A C5603T T6185C G6257A A7146G 
               C7256T  C8281 - 8289d C8428T A8460G C9042T A9545G G9554A G10589A C11143T A11172G  
               G11176A A11641G G11914A G12007A C15136T G15431A  
  
L0a2 C1048T A2245G G2758A T2885C C3516A C3594T G5147A G5231A T6185C A7146G C7256T
 C8281 -8289d C8428T C9042T A9347G G10589A G11176A G12007A C15136T G15431A  
 
L0a2 C3594T C5603T A5711G G9554A G10589A C10664T G10688A T10810C T10915C C11143T 
 A11172G G11176A  
         
L0a2 G2758A T2885C C3516A C3594T T4586C T6185C G6257A A7146G C7256T C9042T A9347G
 G10589A A11641G G12007A T14308C C15136T G15431A 
     
L0a2 G2758A G5231A C7256T A9347G G10589A C10664T G10688A T10810C G11176A
 G14612A 
           
L0a2a2 C1048T A2245G G2758A T2885C C3516A C3594T T4586C C9042T A9347G G10589A C10664T
 G10688A T10810C C11143T A11172G G11176A A11641G G12007A A13105G C13116T 
               T14308C C15136T G15431A         
      
L0a2a2 C1048T G2758A T2885C C3516A T4586C C5603T C8281 - 8289d A9347G G10589A C10664T
 G10688A T10810C T10915C C11143T A11172G G11176A A11641G G12007A A12720G  
               C13116T C13506T T14308C         
       
L0a2a2 C1048T G2758A T2885C C3516A C3594T T4586C A5711G T6185C G6257A C8281 - 8289d C8428T
 A8460G C9042T A9347G A9545G G9554A G10589A C10664T G10688A T10810C T10915C  
               A11641G G11914A C13116T 
        














              A11641G A13105G T14308C         
            
L0a2a C1048T A2245G G2758A T2885C C3516A C3594T T4586C C5603T C7256T A9347G G10589A
 G10688A T10810C T10915C C11143T A11172G G11176A A11641G G12007A A13105G 
               T14308C G14612A G15431A 
         
L0a2 C1048T G2758A T2885C C3516A C3594T T4586C T6185C C7256T A9347G G10589A
 C10664T G10688A T10810C A11172G G11176A A11641G G11914A G12007A A12720G
 A13276G C13506T G15431A  
       
L0a2 G2758A T5090C C5603T A5711G C7256T T6185C C10664T G10688A T10810C T10915C
 G11914A  
          
L0a2a2 C1048T G2758A T2885C C3594T T4586C G5147A G5231A T5442C G5460A C5603T A5711G 
 G6257A A7146G C8281 -8289d C8428T C9042T A9347G G9554A G9755A C9818T G10589A  
               C10664T G10688A T10810C A11172G A11641G G12007A A12720G A13105G C13116T T14308C 
               C15136T G15431A  
    
L0a2c C3594T T5090C C5603T A5711G C7256T A9347G G9755A G11887A G11914A G14612A  
 
L0a2a2 G2758A T2885C C3516A C3594T T4586C T5090C A7146G C7256T C8281 - 8281d C9042T A9347G 
  A9545G G9554A G9755A C9818T G10589A T10810C C11143T A11172G G11176A
 A11641G G12007A A12720G C13116T T14308C C15136T G15431A 
    
L0a2a2 T2885C C5603T A5711G T6185C C7256T C5603T G10688A T10810C G11914A A12720G
 A13105G C13116T  
        
L0a2a2 C1048T G2758A T2885C C3516A C3594T T4586C G5147A G5231A C5603T A5711G T6185C
 G6257A A7146G C7256T C9042T A9347G G9554A G9755A G10688A T10810C C11143T
 A11172G G11176A A11641G G11914A G12007A A12720G A13104G A13105G C13116T
 A13276G C13506T T14308C C15136T G15431A  
  
L0a2a2 C1048T G2758A T2885C C3516A T4586C A5711G T6185C G6257A A7146G C7256T C8281 - 8289d
 A9347G A9545G G9554A G9755A C9818T G10589A G10688A A11641G G11914A G12007A  
               A12720G A13104G A13105G C13116T A13276G C13506T 
   
L0a2 A2245G G2758A T2885C A3579G T4586C A5711G T6185C G6257A A7146G A11172G
 A12720G C13506T  
         
L0a2 A647G C1048T T2885C G5147A G5231A C5603T A5711G C7256T G10688A T10810C
 A12720G A13105G C13506T T14308C  
       
L0a2a2 C1048T A2245G T2885C C3516A C3594T T4586C G5147A G5231A T5442C G5460A A5711G 
               T6185C G6257A A7146G C8281 -8289d  A9545G G9554A G9755A C9818T A11641G G11914A  
               G12007A A12720G A13104G C13116T T14308C 
   
L0a2a2 C1048T A2245G G2758A T2885C C3516A C3594T T4586C G5147A G5231A T5442C C5603T














 G12007A G12192A A12720G A13105G C13116T A13276G C13506T T14308C C15136T
 G15431A 
       
L0a2 T4586C C5603T A5711G C8281d C8282 - 8289d A8460G G9554A T10463C G11914A
 A13105G A13276G C13506T 
         
L0a2a2 C1048T A2245G C3516A C3594T T4586C G5147A T5442C G5460A C5603T T6185C A7146G 
 C7256T C8281 -8289d C8428T C9042T A9347G A9545G G9554A G10688A A11641G G11914A  
               G12007A A12720G C13116T T14308C        
    
L0a2a2 C1048T G2758A T2885C C3516A C3594T T4586C G5147A C5603T A5711G T6185C A7146G 
  C7256T C8281 - 8289d C9042T A9347G G9554A G10589A C11143T A11172G G11176A A11641G  
                G12007A A12720G A13105G C13116T A13276G C13506T 
   
L0a2a2 C1048T G2758A T2885C C3516A T4586C G5147A G5231A T5442C G5460A A5711G T6185C A7146G
 C7256T C8281 - 8281d C9042T A9347G A9545G G9554A G9755A C9818T C11143T
 A11172G G11176A A11641G G12007A A12720G A13104G C13116T T14308C C15136T
 G15431A  
      
L0a2 C3516A C8428T A8460G G9755A C9818T A13105G A13276G C13506T T14308C   
            
L0a2a2 C1048T A2245G G2758A T2885C C3516A C3594T T4586C A5711G C5603T A5711G T6185C
 A7146G C7256T C8281 - 8281d C8428T A8460G C9042T A9347G C10664T G10688A A11641G 
               G11914A G12007A A12720G A13105G C13116T T14308C     
      
L0a2a2 C1048T G2758A T2885C C3516A C3594T T4586C G5147A G5231A C5603T T6185C A7146G 
 C7256T C8281 - 8281d C8428T C9042T G9554A G9755A C9818T C10664T G10688A T10810C 
               T10915C C11143T A11172G G11176A A11641G G11914A G12007A A12720G A13105G C13116T  
               A13276G C13506T T14308C G15431A 
   
L0a2a2 C1048T T4586C C3516A C3594T C8281 - 8289d C8428T A8460G C9042T A9347G A9545G
 G9554A G9755A C9818T G10589A C11143T A11172G G11176A A11641G G12007A 
                A12720G A13105G C13116T T14308C        
       
L0a2a2 G2758A T2885C C3594T C5603T A7146G C5603T C7256T C9042T A9347G A9545G G9554A  
               G10589A G11176A A11641G G11914A G12007A A12720G A13104G A13105G C13116T T14308C 
         
L0a2a2 C1048T A2245G G2758A T2885C C3516A C3594T T4586C A5711G T6185C A7146G C7256T
 C8281 - 8289d C9042T A9347G G9554A G9755A C9818T A11641G G11914A G12007A
 A12720G A13104G A13105G C13116T T14308C 
      
L0a2 A2245G C3594T T4586C G5231A T5442C A5711G G9755A G11914A A13105G A13276G
 C13506T T14308C C15136T G15431A  
       
L0a2a2 C3594T A7146G C7256T G9755A G10589A A11641G G12007A A13104G T14308C  











L0a2 C1048T C3594T C5603T A5711G T6185C C8281 -8289d C8428T A8460G C8468T A13104G
C13506T T14308C 
L0a2 C1048T C3594T T4586C A5711G A7146G C7256T G11914A C12341T A13104G C13506T
T14308C 
L0a2a2 C1048T G2758A T2885C C3516A C3594T A5711G C7256T C8281 - 8289d C8428T A8460G C8468T
C9042T A9545G G9554A A13104G 
L0a2a2 G2758A T2885C C3516A C3594T A5711G T6185C G6257A A7146G C7256T G11914A 
A13104G C13116T 
L0a2a2 A2245G G2758A T2885C C3594T C5603T A5711G T6185C G6257A A7146G C7256T C8428T
C8468T C9042T A9347G G9554A G9755A C9818T A11641G G11914A G12007A A13105G 
  A13276G C13506T T14308C 
L0a2 C1048T C3594T T4586C C5603T A5711G T6185C A7146G C7256T T8286C G10589A
A11641G G12007A A13105G A13276G C13506T G15431A 
L0a2a2 C1048T A3606G T4586C T5442C G5460A C5603T A5711G C7256T C8281 - 8289dC8428T A8460G
C8468T C9042T A9347G C11143T A11172G G11176A A11641G C13116TA13276G C13506T 
T14308C
L0a2 G2758AT2885C C3516A C3594T T4586C G5147A G5231A C5603T A5711G A7146G C7256T
C8281 - 8289d C8428T A8460G C8468T C9042T A9347G A11172G G11176A A11641G
A12720G
L0a2a2 T2885C G5147A G5231A C7256T C9042T A9347G C11143T A11172G G11176A A11641G
G12007A A13104G C13116T 
L0d3 C1048T C3516A C3594T G5460A G5773A C10664T A12720G 
L0d2a C597T C1048T C3516A C3594T T6815C A7146G G8152A G8251A G8392A C9042T
G12007A A12172G A12234G A12720G A12810G G15466A
L0d2a C3516A C3594T T6815C A7146G C7256T G8152A G8251A G8392A T10463C A12810G
A13105G G15466A 
L0d3 A647G C1048T G5460A G5773A G8251A A9347G G10589A C10664T G10688A T10810C 
  T10915C G11914A A12720G 
L0d1 C1048T G2706A C5316A G5773A G8251A T10810C T10915C C10664T A13105G 
L0d2c C1048T C3516A G8251A G8392A A9347G G10589A C10664T G11914A A14007G 
L0d1 C1048T G2706A G3834A G8251A A9347G T10810C G11914A A12172G A12720G A12810G 














L0d1a C1048T G2706 T7389C G8251A A9347G G10589A C10664T G10688A T10810C T10915C
 C13506T 
 
L0d2a C597T C1048T C7256T G8152A G8251A G8392A A9347G G10589A C10664T G10688A T10810C  
               T10915C A12234G G14612A  
    
L0d2a C597T C1048T C3594T C7256T C10664T G10688A T10810C G12007A A12172G A12234G  
               A12720G A12810G A13105G A13276G C13506T 
    
L0d3 C1048T T2885C G5460A G5773A G8251A C9042T A9347G T10810C G11914A G12007A  
               A12720G  
        
L0d3 C1048T C3516A C3594T T5442C G5460A G5773A A7146G G8251A C9042T A9347G 
  G11914A G12007A A12720G G12769A A13105G C13506T     
           
L0d2c C1048T C3594T T6185C T10915C A13105G C13506T A14007G 
     
L0d1a C1048T G2706A C3594T A7146G C7256T T7389C G8251A T10810C T10915C G11914A A13105G  
              C13506T  
         
L0d C3516A C3594T A7146G C7256T G8251A G8392A A9347G G10589A C10664T G10688A
 T10810C T10915C  
         
L0f1 C1048T G2758A T2885C C3516A C3594T T4586C C5603T A7146G C7256T A7364G C9042T
 A9347G T9581C G10589A C10664T G10688A C10692T T10810C A11641G G11914A
 G12007A T14178C  
         
L0f2a1 C2789T C3594T T5108C C7256T C9042T A9347G G10589A C10664T G10688A T10810C T10915C  
               G11914A A12720G A13105G G13145A 
  
     
L0f2a1 C2789T C3594T C7256T C9042T A9347G T9581C G10589A C10664T G10688A T10810C
 G11914A A12720G 
          
L0f2a1 C2789T C3594T T6185C A7364G C9042T A9347G C10692T G11914A A12720G G13590A 
  
L0f1 C1048T G2758A T5090C T5442C A7364G C9042T A9347G G11914A A12720G A13276G
 T14178C  
          
L0f2a1 C2789T C3594T T4586C T5108C T5442C C9042T A9347G G11914A A12720G G13145A
 A13276G C13506T 
          
L0k1 C1048T G2758A C2836T T2885C C3516A C3594T T4586C T5442C C9042T A9347G C9818T
 G10589A A11653G G11914A A12720G G13590A T14371C 
     
L0k1 T921C G2758A C2836T T2885C C3516A C3594T T5442C C7256T C9042T A9347G G13590A
 T14182C T14371C 














L0k1 C1048T G2758A C2836T T2885C C3516A C3594T T4586C T6185C A7146G C7256T C9042T
 A9347G A11653G G11914A G13590A T14182C T14371C  
     
L0k1 C2836T C3594T T4586C T6185C A7146G C7256T C9042T A9347G G10589A C10664T 
 G10688A T10810C T10915C G11914A A12720G C13506T T14371C 
    
L0k1 G2758A C2836T T2885C C3516A C3594T T5442C C7256T C9042T A9347G C9818T G10589A
 C10664T G10688A T10810C T10915C G12007A A12720G G13590A T14182C T14371C 
  
L0k1 C2836T C3594T T6185C C9042T A9347G A11653G G12769A A13105G T14371C  
  
L0k T921C T6185C A7146G C7256T C9042T A9347G C13506T T14371C  
   
L0k1 C2836T C3594T A7146G C7256T C9042T A11653G G11914A G12007A A12720G G13590A
 T14182C T14371C  
         
L0k1 C1048T G2758A C2836T T2885C T4586C T5442C T6185C C7256T C9042T A9347G G10688A
 T10810C A11653G G12007A A12720G T14371C       
           
L1c3a C3594T C4312T A5951G T6071C G6260A A7146G C7256T A9072G C10664T G10688A
 T10810C G11914A          
L1c3a A5951G T6071C G6260A G7055A A7146G C7256T G7789A C8468T A9072G C10664T 
 G10688A T10810C T10915C G11914A A13485G T14178C G14560A G15301A 
   
L1c2a1a C3594T A5951G T6071C G6917A A7146G C7256T T7744C C8468T A9072G C10664T 
 G10688A T10810C A11654G G11914A C12049T A13105G A13276G C13506T C15016T
 G15301A 
           
L1c3a1 G2758A T2885C A3105G C3594T G3666A A5951G T6071C C7256T T7389C G7498A G7789A 
 C8468T A9072G G10586A G10688A T10810C T10915C G11914A C12019T A13105G A13485G  
               C13506T 
         
L1c2 T921C C3594T A5951G T6071C G6150A T6253C C7256T G10586A G11914A G15301A 
  
L1c2 T2885C C3594T A5951G T6071C C10664T G10688A T10810C T10915C C12341T  
  
L1c3b1 G2758A T2885C A3434G C3594T G3666A A5951G T6071C A7146G C7256T A9072G C10664T
 G10688A T10810C A12810G A13485G T14178C G14560A     
            
L1c2a T2885C C3594T G3666A A5951G T6071C G6150A T6253C C7256T G8251A G10586A
 G10688A A10792G C10793T A11654G C12049T A12810G A13149G C13212T A13485G  
            
L1c2 A5951G T6071C G6150A G7055A A7146G C7256T C10664T T10810C T10915C G15301A  
 
L1c2a1a G2758A T2885C C3594T G3666A A5951G T6071C G6917A A7146G C7256T G7337A T7389C
 T7744C G8027A G8251A C8468T A9072G G10688A T10810C T10915C G11914A A12810G 















L1c3a T921C A3579G A5951G T6071C C7256T G7789A C10664T G10688A T10810C T10915C
 A13105G A13485G A14148G  
        
L1c3a A5951G T6071C G6260A C7256T T7389C G7498A G7789A C8468T A9072G G9966A
 C12019T G12501G A12810G A13105G 
        
L1c2a1a G2758A T2885C C3594T G3666A A5951G T6071C G6150A G7337A T7389C T7744C A9072G
 C10664T G10688A T10810C G11914A C12049T A12810G A13149G C13212T A13276G
 C13506T T14178C C15016T  
        
L1c2 T2885C A5951G T6071C C7256T C10664T G10688A T10810C T10915C G11914A A13105G
 G13194A A13276G C13506T 
         
L1c2a1a G2758A T2885C C3594T A5951G T6071C G6150A T6253C G7055A A7146G C7256T G7337A
 T7389C T7744C C8468T A9072G C10664T G10688A T10810C T10915C A11654G G11914A
 C12049T G12192A A13105G A13276G T14178C G14560A 
     
L1c2 T2885C T5090C A5951G T6071C G6150A T6253C G7055A A7146G C8468T C10664T
 G10688A T10810C T10915C G11914A A13105G A13276G C13506T A15311G   
            
L1c2 T2885C A5951G T6071C G6917A A7146G C7256T G8027A A9072G T10321C A13105G
 A13149G C13212T A13485G C13506T  
       
L1c3a G2758A T2885C C3594T A5951G T6071C G6260A A7146G C7256T T7389C G7498A G7789A
 C8468T A9072G G9966A G10586A G10688A G12501G G12769A A12810G A13105G T14178C 
 
L1c2a1a A7146G C7256T T7744C A9072G G10688A A10792G C10793T T10810C G15301A 
  
L1c2 A647G A5951G G2758A T2885C A3606G C7256T G10586A G10688A A10792G C10793T
 T10810C G11914A G12192A G15301A  
       
L1c2 G709A A5951G T6071C G10688A T10810C A11654G G11914A A13105G A13276G C13506T 
 
L1c2a1a G2758A T2885C C3594T G3666A A5951G T6071C G6150A G7055A A7146G C7256T G7337A
 T7389C T7744C A9072G T10321C G10586A A11654G G11914A C13506T T14178C G14560A
 G15301A 
           
L1c2 C3594T G3666A G7337A T7389C G8027A G10688A T10810C A11654G A12810G A13105G
 A13149G A13485G T14178C G14560A  
       
L1c3b1 A3434G C3594T G3666A A5951G T6071C G8027A C10664T T10915C G10586A G11914A
 G14612A  
          
L1c5 G2758A T2885C C3594T A7146G T7175C C7256T C8281- 8289d    C8428T C8468T G10586A
 G11914A G15301A 
          












L1c2a G709A C3594T G3666A A5951G T6071C G8027A G8251A A9072G A13485G G15301A 
L2a1 T2416C G2758A T2885C C3594T T7175C C7256T C7274T G11914A T11944C A15311G 
L2a1 C3594T C7256T C7274T G11914A T11944C A13105G C13506T G13590A A14566G 
L2a C3594T T7175C C7256T C7274T G11914A T11944C A13105G A13276G C13506T  
L2a1h T4772C T7175C C7256T C7274T A7771G G8206A C8468T A9221G T10115C T11944C
A12693G A13105G G13590A A15311G 
L2a1d1 C3594T T7175C C7274T G8206A T10115C T11944C G12007A G12192A A13105G C13506T
G15301A 
L2a1 T2885C T7175C C7256T C7274T A7771G G8206A T10115C C10664T G10688A T10810C
T10915C G11914A T11944C A13105G A13276G C13506T A14566G G15301A A15311G
L2a1h A3205G C3594T T7175C C7256T C7274T A7771G G8206A A9221G C10664T G10688A
T10810C T10915C G11914A T11944C A12693G A13105G A13276G C13506T A14566G
G15301A A15311G 
L2a1 C3594T T7175C C7256T C7274T A7771G G8206A C8468T A9221G C10664T G11914A
T11944C A13105 G13590A A14566G G15301A
L2a1 C3594T T7175C C7256T C7274T A7771G G8206A A9221G C10664T G10688A T10810C
T10915C G11914A T11944C A13105G A13276G C13506T A14566G A15244G G15301A
L2a1 C3594T T7175C C7256T C7274T A7771G A9221G G11914A A12693G A13105G A13276G
G15301A 
L2a1 C3594T T7175C C7256T C7274T A7771G G8206A A9221G C10664T T10810C T10915C
T11944C A13105G C13506T G13590A A14566G
L2a1 T2416C C3594T T7175C C7256T C7274T T11944C A15244G G15301A T15629C 
L2a1 C3594T T7175C C7256T C7274T C10664T G10688A T10810C T10915C G11914A A12693G
G13590A G15301A 
L2a1d1 T825A G2758A T2885C C3594T A7146G T7175C C7256T G8206A C10664T G10688A
T10810C G12007A G12192A A13276G 
L2a1 T2416C T7175C C7256T C7274T A7771G G8206A T10115C C10664T G10688A T10810C
G11914A T11944C A13105G G13590A 
L2a5 T2626C C3594T C3654T T4823C A6080G T6248C T7175C C7274T G8206A A9221G














L2a C3594T T7175C C7274T G8206A C10664T G10688A T10810C T10915C T11944C A13105G
 G13590A 
           
L2a1f T2416C C3594T A5581G T7175C C7274T A7771G A9221G G11914A A12693G A13105G
 C13506T A14566G G15301A 
         
L2a1 C3594T T7175C C7256T C7274T A9221G T11944C G13590A A14566G G15301A 
   
L2a5 G709A C3594T C3654T T4823C A6080G T6248C T7175C C7256T C7274T T10115C G10688A
 T10810C G11914A G12769A G13590A  
       
L2a1 T921C C3594T G8206A A9221G T10463C G11914A G13590A A14566G  
   
L2a1 T921C C3594T C10664T G10688A T10810C T11944C A12693G A13105G  
   
L2a1a C3594T A5285G T7175C C7256T C7274T A7771G G8206A A9221G G10688A T10810C
 T10915C T11944C A12693G G13590A A14566G  
      
L2a1 C3594T T7175C C7256T C7274T G8206A A9221G T10115C G11914A  
   
L2a1h T2416C A3205G C3594T T4772C T7175C C7256T C7274T A7771G G8206A A9221G C10664T
 G10688A T10810C G11914A A12693G C12976T A13276G A14566G G15301A 
   
L2a T2885C C7256T T10115C C10664T G11914A A12693G A14566G  
    
L2a T825A G2758A T2885C C3594T A7146G C7256T T10810C A13105G    
            
L2a1m1 T2416C C3594T T7175C C7256T C7274T A7771G G8206A C8281 -8289d C8468T A9221G
 T10115C G11914A T11944C A12693G G13590A A14566G  
    
L2a1 T2416C C3594T T7175C C7256T C7274T G8206A A9221G G10688A T10810C G11914A
 T11944C A12693G A14566G  
        
L2a5 C3594T C3654T T4823C T7175C C7256T C7274T G8206A G10688A T11944C 
   
L2a1d1 C3594T A7146G T7175C C7256T A9221G G11914A G12007A A13105G A13276G C13506T 
 
L2a1 T2416C C3594T T7175C C7256T C7274T G8206A A9221G T10115C G11914A A12693G
 A13276G G13590A A14566G  
        
L2a1 T2885C C3594T T7175C C7256T C7274T A7771G A9221G T10115C G11914A T11944C
 A12693G A13105G A13276G C13506T G15301A  
      
L2a1 T921C C3594T C7256T C7274T A7771G A9221G A13105G C13506T A14566G 
   
L2a1 T2885C C3594T C3594T T7175C C7256T C7274T A9221G C13506T A15244G 














L2a1m1 G2758A T2885C C3594T A7146G C7256T A7771G G8206A C8281 - 8289d A9221G
 C10664T G10688A T10810C T10915C G11914A T11944C A14566G 
    
L2a1 C3594T T7175C C7256T C7274T G8206A A9221G T10115C A12693G G13590A A15244G
 G15301A T15629C 
          
L2a1h A3205G C3594T C7256T C7274T A7771G G8206A A9221G T10115C C10664T G11914A 
 T11944C A12693G C12976T G13590A A14566G G15301A 
     
L2a1 G709A C3594T T10115C C10664T G10688A T10915C G11914A G13590A A14566G 
  
L2a1 T2416C C3594T T7175C C7256T C7274T G8206A T10115C G11914A T11944C A12693G
 C13506T G13590A A14566G G15301A 
        
L2a T2416C C3594T T7175C C7256T C7274T G8206A A9221G T10115C G11914A A12693G
 G15301A  
          
L2a1 T2416C C3594T C7256T C7274T A7771G G8206A A9221G G11914A T11944C A12693G
 G13590A A14566G 
          
L2a5 C3594T T4823C T6248C A7771G G8206A A9221G C10664T G10688A T10810C G11914A
 T11944C A12693G A15244G G15301A 
        
L2a5 C3594T T4823C T7175C C7256T C7274T A7771G G8206A A9221G T10115C G11914A
 A12693G A13105G G13590A A15244G G15301A 
      
L2a1m1 C3594T C7274T C8281 - 8289d C8468T A9221G T10115C C10664T G10688A T10810C
 T11944C A13105G A13276G C13506T G15301A       
            
L2a5 C3594T T4823C T6248C T7175C C7274T G8206A A9221G G11914A T11944C G13590A
 A14566G  
          
L2a1 T2885C C3594T T7175C C7274T A7771G A9221G G11914A A13105G A13276G C13506T  
L2a1h C3594T T4772C A7146G T7175C A7771G G8206A A9221G T10115C G11914A T11944C
 A13105G A13276G C13506T  
        
L2a1 T2416C C3594T G8206A T10115C A12693G A14566G G15301A  
    
L2a1 T2416C C3594T T7175C C7256T G8206A T10115C G11914A T11944C A13105G C13506T  
 
L2a1 C3594T G8206A A9221G T10115C G11914A A13105G C13506T  
    
L2a C3594T T7175C C7256T C7274T A7771G T10115C T11944C G15301A 
    
L2a1 G709A C3594T T7175C C7256T C7274T A7771G T10115C T11944C C13506T 
   















L3d3a G769A T825A G1018A G2758A T2885C C3498G C3594T A7146G C7648T G10688A T10810C
 T10915C G11914A A13105G A13276G C13506T G15301A 
     
L3d3a G769A G1018A C3594T A7146G C7256T A15061G G15301A 
     
L3d T2885C G7521A C10664T G10688A T10810C T10915C G11914A C12341T A13105G A13276G
 C13506T 
           
L3d3a G769A C3498G T6680C A13276G C13506T C14284T G15301A 
     
L3e A647G T2352C C3594T C7256T A10819G A13105G T13650C T14212C 
    
L3e1e G769A T825A G1018A T10370C A13105G T13650C A14152G T14212C G15301A 
  
L3e1 G769A C6587T C7256T C10664T G10688A A10819G G11914A A13105G A13276G
 C13506T T13650C A14152G T14212C G15301A 
       
L3e1 T2352C C6587T G7521A C10664T A10819G G11914A T13650C T14212C G15301A 
  
L3e3a C2000T G1018A C3594T C8468T A10286G C10664T G10688A T10810C A12397G A13105G
 C13506T G15301A 
          
L3e1 G769A T2352C C6587T C7256T C8468T G11914A T13650C G15301A  
   
L3e1 G769A C6587T C7256T C10664T G10688A T10810C T10915C T13650C A14152G T14212C
 G15301A 
           
L3e1 A647G T2352C A3606G G7521A C10664T G10688A T10810C A10819G G11914A T13650C
 T14212C G15301A 
          
L3e3a C2000T G1018A C3594T A10286G C10664T G10688A T10810C T10915C A12397G A13101C
 T13650C T14212C 
          
L3e1 G769A G1018A C3594T C6587T A10819G T13650C A14152G T14212C  
   
L3e G769A T825A G1018A C7256T G10688A T10810C T10915C G11914A A13276G C13506T
 T14212C  
          
L3e1 G769A T2885C C3594T G5262A C6587T C7256T G7521A G10688A T10810C A10819G
 G11914A A13105G A13276G C13506T T13650C T14212C 
     
L3e1 G1018A A3579G C3594T C7256T G7521A G10688A A10819G T13650C A14152G T14212C
 G15301A  
          
L3e G769A G1018A C2000T T5090C C7256T G10688A T10810C T13650C T14212C  
  
L3e3a G769A T825A G1018A G5262A G7521A A10286G A10819G G11914A A13101C A13105G











L3e1e G769A G1018A C3594T T10370C G11914A T13650C T14212C  
L3e G769A C3594T A10286G C7256T A10819G T14212C G15301A  
L3e3a C2000T C6587T C7256T T10667C A12397G A13101C T13650C T14212C G15301A 
L3e1 T2352C T825A G1018A A13105G T13650C A14152G T14212C  
L3e1f G769A T2885C C3594T G2758A T2885C C3594T A7146G C7256T C8468T T10370C
A10819G 
L3e3a G2758A T10667C A10816G G5262A A10286G T13650C
L3e3a C2000T C6587T T10667C A10819G G11914A A14152G T14212C G15301A
L3e1a1a G3438A G1018A C3594T A10819G A13105G C13506T G15301A
L3e3 G769A G1018A T2352C A10816G A10819G G11914A T13650C G15301A
L3e3a G769A C3594T G5262A C7256T A10286G A10816G A10819G A13101C G15301A











Appendix F: Ethical approval College of Medicine (COMREC) 
. ,,' 
- ... . ' .---.---= ..... 
---._-. .... """' 
", . ..... 20" 
.... f ._ 
CGIIogo ol lOooX'" 
-~ -....... ' 
<#}... =,p 
tlt .• ",-",':0 













Appendix G: Ethical approval University of Cape Town 
